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1 ABSTRACT 
Neuroendocrine tumors are a heterogeneous group of malignancies with an increasing 
prevalence. Since there is not much progress in therapy, model systems are urgently 
needed. We have a CEA424-SV40 TAg transgenic mouse model which develops 
spontaneous tumors in the antral region of the stomach. In addition, several cell lines 
derived from the tumor were established. Gene expression analysis of the tumor tissue 
as well as cell lines revealed neuroendocrine markers. Therefore we further 
characterized this model with special emphasis on the cells of origin and used it for 
testing new targeted treatment protocols.  
To analyze CEA424-SV40 TAg mouse model in more detail, tumor tissue as well as 
the cell lines derived from the primary tumor were investigated by 
immunohistochemistry, immunofluorescence, western blot, and ELISA. Antibodies 
used were directed at SV40 TAg, Ki-67, chromogranin A, chromogranin B, secretin, 
H
+
-K
+
-ATPase, glucagon, and transcription factors NeuroD1 and Nkx2.2. Plasma 
hormone levels of serotonin and secretin were measured by ELISA. Immunostainings 
of SV40 TAg and Ki-67 revealed highly proliferative tumors cells. The tumors stained 
intensively for the neuroendocrine markers chromogranin A, chromogranin B, 
secretin and glucagon. The tumor tissue as well as the cell lines expressed 
transcription factors NeuroD and Nkx2.2, which are involved in the differentiation of 
the neuroendocrine lineage. Hormone levels of serotonin and secretin in the plasma of 
the transgenic mice were dramatically elevated when compared with normal 
littermates, thus supporting the neuroendocrine phenotype. 
As the neuroendocrine phenotype of CEA424-SV40 TAg transgenic mouse was 
confirmed, molecularly targeted therapies were tested in this model system both in 
vitro and in vivo. Cell lines were tested for drug sensitivity with mTOR inhibitors 
(RAD001, NVP-BEZ235), paclitaxel, E2F inhibitor, HSP90 inhibitor, and p53 
stabilizer Nutlin-3a. All the drugs tested in vitro could efficiently inhibit cell 
proliferation in a dose dependent manner. From these drugs the mTOR inhibitor 
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RAD001 was chosen for the in vivo experiment. Daily feeding of 10 mg/kg RAD001 
inhibited the tumor development and prolonged the survival time of the 
CEA424-SV40 TAg transgenic mice dramatically. The effects of the RAD001 
treatment on tumor cells were achieved mainly through inactivating mTOR-p70S6K 
and mTOR-4EBP1 signaling as proven by western blot and immunohistochemistry. 
Still, some cells must develop escape mechanisms, since the tumor tend to grow.  
To gain a better understanding of the T antigen transforming mechanisms as well as 
the possible escape mechanisms, some efforts were made on the tumor originating 
cells in the CEA424-SV40 Tag transgenic mouse model. Possible candidates for these 
tumor originating cells in the stomach are the newly described epithelial as well as 
mesenchymal stem cells. In a first attempt, the expression feature of epithelial and 
mesenchymal stem cell markers were analyzed. Established cell lines as well as tumor 
tissue from the tumor bearing mice were investigated by reverse transcription PCR 
(RT-PCR), immunohistochemistry, immunofluorescence, western blot, and 
microarray analysis. From several markers analyzed, the tumor cell lines showed a 
high expression level of the potential epithelial stem cell marker Bmi1 in RT-PCR and 
cDNA expression array. This could be further substantiated by western-blotting and 
immunostaining. Consequently, Bmi1 message could also be found in the growing 
tumors both in mRNA and protein levels. Experiments using siRNA to knock down 
the SV40-TAg expression showed that the Bmi1 expression went down in the cell 
lines thus showing the interrelationship. On the other hand, the mesenchymal stem 
cell marker Etv1 was also found to be expressed in the tumor tissue and cell lines 
derived from the tumor. More interestingly, Etv1 expression level was up-regulated 
over the time course of the tumor development. From these, an Etv1 positive 
mesenchymal cell could be a possible candidate for transformation. Since the 
CEA-promoter used for the generation of the T-antigen transgenic animals contains 
Etv1 binding sites, it is tempting to speculate, that this may drive the transcription of 
the T antigen.  
In conclusion, our data provide convincing evidence that CEA424-SV40 TAg mice 
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are a clinically relevant model for neuroendocrine tumor. Testing of molecularly 
targeted therapies both in vitro and in vivo offered promising candidates for further 
clinical evaluation. Thus, this new model system could be of great value not only for 
studies on the mechanisms of how SV40 TAg induces neuroendocrine tumors but also 
for exploring novel targeted therapy in a preclinical setting. 
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2 ZUSAMMENFASSUNG 
Neuroendokrine Tumore stellen heterogene Tumore mit ansteigender Prävalenz dar. 
Da es nur geringe Verbesserungen in der Therapie gibt, besteht ein Bedarf an neuen 
Modellsystemen. 
In unserer Arbeitsgruppe wurde das CEA424-SV40-T-Antigen transgene Mausmodell  
entwickelt, in welchem sich spontan Tumore im Bereich des Magenantrums bilden. 
Gleichzeitig wurden Zelllinien aus diesem Tumor etabliert. Die Analyse der 
Genexpression im Tumor und in den Zelllinien ergaben Hinweise auf einen 
neuroendokrinen Tumortyp. Deshalb wurde der Phänotyp des Tumors auch mit Blick 
auf den Ursprung der Tumore analysiert und für die Testung von Therapieoptionen  
eingesetzt. 
Die Analyse der CEA-424-SV40-TAg-Mäuse sowie der Tumorlinien wurden mittels 
Immunhistochemie, Immunfluoreszenz, Westernblot und ELISA untersucht. Dazu 
wurden Antikörper  gegen das SV40-T-Antigen,  den Proliferationsmarker Ki-67, 
Chromogranin A, Chromogranin B, Sekretin, die H-K-ATPase, Glukagon und die 
Transkriptionsfaktoren NeuroD und Nkx2.2 eingesetzt. Die Plasma 
Hormonkonzentrationen von Serotonin und Sekretin wurden mittels ELISA bestimmt. 
Die Färbung für das SV40-T-Antigen und Ki-67 zeigte einen hoch proliferierenden 
Tumor. Dieser war hoch positiv für die neuroendokrinen Marker Chromogranin A, 
Chromogranin B, Sekretin und Glukagon. Sowohl der Tumor als auch die 
Tumorzelllinien exprimierten die Transkriptionsfaktoren NeuroD und Nkx2.2, welche 
an der Differenzierung von neuroendokrinen Zellen beteiligt sind. Die 
Hormonkonzentrationen von Serotonin und Sekretin waren im Plasma der transgenen 
Mäuse deutlich erhöht. Dies ergab das Gesamtbild eines neuroendokrinen Karzinoms. 
In diesem Modell wurden nun verschiedene molekular begründete Therapien in vitro 
und in vivo getestet. So wurde an den Zelllinien die Empfindlichkeit von mTOR 
Inhibitoren (RAD001, NVP-BEZ235), Paclitaxel, E2F -Inhibitor, Hsp90-Inhibitor und 
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dem p53 Inhibitor Nutlin3 getestet. Alle verwendeten Substanzen konnten die 
Proliferation der Tumorzellen dosisabhängig hemmen. Von diesen wurde dann der 
mTOR Inhibitor RAD001 für die in vivo Anwendung ausgewählt.  
RAD001 konnte dabei die Entwicklung der Tumore signifikant hemmen und 
verlängerte das Überleben der Tiere dramatisch. Der Effekt der mTOR Inhibition 
bestand dabei vor allem in der Hemmung des mTOR-p70S6K und mTOR-4EBP1 
Pathways, was im Westernblot und der Immunhistochemie gezeigt werden konnte. 
Trotzdem muss festgehalten werden, dass einige Tumorzellen der Therapie 
entkommen konnten. 
Um nun Informationen über den Transformations- und den Escape-Mechanismus zu 
bekommen, wurde versucht die Tumorursprungszelle zu beschreiben. Mögliche 
Kandidaten dafür sind sowohl die jüngst beschriebenen intestinalen 
Epithelstammzellen als auch mesenchymale Stammzellen. Dazu wurden Marker-Gene 
an den etablierten Zelllinien und den Tumoren mit Hilfe von RT-PCR,  
Immunhistochemie,  Immunfluoreszenz, Westernblot und Microarray untersucht. 
Dabei fand sich in den Tumorzellen eine hohe Expression des möglichen epithelialen 
Stammzellmarkers Bmi1. Dies konnte auch im Westernblot und in der Immunfärbung 
bestätigt werden. Folgerichtig fand sich dieser Marker auch in den wachsenden 
Tumoren. Experimente, in denen mit siRNA die Expression des SV40-T- Antigen 
blockiert wurde, ergaben eine Reduktion der Bmi1-Expression und weisen damit auf 
einen engen Zusammenhang hin. Gleichzeitig fand sich allerdings auch eine hohe 
Expression des mesenchymalen Stammzell-Markergenes Etv1 im Tumor und in den 
etablierten Zelllinien. Etv1 stieg dabei im Verlauf der Tumorentwicklung im Gewebe 
deutlich an. Deshalb könnte es sich bei der ursprünglich transformierten Zelle auch 
um eine mesenchymale Stammzelle handeln. Da der CEA Promotor, der die 
Expression des SV40-T-Antigens in den transgenen Mäusen regulieren soll, einige 
Bindungsstellen für den Transkriptionsfaktor Etv1 hat, liegt die Möglichkeit der 
Induktion des T-Antigens über Etv1 nahe. Dazu stehen aber noch weitere 
Experimente aus. 
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Zusammenfassend zeigen die hier präsentierten Daten, dass es sich bei dem 
CEA424-SV40 Tag-Mausmodell um ein klinisch relevantes Modell für einen 
neuroendokrinen Tumor handelt. Zusammen mit den etablierten Tumorzelllinien  
können daran neue Therapieansätze getestet werden. Damit bietet es die Möglichkeit 
sowohl den Zusammenhang zwischen dem T-Antigen und der Entwicklung des 
neuroendokrinen Phänotyps als auch neue Therapieformen zu untersuchen.  
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3 INTRODUCTION 
3.1 Preclinical mouse model systems for the translational research of 
human cancer 
3.1.1 General 
 
As George D. Snell said, “Of all the laboratory mammals, probably none has 
contributed more to the advancement of knowledge than the common mouse.”
1
 For 
the whole century, laboratory mice played a central role in the study of cancer biology 
and novel drug screening. Their use has been expanded over the past three decades 
since the first genetic model of cancer, termed “oncomice”, was developed in 1980s
2
. 
These mouse models not only offer unique opportunities to investigate the molecular 
mechanisms of cancer development and progression in genetically modified and 
environmentally controlled mammalian systems, but also provide platforms for testing 
therapeutic approaches in conditions that may more precisely mimic the real in vivo 
environment, including various tumor microenvironments which have attracted more 
and more interests of scientists recently. 
3.1.2 The use of cultured tumor cell lines and xenograft mouse models for cancer 
research 
 
Before the development of genetically engineered cancer-prone mice, preclinical 
cancer research was relied to a large extent upon the use of cultured tumor cell lines 
and xenograft mouse models. Cell based tests are designed to determine if the drugs 
can induce anti-tumor effects like apoptosis or cytostasis, and whether these desired 
responses can be achieved at a reasonably low concentration. Although these cell lines 
do help a lot in selecting promising agents from millions of candidate compounds, 
their ability to mimic tumor cells in a native in vivo environment is challenged. These 
cell lines are usually from particularly aggressive tumors and have been selected for 
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optimal proliferation under in vitro culture conditions. They may also acquire 
additional mutations during the long term cultivation
3
. As pure populations, they can 
not provide further information about the impact from supporting cells inside and 
around the tumors and the stress from ongoing immune surveillance
4
. It is also 
impossible to evaluate the interactions between the drugs and the host in a culture 
flask. That is why in vivo animal model systems are essential for novel drug 
screening.  
Currently, xenograft mouse models are still the most commonly used animal models 
for human cancer research
5
. In this case, tumor cell lines or small tumor masses are 
injected or transplanted into immunodeficient mice
5
. Although these models conserve 
some molecular pathways and can provide valuable information missed in cell/tissue 
culture systems, their predictive abilities are still being debated. Essentially, xenograft 
mouse model based experiments still focus on cell lines. These propagated cells may 
behave quite differently from the original malignant cells. Even carefully designed 
xenograft models may still fail to fully represent the behavior of an in situ developed 
tumor in its native in vivo environment
5
. The complex interaction between the host 
and the tumor are interrupted and the prognostic usefulness of these testing systems 
for human clinical trials has been limited
5, 6
. According to a broad study of in vitro 
and xenografts models from the National Cancer Institute, the predictive ability of 
these testing systems for drug responses in phase II clinical trials is not as optimistic
5, 
7
. Still, these highly imperfect tumor cell lines and xenograft models are valuable 
testing systems available and are unlikely to be completely replaced by the improved 
animal models of human cancer in the near future. 
3.1.3 The contribution of genetically engineered mouse models for human cancer 
research 
 
With the improved tools for genomic analysis, especially the gene expression array 
technologies, and the increasingly refined methods of genetic manipulation, a 
dramatic progress of genetically engineered mouse models in recent years provided 
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key insights into the complexity of human cancers. Despite more expensive and 
time-consuming, the use of genetically engineered mouse models can overcome many 
shortcomings of cell based and xenografts models. These mouse models develop in 
situ tumors in an intact host immune system as well as in the context of the tumor 
microenvironment, which can better mimic the oncogenesis of human cancer and may 
provide more valuable information regarding safety and efficacy of novel drugs for 
clinical evaluation.  
The main principles for genetic modeling of human malignancy include the 
expression of oncogenes like the SV40 T antigen, the knock-in of genetic point 
mutations, or the knock-out of tumor suppressor genes like Trp53
8
. Nowadays, as a 
consequence of advanced gene targeting technology, the conditional induced 
alterations of the genome in tissue specific compartments have become more 
common
9
. It is hoped that these genetically engineered mouse models can be powerful 
translational tools for human cancer research. 
 
3.2 Established CEA424-SV40 T antigen transgenic mouse model 
3.2.1 SV40 T Ag induced transformation 
 
Simian virus 40 (SV40) is a DNA polyomavirus. Under certain conditions, it has the 
potential to be oncogenic in animals and capable of inducing transformation of 
various cell lines in vitro
10, 11
. SV40 is also found to be associated with several human 
tumors, like lymphoma, osteosarcomas, ependymomas, choroid plexus tumors, and 
mesotheliomas
12-16
. Two proteins, the large T antigen (T Ag) and the small t antigen (t 
Ag) are encoded by SV40 for its transforming ability. The large T antigen (T Ag) 
contains 708 amino acids, and is a product of an early gene transcribed during SV40 
infection
10
. The T Ag, which is involved in multiple activities for the replication of 
the virus and the regulation of the host cellular processes
17
, is necessary and in most 
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cases sufficient for tumorigenesis
10, 14-16, 18, 19
. The SV40 T Ag interacts with host 
cellular proteins through several folding domains/regions
10, 18, 20
. The tumor 
suppressor protein p53, which is found to be mutated or deleted in most of human 
cancers, can be inactivated by the C-terminus of T Ag
10, 21-24
. On the other hand, the 
N-terminus of TAg, where the LXCXE motif and the J domain reside, is involved in 
the inactivation of Rb family members
10, 25, 26
. The E2F, which takes an important role 
in cell-cycle progression and oncogenesis, is then set free from Rb and this 
subsequently leads to the progression of cells into the S phase
27-29
. It has also been 
reported that T Ag binds to some other cellular factors like p300 and CBP, which may 
contribute to its powerful oncoprotein function
20
. 
3.2.2 CEA424-SV40 T antigen transgenic mice  
 
Since SV40 T antigen gene is such a potent oncogene, it has widely been used to 
generate tumors in transgenic mice. Certain tissue-specific gene promoters are often 
used to regulate the expression of SV40 T antigen gene so as to generate tumors in 
targeted organs.  
About 10 years ago, Thompson et al successfully established a transgenic C57BL/6 
mouse model based on the SV40 T Ag transgene controlled by a small 424 bp 
promoter of the human carcinoembryonic antigen (CEA) gene
30
. One transgenic line 
(L5496), which was later named as CEA424-SV40 T antigen transgenic mouse, 
spontaneously developed gastric tumors in the pyloric region in 100% of the offspring. 
Tumors can already be observed in the stomach of 37 days old CEA424-SV40 T 
antigen transgenic mice as small multi-focal tumor areas. Around day-90, these mice 
start to lose weight and gradually become moribund before finally die probably of 
undernourishment due to pyloric stenosis by the tumor mass. Several cell lines were 
also established from the primary tumors of these transgenic mice, like 424GC, 
mGC3, mGC5 and mGC8
31
. This model system has been used for testing anti-tumor 
strategy since then
32-35
. 
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3.2.3 Preliminarily detected neuroendocrine signature in CEA424-SV40 T 
antigen transgenic mouse  
 
When the CEA424-SV40 T antigen transgenic mouse model was established, the 
tumors developed in the stomach were tentatively identified as adenocarcinomas for 
several reasons. First, CEA has been used as a marker for adenocarcinomas in many 
organs, including almost all colorectal adenocarcinomas, as well as lung, breast and 
pancreatic carcinomas
36
. Second, the cell lines derived from the tumor express mucin 
and some cell adhesion molecules like EpCAM and CEACAM1, which indicated a 
possible epithelial origin
31
.  
In an attempt to further characterize these tumors, RNA from the antral region of 30, 
60 and 90 days old CEA424-SV40 TAg transgenic mice and normal littermates was 
used for genome-wide expression analysis
37
. Interestingly and surprisingly, a 
neuroendocrine gene signature was revealed. The expression levels of 4, 27 and 329 
probe sets/genes were more than 5 folds up-regulated in 30, 60 and 90 days old 
tumor-bearing mice, respectively, when compared with normal mice
37
. Among them, 
the majority of the most strongly up-regulated genes were found to be typical for the 
neuroendocrine lineage
37
. Knock down of the SV40-T Ag expression by siRNA also 
led to down-regulation of neuroendocrine gene expression in 424GC cell line (cell 
line derived from the primary tumor). In addition, transmission electron microscopic 
analysis of a typical tumor cell in a tumor from a 90 days old CEA424-SV40 TAg 
mouse revealed numerous electron-dense secretory granules which are characteristic 
for a neuroendocrine phenotype
37
. All these information indicated that the gastric 
tumors developed in the CEA424-SV40 TAg mouse may be a neuroendocrine tumor 
and this model system could be of grate value not only for studies on the mechanisms 
of how SV40 TAg induces neuroendocrine tumors but also for testing new targeted 
therapy in a preclinical setting. Nonetheless, additional evidence should be provided 
to make this conclusion solid and many open questions like where the tumor cells 
come from and how this neuroendocrine phenotype is obtained are to be answered.  
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3.3 Neuroendocrine tumor model system for better understanding of 
disease biology and preclinical testing 
3.3.1 General introduction and epidemiology of neuroendocrine tumors 
 
Neuroendocrine tumors (NETs) are a highly heterogeneous group of tumors that can 
arise from neuroendocrine cells throughout the body
38
. These tumors are characterized 
by distinct clinical syndromes caused by various secreted peptides and neuroamines
3
. 
The term “carcinoid” was used to describe these tumors for the first time by Siegfried 
Oberndofer in 1907. Although these tumors were considered to be benign and 
indolent at that time, it has now become apparent that tumors of this group also 
consist of a spectrum of malignancies which can be aggressive and resistant to 
therapy.   
Recent data indicated that the incidence and prevalence of gastroenteropancreatic 
neuroendocrine tumors (GEP-NETs) has been increasing substantially over the last 
three decades, with carcinoids arising from gastrointestinal tract making up the 
majority
38-41
. An analysis of the Surveillance, Epidemiology, and End Results (SEER) 
database reported that the incidence of NETs in the United States was 5.25 per 
100000 in 2004 and the prevalence of individuals with NETs may exceed 100000 in 
this country (NCCN Guidelines Version 1.2011)
38
. GEP-NETs represent up to 2% of 
all malignancies and are the second most common gastrointestinal malignancy after 
colorectal cancer
3, 42
. Among these, gastric carcinoids comprise 23% of all digestive 
neuroendocrine neoplasms with a yearly age-adjusted incidence of around 0.2 per 
100,000 population
43
. The five year survival of the patients with carcinoid tumors 
arising from stomach is the lowest comparing to small intestine, rectum, and 
appendix
44
. The tendency of the increasing incidence may partly reflect the 
improvement in disease awareness and diagnostic techniques including the increased 
availability of advanced endoscopic and radiologic imaging
3, 38, 42
, although the 
number of the patients with NETs is still believed to be underestimated. 
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A study in the USA based on over 13000 neuroendocrine tumor patients showed that 
approximately 20% of these patients were associated with other neoplasms, one third 
of which belong to the gastrointestinal tract
44, 45
. The complexity and heterogeneity of 
the disease itself usually results in long terms of misdiagnosis with metastases evident 
at presentation in 60-80% of the patients
42, 46
. The 5-year overall survival from 
carcinoids at all sites has not changed since 1973 according to the SEER database (US 
National Cancer Institute. SEER Database. http://seer.cancer.gov/). A better 
understanding of the disease biology with emphasis on molecular genetics and disease 
modeling is therefore urgently needed to improve the clinical management for 
GEP-NETs. 
3.3.2 Shortage of in vitro and animal model systems for neuroendocrine tumors 
 
One major limit for the progress in gastroenteropancreatic neuroendocrine tumors 
includes limited understanding of the cellular biology of neuroendocrine cells and the 
molecular mechanisms of tumorigenesis
47
. Thus model systems for studying disease 
pathogenesis and screening novel treatment approach are needed.  
The two most frequently used neuroendocrine tumor cell lines are BON1 and GOT1. 
BON1 is derived from a human pancreatic carcinoid and GOT1 is from liver 
metastasis of a midgut carcinoid
3
. There are few well characterized neuroendocrine 
tumor cell lines from the gastrointestinal system. The use of xenograft models are also 
hampered by the lack of such cell lines. There are now some genetically engineered 
murine models available for neuroendocrine tumors in pancrease 
48, 49
, prostate
50-52
 
and colon
53
, while there are few well described model for NETs in stomach, like 
Apt4b-SV40 TAg transgenic mouse
54
. The shortage of in vitro and animal model 
systems in general is one of the considerable impediments for further studies on the 
molecular biology of this disease as well as preclinical evaluation of new therapeutic 
approach.  
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3.4 Emerging molecularly targeted therapy for neuroendocrine 
tumors 
3.4.1 Targeting the PI3K-Akt-mTOR Pathway  
 
mTOR is an atypical intracellular serine/threonine protein kinase which takes a key 
role in several physiological processes, including protein translation, cell growth, 
proliferation, survival, metabolism, angiogenesis and autophagy
55-57
. mTOR has 
drawn much attention recently because of its involvement in human tumorigenesis. 
Aberrant activation of PI3K-Akt-mTOR pathway has also been reported in a 
significant proportion of patients with NETs, for example, multiple endocrine 
neoplasia type 1 (MEN1), neurofibromatosis-1 (NF-1), tuberous sclerosis 2 (TSC2), 
and von Hippel-Lindau (VHL) disease
58-60
. A decreased expression of tumor 
suppressors and inhibitors of mTOR like TSC2 and phosphatase tensin homologue 
(PTEN) is also found in pancreatic NETs
58
. The importance of the PI3K-Akt-mTOR 
pathway in the tumorigenesis of NETs makes it a promising target for novel 
anti-tumor management. There have been more than one thousand clinical trails for 
mTOR inhibitors alone or in combination with other agents. In a phase III study on 
pancreatic NET (RAD001 In Advanced Neuroendocrine Tumors; RADIANT-3), 
patients treated with everolimus (10 mg/day orally) achieved significant clinical 
benefit and improvement of progression free survival (11 months for patients treated 
with everolimus plus best supportive care compared to 4 months for patients received 
placebo plus best supportive care). In a Japanese subgroup analysis, Ito et al also 
reported a significant prolonged progression free survival (PFS) by almost 17 
months
61, 62
. 
3.4.2 Targeting angiogenesis 
 
The role of angiogenesis in tumor development has been well described and inspiring 
results from clinical trails with antiangiogenic therapies have been reported in a 
variety of tumor types
63
. NETs are among the most vascularized tumors with high 
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expression of proangiogenic factors, such as the vascular endothelial growth factor 
(VEGF) and platelet-derived growth factor (PDGF)
58, 64
. It has been reported that the 
expression level of VEGF was correlated with progression free survival (PFS) in 
low-grade neuroendocrine tumors
65
, and a high expression of PDGFRA was 
significantly correlated with shorter patients’ survival and could serve as a prognostic 
marker
66
. There are now many antiangiogenic compounds available, including the 
VEGF monoclonal antibody bevacizumab and the newer compound, VEGF-trap, 
which target the circulating VEGF, and the compounds which target the receptor 
tyrosine kinase domains of VEGFR and PDGFR, such as sunitinib, sorafenib and 
valatanib
58
. There are also endogenous angiogenesis inhibitors such as thalidomide or 
endostatin
58, 67
. In a phase II trial for patients with advanced, well-differentiated 
GI-NETs, treatment with bevacizumab (15 mg/kg every 3 weeks) in combination with 
octreotide LAR resulted in partial tumor remission in 18% of patients, and stable 
disease was achieved in 77% of the patients
68
. 18 weeks of monotherapy with 
bevacizumab achieved 30% higher progression free rates than on the PEG interferon 
arm
68
.  In a multinational, randomized, double-blind, placebo-controlled phase III 
trial of sunitinib in patients with advanced, well-differentiated pancreatic 
neuroendocrine tumors, patients treated with sunitinib (37.5 mg per day) achieved 
better progression-free survival, overall survival, and the objective response rate
69
.  
3.4.3 Targeting growth factor receptors and other parthways 
 
The expression level of EGFR in NET varies among different tumor types
70-75
. One 
study showed that the expression of EGFR and activated EGFR (p-EGFR) is more 
common in gastrointestinal carcinoid tumors compared to pancreatic endocrine 
tumors, and p-EGFR expression in the primary tumor of pancreatic NET indicated a 
worse prognosis 
73
. A small molecule inhibitor of the EGFR tyrosine kinase, gefitinib, 
has been tested in a single phase II study which included 39 pancreatic NET and 57 
carcinoids. Although tumor remissions were rare (6.5% for pancreatic NET and 2.5% 
for carcinoids), the treatment achieved minor responses and the progression-free rate 
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at 6 months were 30% and 60% respectively
58
. Furthermore, as EGFR is one of the 
upstream activators of Akt/mTOR signaling pathways, EGFR inhibitors may yield 
synergistic effects and interfere with the drug resistance in the mTOR inhibitor 
therapy. Several preclinical studies using NET cell lines and animal models have 
already shown this effect
59, 76
 which provided a rationale for clinical trails of erlotinib 
and everolimus
58
.  
IGF-1 and its receptor is frequently expressed in NETs including gastric NETs
71, 77, 78
. 
Despite a compelling preclinical rationale and promising data from a phase I trial with 
AMG 479 (a human monoclonal antibody to IGFR-1)
79
, no partial or complete 
respons was observed in a phase II study for MK-0646 (another human monoclonal 
antibody to IGFR-1)
80
. Further investigation for IGF-1R antibodies is needed and the 
combination of IGF-1R antibodies with mTOR inhibitors is currently under clinical 
trails
58
. 
Several other drugs like LX1606 (peripheral tryptophan hydroxylase inhibitor), and 
atiprimod, which targets STAT3, IL-6 and VEGF signaling pathways, are under 
investigation in clinical trails and may be promising candidates for the management of 
NETs
58
. 
 
3.5 Tumor initiating cells of neuroendocrine tumors in the 
gastrointestinal system 
Despite these many attempts for a potent therapy as described above, the response rate 
is not compelling. One explanation might be that putative tumor stem cells escape the 
treatment. 
The origin of the cells from which GEP-NETs arise is not well understood. Looking 
for the tumor initiating cells is helpful for gaining a better understanding of the 
molecular mechanisms of tumorigenesis and establishing more targeted therapies. 
Possible candidates for these tumor originating cells are the newly described epithelial 
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as well as mesenchymal stem cells.  
3.5.1 Epithelial stem cells in the gastrointestinal system 
 
“Stem cell” research has been a highlight since 1960s. These small populations of 
resident stem cells, which are characteristic for their “self-renewal” and 
“multi-potency”, are responsible for the maintenance and repair of adult tissues
81
. The 
ability to identify the stem cell populations and a better concept of their biology could 
accelerate our understanding of their role in tissue homeostasis and various diseases 
including cancer. Much effort has been invested in searching for reliable stem cell 
markers for different organs and great progress has been achieved in the 
gastrointestinal system. 
3.5.1.1 Adult epithelial stem cells in the stomach 
 
The first evidence of the existence of multipotent, self-renewing stem cells in the 
stomach from in vivo lineage tracing study was provided by Bjerknes and Cheng in 
2002 
82
. By labelling random epithelial cells in adult hemizygous ROSA26 mice, they 
were able to show the existence of functional multi-potential stem cells in the adult 
mouse gastric epithelium. The observation of LACZ-negative clones in a single-cell 
lineage also indicated the possible presence of long-lived progenitors. McDonald et al 
also demonstrated the existence of multiple adult stem cells in human gastric units in 
another separate study
83
. However, the definitive identification of these cells has been 
hampered by the lack of stem cell markers.  
In 2010
84
, Nick Barker et al reported that Lgr5
+ve
 cells, which are predominantly 
restricted to the base of adult pyloric glands, are multi-potent, self-renewing stem 
cells responsible for the long-term renewal of the gastric epithelium
84
. In their newly 
described in vitro culture system, these single Lgr5
+ve
 cells could efficiently generate 
long-lived organoids resembling the mature pyloric epithelium. These results 
indicated that Lgr5 had an important function in gastric epithelial homeostasis as it 
did in intestine and might be regarded as a unique marker of adult stem cells in the 
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distal stomach. However, the location of the Lgr5
+ve
 cells was in contrast to the 
“isthmus model”, which favors that the gastric stem cells may reside between the 
gland and the pit. This opposing view is largely based on the detection of immature, 
granule-free cells in this region and that cellular proliferation is most predominant in 
this location
85-89
. It is difficult to reconcile these two models due to the lack of 
specific markers for the isthmus population. One possible explanation could be that 
the immediate progeny of the Lgr5
+ve
 cells rapidly migrate from the base of the crypt 
to the isthmus and undergo transit amplification before the terminal differentiation
90
. 
3.5.1.2 Adult epithelial stem cells in the intestine 
 
The adult stem cells have been much better investigated in the intestine than in the 
stomach. Early genetic labelling studies in 1990s demonstrated that individual adult 
crypts originated from a single multi-potent stem cell, which is active during early 
intestinal development
81, 91, 92
. However, even today, there is still an intense debate on 
the identity of the stem cells in the intestine. The two most popular models are the 
“+4” model and the stem cell zone model. In 1965, cell tracking experiments from 
Cairnie et al predicted an epithelial stem cell pool at position 4–5, just above the 
differentiated Paneth cell compartment
93
. Later, Potten et al reported that cells at 
positions ranging from +2 to +7, but on average at +4, are radiation-sensitive and 
DNA label-retaining
94
. Later lineage tracing experiment showed that Bmi1 was 
specifically expressed in these “+4” cells 
95
. These “+4” cells are slower-cycling and 
crucial for crypt maintenance
95-97
. Molecular markers for this cell pool include Bmi1
95
, 
mTert
97, 98
, Hopx
99
, Lrig1
100
, Sox4
101
, sFrp5
102, 103
 and Dcamkl-1
104-107
. Another stem 
cell zone model represents Lgr5-expressing cells, also known as crypt base columnar 
cells (CBCs) 
108
, which cycle rapidly and are confined between Paneth cells at the 
crypt base 
109
. Lineage tracing demonstrated that these Lgr5
hi
 cells can generate all 
cell lineages of the small intestinal epithelium throughout life
109-111
. Single Lgr5
hi
 
cells cultured in vitro can also give rise to ever-growing crypt–villus organoids, which 
possess all characteristics of the epithelial tissue in living mice
112
. Prom1/CD133
113, 
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114
, Olfm4
115
, Sox9
116, 117
, Ascl2
118
 are also considered as molecular markers for the 
CBCs and similar data from the lineage tracing based on Prom1/CD133 expression 
were published
113
. Lgr5
+
 stem cells were also regarded as the cell-of-origin for 
intestinal cancer
119
. There is still quite a big debate about which cell pool represents 
the real stem cell populations. Recently there have been some studies which made 
efforts to describe the functional distinction and the interrelationship between these 
two potential “ISCs” cell pools. Tian et al showed that Bmi1-expressing cells can give 
rise to Lgr5-expressing cells after ablation of Lgr5-expressing cells, indicating a 
hierarchy of stem cells in the small intestine
96
. However, in 2012, Munoz et al 
reported that the proposed quiescent/“+4” stem cell markers Bmi1, Tert, Hopx and 
Lrig1 are robustly expressed in CBC cells
120
. Wong et al also showed in an 
independent study that Lrig1 is most highly expressed in CBC cells
121
. So the Lgr5
+
 
cells are responsible for the self-renewal of the small intestine, while another 
population of quiescent Lgr5
- 
stem cells may exist above the crypt base and serve as 
an alternative stem cell pool
96, 122
. Since it has been shown that Lgr5
+ 
cells can give 
rise to chromogranin A positive cells
96, 123
, they may be candidates for the tumor 
originating cells of the neuroendocrine tumor described in the CEA424-SV40 TAg 
transgenic mouse model. 
3.5.2 Mesenchymal stem cells 
 
Beside epithelial stem cells, there are other cell types, mesenchymal stem cells, which 
could give rise to tumors. Mesenchymal stem cells (MSCs) are a heterogeneous 
multipotent population of nonhematopoietic progenitor cells that can be isolated from 
almost all kinds of supportive stromal tissue compartments, like adipose tissue, 
umbilical cord and bone marrow
124, 125
. They can be distinguished from other cell 
types by their fibroblast like morphology, plastic adherent ability and potential of 
differentiating into adipocyte, osteoblast and chondrocyte of mesodermal lineage
125
 as 
well as cells of endodermal
126
 and neuroectodermal lineage
125
. The criterias for MSCs 
definition are still controversial due to the lack of specific markers. However, the 
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International Society for Cellular Therapy has proposed a phenotype definition for 
MSCs. As a general consensus, CD73, CD90 and CD105 should be positively 
expressed in MSCs while the expression of CD11b and CD14 (markers for monocyte 
and macrophage), CD34 (a marker for haematopoietic progenitor and endothelial cell), 
CD45 (a marker for leukocyte), CD19 and CD79a (markers for B cell) and HLA-DR 
should be negative
124, 125
. 
Recent investigations of the immunoregulatory and regenerative properties of MSCs 
have highlighted the clinical benefit of including MSCs in the therapeutic 
management. Meanwhile, more detailed studies with the purpose of identifying MSCs 
have revealed new molecular markers and led to fresh insight into the role of MSCs in 
oncogenesis. For example, ETV1, a member of the PEA3 subfamily of ETS 
transcription factors
127
, has been shown to be important for the self-renewal capacity 
of MSCs
128
. ETV1 is also found to be highly expressed in gastrointestinal stromal 
tumors (GISTs) and functions as a crucial regulator during the tumorigenesis in 
cooperation with KIT
129, 130
. These new findings revealed the possible role of MSCs in 
oncogenesis which may promote the study for tumor initiating issue. 
 
Thus, epithelial as well as mesenchymal stem cells could be the source of tumor 
originating cells in the tumor mouse model presented here. 
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4 AIM OF THE WORK 
Neuroendocrine tumors are a heterogeneous group of malignancies with an increasing 
incidence and prevalence over the past decades. Neuroendocrine phenotypes 
frequently indicate poor prognosis in some tumor types, for example prostate cancer 
and breast cancer. Since there is no real break through in the management of this kind 
of tumors, model systems are urgently needed. We have a transgenic mouse model 
where a minimal CEA promoter drives the expression of the SV40 large T Antigen. 
One mouse strain developed solid tumors in the antral region of the stomach 
spontaneously with 100% penetrance 
30
. These tumors were tentatively classified as 
adenocarcinomas when the mouse model was established. Surprisingly, gene 
expression analysis of the tumor tissue as well as cell lines derived from the tumor 
revealed neuroendocrine markers
37
. These information directing neuroendocrine 
signatures prompted us to further characterize this model with special emphasis on the 
cells of origin and test it for screening of new treatment protocols. Therefore, several 
questions were put forward: 
4.1 Is the gastric tumor developed in CEA424-SV40 T Ag transgenic mouse a 
neuroendocrine tumor? 
To confirm the neuroendocrine phenotype of the CEA424-SV40 T Ag transgenic 
mouse, further characterization of the gastric tumors developed in these mice as well 
as the established cell lines derived from the primary tumors should be performed. 
This analysis includes a more detailed characterization of neuroendocrine marker 
genes as well as hormone concentration in plasma. In addition, the expression of 
transcription factors with a role in the differentiation of neuroendocrine lineage should 
be checked both in the tumor tissue and the cell lines from the tumor. Further more, 
the proliferation status of the tumor should also be determined which is essential for 
the grading of the tumor.  
 
 
 28 
4.2 Can the tumor cell lines derived from the CEA424-SV40 T Ag gastric 
tumors be used for screening novel drugs? Are these selected novel therapies 
applicable in vivo? How is the efficiency and safety of these treatment?   
For testing novel molecularly targeted therapies, it makes sense to use the cell lines 
first to select promising candidates for in vivo study. Drugs inducing efficient 
responses will be further tested in vivo to see whether they can hamper the 
tumorigenic process, improve the survival of the tumor bearing mice and whether they 
are well tolerated. 
For testing novel therapies in a preclinical setting, the following molecular-targets 
were chosen for the work in this thesis: the molecular markers for NETs like mTOR 
and HSP90, and the targets related to the tumorigenic pathways activated by T antigen 
which induced tumor in our transgenic mice, like E2F and p53.  
 
4.3 Are there any candidates for the tumor originating cells of the gastric 
tumors developed in CEA424-SV40 T Ag transgenic mouse? 
SV40 T antigen has long been used to generate tumors under the regulation of tissue 
specific gene promoters in transgenic mice. However, the intriguing question about 
where these tumor cells come from still remains unanswered in most of these models. 
Looking for the origin of the tumor cells is not only crucial for a better understanding 
of the basic transformation steps induced by the SV40-T antigen, but also on a wider 
view for understanding the reason why the change to a neuroendocrine phenotype is 
frequently an indicator of poor prognosis in several tumors. Possible candidates for 
these tumor originating cells in the stomach are the newly described epithelial as well 
as mesenchymal stem cells.  
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5 MATERIALS AND METHODS 
5.1 Cell culture 
5.1.1  Reagents and buffers 
 
Reagents / Buffer Manufacturers 
RPMI 1640 with L-Glutamine 500 ml  Lonza, Köln, Germany 
Fetal Bovine Serum gold 500 ml PAA, Cölbe, Germany 
L-Glutamin Lonza, Köln, Germany 
Nonessential amino acids (NEAA) Lonza, Köln, Germany 
Sodium pyruvate Lonza, Köln, Germany 
 β-mercaptoethanol SERVA, Heidelberg, Germany 
Trypsin0.05%/EDTA0.02 % in PBS PAN Biotech GmbH, Germany 
Lipofectamine
®
 2000 Reagent 
Life Technologies/Invitrogen, Darmstadt, 
Germany 
Opti-MEM Reduced Serum Medium, 
GlutaMAX 
Life Technologies, Darmstadt, Germany 
PBS Biochrom AG, Berlin, Germany 
DMSO (Dimethylsμlphoxide) Sigma-Aldrich, Taufkirchen, Germany 
Trypan Blue (0.4%) Sigma-Aldrich, Taufkirchen, Germany 
Crystal violet Merck, Darmstadt, Germany 
Methanol Merck, Darmstadt, Germany 
Cell proliferation reagent WST-1 Roche, Germany 
Annexin V-FITC Kit Miltenyi Biotec, Germany 
siRNA-TAg 
Life Technologies/Invitrogen, Darmstadt, 
Germany 
esiRNA-Bmi1 Sigma-Aldrich, Taufkirchen, Germany 
Cell culture medium RPMI 1640 with L-Glutamine 500 ml + 
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Fetal Bovine Serum gold 50 ml + 
Glutamin 15 ml + 
Nonessential amino acids (NEAA) 5 ml + 
Sodium pyruvate 5 ml + 
β-mercaptoethanol 3 ul 
Cell frozen stock solution 
Cell culture medium 27.5 ml + 
DMSO 5 ml + 
Fetal Bovine Serum gold 15 ml 
 
5.1.2 Agents 
 
Agents Manufacturers 
RAD001 Novartis Pharma, Basel, Switzland 
NVP-BEZ235 Novartis Pharma, Basel, Switzland 
Paclitaxel Apotheke Klinikum Grosshadern, Germany 
Nutlin-3a Cayman Chemical, USA 
E2F inhibitor (HLM006474) Calbiochem, Germany 
HSP90 inhibitor (NW457) Calbiochem, Germany 
 
5.1.3  Cell lines 
 
Three cell lines, 424GC, mGC3, mGC8, originally established by Robert Kammerer, 
were kindly provided by Prof. Zimmermann. These cell lines were derived from 
spontaneously developing tumors of three different, 13 weeks old CEA424 SV40 TAg 
transgenic mice (C57BL/6-Tg(CEACAM5-TAg)L5496Wzm), which have been 
described previously
30, 31
.  
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5.1.4  Methods 
5.1.4.1  Cultivation of cells 
 
Cell lines were cultured in 75-cm
2
 or 175-cm
2 
flasks in an incubator at 37°C with 5% 
CO2. The humidity of the incubator was 98%. Culture medium was changed every 2-3 
days. Upon reaching 70-80% confluence, the cells were washed with sterile PBS for 2 
times and detached by typsin-EDTA solution. The cells were then resuspended with 
fresh medium and an appropriate number of cells were seeded into a new flask. 
5.1.4.2  Determination of cell number 
 
Cell suspension was mixed with an equal volume of 0.4% Trypan Blue to identify 
dead cells. The number of viable (unstained) cells was then counted in a 
hemacytometer (Neubauer advanced). 
5.1.4.3  Storage and recultivation of the cells 
5.1.4.3.1  Cell freezing 
 
Cell culture medium was removed from the cells. The cells were washed with PBS for 
2 times before trypsin/EDTA was added. The cells were resuspended with fresh 
medium and the cell number was determined. The cell suspension was centrifuged at 
300g for 5min and the supernatant was removed. The cell pellet was resuspended in 
freezing medium (10% DMSO, 35% FCS, 55% culture medium) at a concentration 
of  1-6 million/ml. This suspension was aliquoted into cryo-vials (1 ml/vial). The vials 
were kept in a -80 °C freezer for at least 24 hours before being moved to a liquid 
nitrogen tank for long-time storage. 
5.1.4.3.2  Cell recultivation 
 
Cells in the cryo-vials were shortly warmed in the 37 °C water bath for 1-2 minutes 
and then immediately transfered into to flasks filled with fresh medium prewarmed to 
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37 °C . The medium was changed the next day to avoid toxic effect of the remaining 
DMSO.  
5.1.4.4  Cell proliferation assay 
 
Cells were seeded into 96-well plate at an appropriate concentration (424GC: 2×10
4
, 
mGC3: 1.5×10
4
, mGC8: 1.5×10
4
) in 100 μl culture medium and incubated overnight 
at 37 °C to allow adherance of the cells. Drugs were suspended at twice the test 
concentrations and added in 100 μl aliquots. The cells were then further incubated at 
37 °C for 72 h. At the end of the experiment, supernatant was removed and 100 μl 
fresh medium was added into each well. For the cell proliferation assay, 10 μl WST-1 
reagent (Roche, Germany) was added into each well. The plate was incubated at 37°C 
with 5% CO2 for 4 h. The amount of formazen dye formed directly correlated with the 
number of metabolically active cells in the culture. The absorbance of the dye solution 
was measured with a microplate ELISA reader. The wave length for measuring the 
absorbance of the formazan product was 460 nm. The reference wavelength was set to 
690 nm.  
5.1.4.5  Colony formation assay 
 
Cells treated for 24 or 72 h in 12-well plate were washed with PBS twice and 
detached by typsin-EDTA solution. Then, cells were resuspended with fresh medium 
and the cell number was determined. For 424GC, cells were seeded into 6-well plate 
at a concentration of 1000 cells/well, while for mGC3 and mGC8, at 800 cells/well. 
Cultivation was performed for 3 weeks and medium was changed every 4 days during 
this time. The clones were then washed carefully with PBS twice, fixed with methanol 
for 30 minutes and stained with 0.1% crystal violet in distilled water for 30 minutes. 
Subsequently, the plates were washed with tap water twice before they were 
photographed. The clone number was counted using Image J (NIH.GOV). 
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5.1.4.6  Flow cytometry analysis for cell apoptosis 
 
Cells treated with 100 nM RAD001 or 100 nM NVP-BEZ235 for 72 h were analyzed 
by FACS. Cells incubated with culture medium were used as control. Cells were 
washed in 1× Binding Buffer and centrifuged at 300g for 10 minutes. The supernatant 
was completely removed. The cell pellet was resuspended in 100 µl of 1× Binding 
Buffer and 10 µl of Annexin V-FITC was then added per 10
6
 cells. After careful 
mixing, the cells were incubated in the dark for 15 minutes at room temperature. 
Thereafter, 5 µl of PI solution (100 µg/ml) was added immediately prior to analysis.  
5.1.4.7 siRNA/esiRNA transfection assay 
 
Appropriate number of cells were seeded into 12 well plates one day before 
transfection. On the next day, cell cultured medium was removed and 800 µl fresh 
medium was added into each well. siRNA/esiRNA was diluted in 100 µl Opti-MEM I 
and mixed gently. In a separate vial, 2 µl Lipofectamine
®
 2000 Reagent was mixed 
gently with 100 µl Opti-MEM I and incubated at room temperature for 5 minutes. 
Then the diluted siRNA/esiRNA was combined with the diluted Lipofectamine
®
 2000 
Reagent. The mixture was incubated at room temperature for another 20 minutes. 
After this incubation, 200 µl siRNA/esiRNA- Lipofectamine
®
 2000 complexes were 
added into each well. The plate was gently rocked back and forth for several times to 
allow even distribution. The cells were then incubated at 37 °C in a CO2 incubator for 
48 and 96 hours respectively before being harvested for RNA or protein samples.  
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5.2 Animal experiments 
5.2.1  Reagents and buffers 
 
Reagents / Agents Manufacturers 
Isoflurane Abbott, Wiesbaden, Germany 
RAD001/Placebo Novartis Pharma, Basel, Switzerland 
5.2.2  Animals  
 
50 days old CEA424-SV40 TAg mice were used for the in vivo experiment. The 
CEA424-SV40 TAg transgenic mice were kept and bred in Walter Brendel Centre of 
Experimental Medicine. Animals were housed under conventional conditions with 
free access to food and water. All animal work has been conducted according to 
relevant national and international guidelines. Animal studies within this work were 
registered with and accredited by the local regulatory agency (Reg. Oberbayern 
55.2-1-54-2532-47-11). 
5.2.3  Methods 
5.2.3.1  General experimental setting 
 
All mice were randomized into the respective experimental groups. 
Experiment A: To study the effect of the treatment, animals receiving RAD001 or 
placebo were sacrificed when they lost 20% of their peak weight. This was the end 
point according to the legal restriction by animal right (Reg. Oberbayern 
55.2-1-54-2532-47-11).  
Experiment B: In this experiment, animals were treated as above. In contrast to 
experiment A, all animals were sacrificed when the first control mouse started to lose 
weight.  
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5.2.3.2 Dosing 
 
Treated group: RAD001 was fed by gavage daily from day1 to day5 every week, with 
two days intervals until the end of the experiment. The dose used was 10 mg/kg (10 
ml/kg). 
Control group: Placebo was fed by gavage daily from day1 to day5 every week, with 
two days intervals until the end of the experiment. The dose used was 10 mg/kg (10 
ml/kg). 
5.2.3.3  Feeding 
5.2.3.3.1  Drug preparation  
 
RAD001 stock solution and placebo was aliquoted and stored at -20 °C in dark. 
Before feeding, one aliquot of RAD001 stock solution was thawed at room 
temperature and then diluted with distilled water to a final concentration of 1 mg/ml. 
After careful mixing on a vortex, the drug was given to mice by gavage within 1 hour 
according to the datasheet provided by Novartis. RAD001 was fed in a final volume 
of 10 μl diluted solution per gram body weight. 
5.2.3.3.2 Oral gavage procedure  
 
     
Figure 1. The feeding tubes and the oral gavage procedure 
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For feeding, a plastic tube was connected with a 0.9×0.4 cm syringe needle which was 
then fixed onto a 1 ml syringe. The length of the tube was adapted to the distance 
between the mouth and the last rib of the mouse, which indicated the position of the 
stomach. The tube was then marked at the incisors of the mouse as the point which 
should not be past during the procedure to avoid perforating the stomach. Before 
feeding, mice were lightly anesthetized with isoflurane in a covered beaker for about 
one minute to avoid violent struggle which might cause trauma to the esophagus. The 
loose skin of the neck and back of the mouse was grasped so that the mouse could not 
move its head. The tail was fixed between ring finger and little finger. The head of the 
mouse was held in vertical alignment with the esophagus. The tube was inserted 
behind the incisors in either side of the mouth and directed towards the back of the 
throat before finally went through the esophagus. Appropriate volume of the prepared 
drug was injected slowly. The color of the mouse's mucosa was monitored during the 
procedure. The tube was then pulled out gently after dosing. The mouse was put back 
into the cage and monitored for 5-10 minutes for any sign of labored breathing or 
distress. This gavage procedure was performed daily from day 1 to day 5 every week.  
5.2.3.4  Weight monitoring 
Before feeding, the weight of each mice was determined every day.  
 
5.3 RNA isolation and reverse transcription PCR 
5.3.1  Reagents and buffers 
 
Reagents / Buffer Manufacturers 
NucleoSpin RNA II kit Macherey-Nagel, Düren, Germany 
RNALater SIGMA, Missouri, USA 
Tris(2-carboxyethyl)phosphine 
hydrochloride   (TCEP-HCl) 
Thermo scientific, Rockford, USA 
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50× TAE Buffer 5 PRIME, Hamburg, Germany 
45 µM Oligo (dT)15  Roche, Mannheim, Germany 
5× First Strand Buffer 
Life Technologies/Invitrogen, 
Darmstadt, Germany 
10 mM dNTP-Mix Fermentas, Canada 
RNAse Inhibitor 5 PRIME, Hamburg, Germany 
M-MLV-RT 
Life Technologies/Invitrogen, 
Darmstadt, Germany 
10× PCR Buffer PAN Biotech, Germany 
50 mM MgCl2 PAN Biotech, Germany 
PAN-DNA-Polymerase PAN Biotech, Germany 
6× MassRuler™ DNA Loading Dye Fermentas, Canada 
MassRuler™ Express DNA Ladder, LR 
Forward, 28ng/l 
Fermentas, Canada 
Agurose Promega corporation, Madison, USA 
GelRed Bio Trend, Germany 
5.3.2 Primers 
 
Primer Sequences Annealing temperature 
Ahr-f 5’-GCGCAAGCCGGTGCAGAAAACA-3’ 
62°C 
Ahr-r 5’-ACCAGCACAAAGCCATTCAGCGCC-3’ 
Bmi1-f 5’-AGATGGCCGCTTGGCTCGCATT-3’ 
56°C 
Bmi1-r 5’-GCCATTGGCAGCATCAGCTGACG-3’ 
Dclk1-f 5’-CCGCTGGGAAGACGTCAGCCTT-3’ 
62°C 
Dclk1-r 5’-TTGGTGACTTGCCCGAGCGTGG-3’ 
Gapdh-f 5’-TGCCATTTGCAGTGGCAAAGTGG -3’ 
58°C 
Gapdh-r 5’-TTGTCATGGATGACCTTGGCCAGG -3’ 
Lgr5-f 5’-ATCAGTCAGCTACCCGCCAGTC -3’ 
60°C 
Lgr5-r 5’-CAGGCCGCTGAAACAGCTGGGT -3’ 
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Olfm4-f 5’-AGCAAGCACTGTGGGCAATTTA-3’ 
52°C 
Olfm4-r 5’-GGTTGCCTTCCCTCTCTFTFTT-3’ 
Prom1-f 5’-GCGGACCCTCTGAATTTGTTCT-3’ 
52°C 
Prom1-r 5’-CGGGCTTGTCATAACAGGATTG-3’ 
Sox9-f 5’-GCACAACGCGGAGCTCAGCA -3’ 
60°C 
Sox9-r 5’-CTGCTCAGTTCACCGATGTCC -3’ 
Tert-f 5’-TGCGCTTCATCCCCAAGCCCAA-3’ 
62°C 
Tert-r 5’-AGAGCACGCACACACGGCACAA-3’ 
Hopx-f 5’-GCCTGCCCACGCTGCAGGTTTT-3’ 
64°C 
Hopx-r 5’-CCTCGGCTGCGATGAGGCACAG-3’ 
5.3.3  Methods 
5.3.3.1  RNA isolation 
5.3.3.1.1  Tissue 
 
Tissue from mice was washed three times with ice cold PBS and cut into small pieces. 
Extra fluid on the tissue was removed with a piece of absorbent paper before the 
tisssue was immersed into RNALater. The tissue samples in RNALater were kept at 
4°C for 24 hours to allow even diffusion of the solution to the tissue and then stored at 
-20 °C for long-term storage. For RNA isolation, one piece of tissue (10 mg to 30 mg) 
was homogenized in 600 μl Lysis buffer (RA1 in NucleoSpin RNA II kit) + 24 μl 
TCEP-HCl with an auto cutting machine. The following RNA isolation steps were 
performed according to the manufacturer’s instructions of the NucleoSpin RNA II kit.  
5.3.3.1.2 Cells 
 
Cells in culture were washed with sterile PBS for 2 times and detached by 
typsin-EDTA solution. The cells were then resuspended with fresh medium and 
centrifuged at 300 g for 5 min. The supernatant was aspirated and 350 μl Lysis buffer 
RA1 (NucleoSpin RNA II kit) + 14 μl TCEP-HCl was added to each sample. The 
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following RNA isolation steps were performed according to the manufacturer’s 
instructions of the NucleoSpin RNA II kit. 
5.3.3.2  Measurement of RNA concentration 
 
A 2 μl RNA sample was mixed with 70 μl Tris-HCl buffer (10 mM, pH 8.0). The 
RNA concentration was determined by measuring the absorption at 260 nm on a 
Biophotometer (Eppendorf). 1 OD corresponds to an RNA concentration of 40 μg/ml. 
OD values at 280 nm were used for measuring protein contamination. A ratio for 
OD260/280 of 1.8-2.0 was used as an indicator of purity. RNA samples were further 
characterized on an agarose gel. 
5.3.3.3  cDNA synthesis 
 
For cDNA synthesis, 2 μg RNA was mixed with ddH2O to a final volume of 19.5μl. 
For denaturation, the samples were heated at 75 °C for 3 minutes and then transferred 
onto ice. The synthesis reaction solution was prepared according to the following 
recipe: 
Synthesis: 1×Mix (final volume: 30 μl) 
45 µM Oligo (dT)15 1.0 μl 
5×First Strand Buffer 6.0 μl 
10 mM dNTP-Mix 1.5 μl 
RNAse Inhibitor 1.0 μl 
M-MLV-RT 1.0 μl 
Denatured RNA 2 μg in 19.5 μl total volume 
The reaction was started by an incubation at 37 °C for 60 minutes and stopped by 
heating the samples to 95 °C for 10 minutes. The cDNA samples were spun for some 
seconds and stored at -80 °C. 
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5.3.3.4 Reverse transcription polymerase chain reaction (RT-PCR) 
 
The PCR reaction mixture was prepared according to the following recipe: 
PCR stock solution 1×Mix 
10 × complete reaction buffer 5 μl 
50 mM MgCl2 1.5 μl 
Forward primer (10 mM)    1 μl 
Reverse primer (10 mM)    1 μl 
10 mM dNTP-Mix 0.5 μl 
DNA-Polymerase 0.2 μl 
ddH2O 37.8 μl 
Template (cDNA) 3 μl (0.2 μg) 
Final volume: 50 μl 
The reaction mixture was prepared in PCR soft tubes of 0.5 ml. Subsequently, the 
amplification of the target sequence was carried out in a Stratagene Robocycler 
Gradient 40. The amplification was carried out for 23-35 cycles depending on the 
primers. Each cycle consists of the following individual steps:   
1. Denaturation: melting of the deoxyribonucleic acid (DNA) duplexes for 45 seconds 
at 95 °C. 
2. Primer hybridization: annealing of primers to the DNA single strands for 45 
seconds at the appropriate temperature. 
3. Elongation: synthesis of the complementary strand at 72 °C for 60 seconds. 
Before the first cycle, there was an initial 60 seconds denaturation at 95°C. At the end, 
the reaction was kept at 72 °C for 10 min to allow completion of the reactions. Then 
the PCR products were kept at 4°C. 
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5.3.3.5  Agarose gel electrophoresis 
 
The fragments of the PCR products were separated on a 2% agarose gel by 
electrophoresis. The agarose gel was prepared by dissolving 2 g agarose in 100 ml 
1×TAE buffer on a heating plate. 4 μl GelRed was added per 100 ml agarose gel . The 
comb was kept standing in the agarose-TAE solution until the gel was solid. 10 μl 
PCR products were mixed with 2 μl 6× MassRuler™ DNA Loading Dye and loaded 
onto the gel. Electrophoresis was performed at 90 V, 70mA in 1×TAE buffer for 90 
min. At the end, the DNA was visualized under UV light and photografts were taken 
for densitometry. 
 
5.4  Immunohistochemistry and immunofluorescence 
5.4.1  Reagents, buffers and antibodies 
 
Reagents / Buffer Manufacturers 
Xylene Applichem, Darmstadt, Gemany 
Ethanol  70%, 80%, 96%, 100% CLN GmbH, Niederhummel, Germany 
Paraplast Plus® Sigma-Aldrich, Taufkirchen, Germany 
Image-iT™ FX Signal Enhancer (I36933) 
Life Technologies/Invitrogen, 
Darmstadt, Germany 
PBS Biochrom AG, Berlin, Germany 
Natrum Citrate Merck, Darmstadt, Gemany 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Hydrogen peroxide 30% (H2O2) Merck, Darmstadt, Gemany 
Triton
®
 X-100 Sigma-Aldrich, Taufkirchen, Germany 
Alcian Blue Sigma-Aldrich, Taufkirchen, Germany 
Mayer’s hemalum solution  Merck, Darmstadt, Gemany 
Hoechst Sigma-Aldrich, Taufkirchen, Germany 
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Gelatin Merck, Darmstadt, Gemany 
Liquid DAB+ substrate chromogen system Dako, CA, USA 
AEC chromogen kit Sigma-Aldrich, Taufkirchen, Germany 
Kaiser’s glycerol gelatine Merck, Darmstadt, Gemany 
VectaMount Permanent Mounting Medium Vector, CA, USA 
Immunoselect Antifading Mounting 
Medium 
Dianova, Hamburg, Germany 
VECTASTAIN Elite ABC Kit  
(Rat IgG, Mouse IgG, Goat IgG )  
Vector, CA, USA 
ImmPRESS™ REAGENT. Anti-Rabbit Ig. 
Peroxidase kit 
Vector, CA, USA  
Polyclonal rabbit anti-Glucagon antibody 
(#2760)  
Cell signaling, Frankfurt, Germany 
Polyclonal rabbit anti-Bmi1 antibody 
(ab38295) 
Abcam, UK 
Polyclonal goat anti-Chr-A (C-20) antibody 
(sc-1488) 
Santa Cruz, USA 
Polyclonal rabbit anti-Chr-B (H-300) 
antibody (sc-20135) 
Santa Cruz, USA 
Polyclonal rabbit anti-Secretin antibody 
(ab8495） 
Abcam, UK 
Monoclonol mouse anti-Hydrogen 
Potassium ATPase Beta antibody (ab2866) 
Abcam, UK 
Polyclonal rabbit anti-SV40 T Ag (v-300) 
antibody (sc-20800) 
Santa Cruz, USA 
Monoclonol rat anti-Ki67 antibody (M7247) Dako, UK 
Polyclonal rabbit anti-ER81 antibody 
(ab81086) 
Abcam, UK 
Monoclonol rabbit anti-Bmi1(D42B3) 
antibody (#5856) 
Cell signaling, Frankfurt, Germany 
Phospho-S6 Ribosomal Protein 
(Ser235/236) (D57.2.2E) Rabbit antibody 
(#4858P) 
Cell signaling, Frankfurt, Germany 
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Phospho-S6 Ribosomal Protein 
(Ser240/244) (D68F8) Rabbit antibody 
(#5364P) 
Cell signaling, Frankfurt, Germany 
Alexa Fluor 488 Goat-anti-rabbit IgG (H+L)  
Life Technologies/Invitrogen, 
Darmstadt, Germany 
Alexa Fluor 546 Goat-anti-mouse IgG 
(H+L) 
Life Technologies/Invitrogen, 
Darmstadt, Germany 
Alexa Fluor 546 Goat-anti-rabbit IgG (H+L) 
Life Technologies/Invitrogen, 
Darmstadt, Germany 
Alexa Fluor 647 Chicken-anti-goat IgG 
(H+L) 
Life Technologies/Invitrogen, 
Darmstadt, Germany 
Alexa Fluor 488 Donkey-anti-rat IgG (H+L) 
Life Technologies/Invitrogen, 
Darmstadt, Germany 
5.4.2  Methods 
5.4.2.1  Preparation for tissue samples 
 
The stomachs taken from mice were opened in the minor curvature and washed 
thoroughly in PBS. The tissue was then transferred to a cork oriented with the mucosa 
layer facing up. The crimped margin was smoothed carefully with a needle. The tissue 
was fixed in 4% formaldehyde for 2 hours followed by 1 hours washing in tap running 
water. Then the tissue was dehydrated and embedded in paraffin wax. The 
dehydration protocol was listed below: 
Reagent Time 
70% Ethanol I 1 hour 
70% Ethanol II 1 hour 
96% Ethanol I 1 hour 
96% Ethanol II 1 hour 
96% Ethanol III 1 hour 
100% Ethanol I 1 hour 
100% Ethanol II 1 hour 
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100% Ethanol III 1 hour 
Xylene I 1.5 hours 
Xylene II 1.5 hours 
Paraffin I 1.5 hours 
Paraffin II 1.5 hours 
                                   Total time: 14 hours 
5.4.2.2 Protocol for immunohistochemistry 
 
Sections of 2-3 µm were generated and mounted onto Superfrost® Plus microscope 
slides. The slides were dried overnight at room temperature and then heated at 50 °C 
for 2 hours in an oven. Sections were deparaffinized in xylene, and rehydrated in a 
graded series of ethanol. Antigen retrieval was performed when necessary in boiling 
sodium citrate buffer (pH 6.0) on a heating plate for 15 min. After cooling down at 
room temperature for 30 min in the retrieval buffer, the sections were washed with 
PBS for 5 min/twice. Endogenous peroxidase was blocked by incubation with 3% 
hydrogen peroxide (H2O2) for 10 min or 0.3% H2O2 for 30 min. The sections were 
further treated with blocking solution (according to the host species of the secondary 
antibody) for 20-60 min before the primary antibody was applied. For rabbit primary 
antibodies, sections were incubated in primary antibody for 2 h followed by washing 
steps and incubation in anti-rabbit secondary antibody (ImmPRESS Anti-Rabbit Ig 
(peroxidase) Polymer Detection Kit, VECTOR) for 1 h at room temperature. For the 
other primary antibodies, the VECTASTAIN Elite ABC system (VECTASTAIN Elite 
ABC Kit: Mouse IgG, Rat IgG) was used. The sections were incubated in primary 
antibody for 0.5-2 h followed by 0.5 h of incubation with the respective biotinylated 
secondary antibody. The ABC reagent was then applied for signal amplification at 
room temperature for 0.5 h. Between the incubation steps, the slides were washed 
with PBS. Freshly prepared peroxidase substrate solution AEC (SIGMA, Germany) or 
DAB (Dako, Germany) was then added onto the sections until a desired staining 
intensity was developed. Finally, the slides were counterstained with hematoxylin and 
 
 45 
mounted in Kaiser’s glycerol gelatine or VectaMount Permanent Mounting Medium.  
 
5.4.2.3  Protocol for immunofluorescence on tissue paraffin sections 
 
Sections were deparaffinized in xylene, and rehydrated in a graded series of ethanol. 
Antigen retrieval was the same as for immunohistochemistry. Image-iT ™ FX Signal 
Enhancer (I36933) was then applied to the sections for blocking (room temperature, 
30min). After thoroughly washing with PBS, the sections were incubated with a 
single primary antibody or two mixed primary antibodies at room temperature for 2 h. 
After washing with PBS, the sections were incubated with the appropriate secondary 
antibodies for 1 h at RT. Slides were washed, counterstained with Hoechst 33342 and 
mounted with Immunoselect Antifading Mounting Medium. 
5.4.2.4  Protocol for immunofluorescence on cells 
 
For staining cells, gelatin coated coverslips were used. 13mm coverslips were put into 
24-well-plate and incubated with 1.5% gelatin for 20 min at 4 °C. Appropriate 
number of cells were seeded into the wells and cultured in medium for 24-48 hours. 
Prior to staining, cells were fixed with 2% formaldehyde for 2 min followed by 4% 
formaldehyde for 10 min at room temperature. After the wash step with PBS, cells 
were permeabilized with 0.25% Triton
®
 X-100 diluted in PBS for 10 min. The 
coverslips were then washed with PBS, and transferred onto slides wrapped with 
parafilm. Appropriate serum (according to the species that the secondary antibody 
was raised in) was used for blocking for 30-60 min at room temperature. Cells were 
then incubated with the primary antibody diluted in 1% BSA (in PBST) in a 
humidified chamber for 2 h at room temperature. The excess solution was decanted 
carefully and the cells were washed three times with PBS for 5 min each. Then, cells 
were incubated with the secondary antibody in the dark for 1 h at room temperature. 
The wash step was repeated twice before Hoechst 33342 staining and the cells were 
finally mounted with Immunoselect Antifading Mounting Medium by putting the 
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coverslips inversely on new slides. 
 
5.5  ELISA 
5.5.1  Materials 
 
ELISA Kit Manufacturers 
Secretin ELISA USCNK, Wuhan, China 
Serotonin ELISA IBL, Hamburg, Germany 
5.5.2  ELISA protocol 
5.5.2.1  Plasma preparation 
 
Whole blood from 100-day old CEA424-SV40 TAg mice supplemented with EDTA 
was centrifuged at 1500 g at 4 °C for 15 min. The supernatant was aliquoted and 
stored at -20 °C. 
5.5.2.2 ELISA for serotonin 
 
Serotonin concentrations were measured in EDTA plasma by a competition ELISA 
(IBL, Hamburg, Germany) according to the manufacture’s protocol. Briefly, the 
plasma samples were first acylated by mixing 50 μl plasma sample with 100 μl assay 
buffer in a glass test tube. 25 μl of the acylation reagent was then added and the tube 
was incubated at 37 °C in a waterbath for 15 min. Thereafter, 1 ml assay buffer was 
added into the tube and all the tubes were centrifuged at 1500 g for 10 min. After 
acylation, 50 μl of each standard, acylated control and acylated plasma samples were 
pipetted into the respective wells of the microtiter plate. 50 μl of biotinylated 
serotonin was added into each well, and 50 μl of serotonin antiserum was then added. 
The plate was covered with adhesive foil and shaked carefully. Finally, the plate was 
incubated overnight at 4 °C. On the second day, the plate was washed three times with 
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250 μl wash buffer and 150 μl freshly prepared enzyme conjugate was added into 
each well. The plate was incubated 60 min at room temperature on a shaker. After the 
washing step, 200 μl freshly prepared PNPP (p-nitrophenyl phosphate) substrate 
solution was added into each well. The plate was incubated for 30 min at room 
temperature on a shaker before 50 μl PNPP stop solution was added. Finally, the 
optical density was measured at 405 nm with a microplate ELISA reader. 
5.5.2.3  ELISA for secretin 
 
The ELISA for secretin was performed according to the manufacturer’s instructions 
(USCNK, China) given for a direct ELISA. Briefly, 100 μl of standard, blank and 
samples were added into the appropriate wells and the plate was incubated at 37 °C 
for 2 h. Then the solution was removed and 100 μl of detection reagent A was added 
into each well. The plate was incubated at 37 °C for 1 h. After the washing step, 100 
μl of detection reagent B was added into each well. The plate was incubated for 
another 0.5 h at 37 °C. 90 μl of substrate solution was added into each well after the 
washing step, and plate was incubated for 25 min at 37 °C in dark. Finally, 50 μl stop 
solution was added and the absorption was immediately measured at 450 nm on a 
microplate ELISA reader. 
 
5.6  Western blot 
5.6.1  Reagents and buffers 
 
Reagents Manufacturers 
Roti-Load1 4x Konz Roth, Karlsruhe, Germany 
Tris Base Sigma, USA 
HEPES Applicam, Germany 
SDS SERVA, USA 
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Methanol Merck, Darmstadt, Germany 
6-aminocaproic acid Sigma-Aldrich, Taufkirchen, Germany 
Tween20 Sigma-Aldrich, Taufkirchen, Germany 
Non-fat dry milk Bio-Rad, München, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Supersignal West Femto Maximum 
Sensitivity Substrate 
Thermo Scientific, USA 
PageRuler prestained protein ladder Thermo Scientific, USA 
Bio-Rad protein assay dye reagent Bio-Rad, München, Germany 
PhosphoSafe Extraction Reagent Novagen, Germany 
Complete, Mini (protease inhibitor) Roche, Germany 
Monoclonol rabbit anti-Bmi1(D42B3) 
antibody (#5856) 
Cell signaling, Frankfurt, Germany 
Polyclonal rabbit anti-actin antibody 
(sc-1616-R) 
Santa Cruz, USA 
Monoclonol rabbit anti-NeuroD (D35G2) 
antibody (#54373) 
Cell signaling, Frankfurt, Germany 
Polyclonal rabbit anti-NKX2-2 antibody Aviva Systems Biology, USA 
Polyclonal rabbit 
anti-phospho-Akt(Thr308) antibody 
(#9275) 
Cell signaling, Frankfurt, Germany 
Polyclonal rabbit anti-Akt antibody 
(#9272) 
Cell signaling, Frankfurt, Germany 
Phospho-p70S6 Kinase (Thr389) 
(108D2) Rabbit mAb (#9234P) 
Cell signaling, Frankfurt, Germany 
p70S6 Kinase (49D7) Rabbit mAb 
(#2708P) 
Cell signaling, Frankfurt, Germany 
4EBP1 (#9644P) Cell signaling, Frankfurt, Germany 
Phospho-4EBP1(#2855P) Cell signaling, Frankfurt, Germany 
Anti-rabbit IgG, HRP-linked Antibody 
(#7074) 
Cell signaling, Frankfurt, Germany 
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Buffers Manufacturers 
10× Tris-HEPES-SDS Running buffer 
Tris Base               121 g 
HEPES                 238 g 
SDS                   10 g 
Add H2O to             1000 ml 
Anode Buffer I   300mM Tris, pH 10.4 
Tris base               18.15 g 
Methanol              100 ml 
Add water to            500 ml 
Anode Buffer II  25mM Tris, pH 10.4 
Tris base               1.52 g 
Methanol               100 ml 
Add water to            500 ml 
Cathode Buffer   25mM Tris, pH 7.6 
6-aminocaproic acid      2.6 g 
Methanol               100 ml 
Add water to            500 ml 
PBST 0.1% Tween20 in PBS 
Blocking buffer 5% non-fat milk in PBST 
Primary antibody diluent 5% BSA in PBST 
Secondary antibody diluent 5% non-fat milk in PBST 
5.6.2  Methods 
5.6.2.1  Cell lysate preparation 
 
Cells in 10 cm dish were taken from the incubator. The supernatant was discarded and 
the cells were washed with PBS twice. PBS was then carefully and completely 
removed. Lysis buffer (PhosphoSafe™ Extraction Reagent) was added directly into 
the well and the plate was incubated at room temperature for 5 min. Cell lysate was 
scraped off the plate and transfered to a tube before being incubated on ice for another 
30 min. The cell lysate was finally centrifuged at 16,000 g at 4 °C for 10 min. The 
supernatant was aliquoted and stored at -80 °C.  
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5.6.2.2 Protein concentration measurement 
 
Protein concentrations were measured with the Bio-Rad Protein Assay (Bradford 
Assay). A serially diluted ovalbumin solution (10 g/ml) was used as a standard. 5 μl 
of protein lysate was mixed with 395 μl PBS and 100 μl Bio-Rad reagent in a clean 
and dry eppendorf tube. Samples were added in duplicate into a 96-well plate at 200μl 
per well. The plate was incubated at room temperature for 10 min before the 
absorbance was measured at 595 nm with a microplate reader. 
5.6.2.3  Western-blot protocol 
5.6.2.3.1  Gel running 
 
The cell lysates were mixed with loading buffer (3 volumes of sample + 1 volume of 
Roti-load1), boiled at 95 °C for 5 min and centrifuged at 16,000 g at 4 °C for 5 min. 
The samples were then applied on to 8-16% polyacrylamide gels. 6 μl marker (Page 
Ruler) was loaded as molecular weight standard. The running condition was 20 mA 
for 120-150 min at RT 
5.6.2.3.2  Transfer 
 
After separation, proteins were transferred to a nitrocellulose membrane in a semidry 
transfer chamber (LKB, Sweden). Before transfer, the membrane was briefly washed 
in distilled water and then immersed in Anode Buffer II for several minutes. The 
transfer took place in a semidry transfer unit at a constant flow of 55 mA for 120 min 
at RT. 
Transfer structure:   
     Cover plate (cathode plate) 
Nine layers of gel blotting paper from Cathode Buffer       
SDS-polyacrylamide gel  
nitrocellulose membrane 
Three layers of gel blotting paper from Anode Buffer II 
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Six layers of gel blotting paper from Anode Buffer I                   
     Bottom plate (anode plate) 
5.6.2.3.3  Blotting 
 
After transfer, the nitrocellulose membrane was washed in PBST for 5min on a shaker 
and then transferred to blocking buffer (5% non-fat milk in PBST). The blocking 
membrane was rocked on a shaker for 1 hour at room temperature. Subsequently, the 
membrane was incubated with the primary antibodies overnight at 4 °C on a rotating 
platform. The primary antibodies were diluted with 5% bovine serum albumin in 
PBST.  
The membrane was washed in PBST for 5 min  3 and then incubated in the 
corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 
hour at room temperature. Finally, the membrane was washed again three times for 5 
min with PBST buffer. The detection of the HRP coupled antibodies was carried out 
with SuperSignal
®
 West Femto Maximum Sensitivity Substrate. 0.5-1 ml working 
solution was added to each membrane in a plastic wrap. The signal was detected with 
a Hamamatsu Aequoria system (Hamamatsu Photonics, Herrsching, Germany). 
 
5.7  Statistical analysis 
Statistical significance was assessed by comparing median values using the 
non-parametric Mann-Whitney-U test for independent samples and t-test for random 
samples (Sigma plot 10.0). P values <0.05 were considered significant. For in vivo 
experiment, the sample size was calculated for stark effects and a p <0.05 value was 
calculated with Sigma plot 10.0. 
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6 RESULTS 
6.1 Phenotypical characterization of CEA424-SV40 TAg gastric 
tumors 
6.1.1 Tumor development in the antral region of stomach 
 
The expression of SV40 TAg was detected by immunohistochemistry on sections 
from the stomachs of CEA424-SV40 TAg mice to identify the tumor cells. As shown 
in Figure 2, tumor cells can already be observed in the pyloric region in 38 days old 
CEA424-SV40 TAg transgenic mice. At that time, these tumor lesions are small and 
multifocal, which then gradually grow into extended tumors invading the whole 
mucosa layer (Figure 2 and 3).  
 
 
Figure 2. Immunohistochemistry for SV40-TAg in the antral region of the 
stomach. Tissue sections from day-38, day-43 and day-92 CEA424-SV40 TAg 
transgenic mice were used for staining. Scale bars: 50µm. 
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Figure 3. Tumors developed in the antral region of the stomach. a) Anti-SV40 
TAg immunohistochemical staining in the stomachs of 90-100 days old 
CEA424-SV40 TAg transgenic mice. Scale bars: 50µm. b) Macroscopic picture of the 
tumor in the antral region of the stomach. c) Enlarged gall bladder. 
 
At an age around 90 days, these CEA424-SV40 TAg mice start to lose weight and 
become moribund probably because of undernourishment due to pyloric stenosis by 
the tumor mass. In Figure 4, the weight curves of four CEA424-SV40 TAg mice are 
shown. The monitoring started on day 50 and ended when the mice lost 20% of their 
peak weight. At that time, the mice were sacrificed according to the legal restriction. 
Besides, increased size of the duodenum and cecum, as well as a high frequncy of 
enlarged gall bladder were also observed in mice over 90 days old (Figure 3).  
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6.1.2 The proliferative status of CEA424-SV40 TAg gastric tumors 
 
In order to investigate the proliferative status of tumors developing in the stomach of 
CEA424-SV40 TAg transgenic mouse, double immunofluorescent staining was 
carried out on stomach sections from 92-95 days old CEA424-SV40 TAg transgenic 
mice to detect the expression of SV40 TAg together with Ki-67. The Ki-67 protein is 
present in cells in the active cell cycle and is therefore used as a maker for cellular  
proliferation. Staining showed a high frequency of Ki-67 positive rate in the tumor 
area as shown in Figure 5. To further quantify the Ki-67 index of the tumor area, 
tumor tissue from four CEA424-SV40 TAg transgenic mice was examined for Ki-67 
expression by immunohistochemistry (Figure 6). Serial-sections were used for SV40 
TAg staining to confirm the tumor area. The Ki-67 index was evaluated in several 
randomly selected 400 magnification tumor areas for each mouse. The average 
Ki-67 index (Ki-67 positive nuclei/all nuclei) of the four examined CEA424-SV40 
TAg transgenic mice was 59.6812.27%. This shows a quite impressive proliferation 
rate, which indicates that the tumors developed in CEA424-SV40 TAg transgenic 
mice are of high grade proliferation. 
 
Figure 4. Weight curves of 
CEA424-SV40 TAg transgenic 
mice. Weight curves of four 
individual CEA424-SV40 TAg 
transgenic mice are shown. Data 
are given as percentage of the 
weight on day 90, when most of 
the animals reached their peak 
weight. 
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Figure 5. Double staining for SV40 TAg and Ki-67 in the antral region of the 
stomach. a, d: SV40 TAg: red (Alexa-546); b, e: Ki-67: green (Alexa-488); c, f: 
Merged images from Alexa-546 + Alexa-488 + Hoechst 33342. Images of 400 
magnifications are shown. 
 
Figure 6. Immunohistochemistry for Ki-67 on stomachs of CEA424-SV40 TAg 
transgenic mice. The numbers represent individual mice. Scale bars: 50µm. 
 
6.1.3 Expression analysis of neuroendocrine markers in the CEA424-SV40 TAg 
gastric tumor 
 
One of the distinct characteristics of neuroendocrine tumors (NETs) is the secretion of 
various peptides and neuroamines. Molecular markers identified for NETs include the 
hormones secreted by tumor cells, like serotonin, secretin and glucagon, and the 
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proteins which have important roles in the biosynthesis or secretion of these hormones, 
like tryptophan hydroxylase 1 and the chromogranin family.  
Previously, transcriptome analysis of RNA from antral tumors of 90 days old 
CEA424-SV40 TAg transgenic mice was performed. Only probe sets exhibiting a 
fluorescence of >100 (RFU) were considered as positive in this assay. Genes 
characteristic for neuroendocrine lineage were found to be highly up-regulated when 
compared with the normal antral tissue from non-transgenic mice of the same age 
(Figure 7). Proteins encoded by these genes include tryptophan hydroxylase 1, which 
is an enzyme involved in the synthesis of the neurotransmitter serotonin, hormones 
like secretin and glucagon, and proteins from the chromogranin family. Additional 
transcriptome analysis of RNA from 424GC, one of the cell lines derived from the 
CEA424-SV40 TAg gastric tumor, was also performed. As shown in Figure 8, the 
genes mentioned above were also highly expressed. Based on these observations, we 
asked whether the up-regulation of neuroendocrine gene expression could translate 
into functional proteins. 
 
 
Figure 7. Up-regulation of selected genes in the tumor tissue of 90-day-old 
CEA424-SV40 TAg mice. A list of highly up-regulated genes characteristic for 
neuroendocrine lineage is shown. Data are shown as fold change (tumor tissue/ 
normal antral tissue). Chgb: chromogranin B; Tph1: tryptophan hydroxylase 1; Calca: 
calcitonin; Gcg: glucagon; Scg2: secretogranin II (chromogranin C); Sct: secretin. 
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Figure 8. Expression level of selected genes in the cell line 424GC. Sct: secretin; 
Chgb: chromogranin B; Tph1: tryptophan hydroxylase 1; Chga: chromogranin A; Gcg: 
glucagon. 
 
6.1.3.1 Immunohistochemistry for chromogranin B in the gastric tumors of 30, 
60 and 90 days old CEA424-SV40 TAg transgenic mouse 
 
Chromogranin B, a member of the chromogranin family, is a 33-amino acid 
neuropeptide derived from Scg-1. The expression of chromogranin B has been 
documented in various human neuroendocrine tumors from the gastroenteropancreatic 
system including carcinoid, gastrinoma, glucagonoma and insulinoma
131
. 
Immunoreactivity for chromogranin B can also be detected in pheochromocytoma, 
carcinoid of liver and lung, and many types of neuroendocrine tumor from the anterior 
pituitary
131
. Initially, genome-wide expression analysis was performed with RNA 
from the antral region of the transgenic mice by microarray. The expression level of 
chromogranin B was found to be nearly 200 times higher in the tumor tissue than in 
the tissue from the same region of non-transgenic mice (Figure 7). Thus, we further 
confirmed the expression of chromogranin B in the tumor area on stomach sections 
from 30, 60 and 90 days old mice by immunohistochemistry. As shown in Figure 9, 
intensive cytoplasmic staining could be found in the tumor areas at all three time 
points. The expression pattern of chromogranin B in the tumor area overlapped with 
the staining for SV40 TAg, which meant that the tumor cells clearly produced 
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chromogranin B. 
 
Figure 9. Immunohistochemistry for chromogranin B on stomachs of 30, 60 and 
90 days old CEA424-SV40 TAg transgenic mice. Scale bars: 50µm. 
 
6.1.3.2 Double labeling of chromogranin A and SV40-TAg in the gastric tumors 
of young CEA424-SV40 TAg transgenic mice 
 
Chromogranin A is another member of the granin family of secretory proteins. 
Although first being isolated from chromaffin cells of the adrenal medulla, it is now 
believed to be located in secretory vesicles present throughout the neuroendocrine 
system and in various neurons
131-133
. Chromogranin A is also considered to be one of 
the most sensitive markers for biochemical diagnosis and surveillance of gastric 
neuroendocrine tumors
134
 (NCCN guidelines 2011). Thus, the expression of 
chromogranin A in the tumor area was examined. Double immunofluorescent labeling 
directed at SV40 TAg and chromogranin A was carried out on stomach sections from 
young CEA424-SV40 TAg transgenic mice. Co-expression of SV40-T antigen and 
chromogranin A was observed in some tumor areas. The detection of chromogranin A 
expression in tumor cells indicated neuroendocrine signature at early time points of 
the tumor development (Figure 10). 
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Figure 10. Double staining for SV40 TAg and chromogranin A on stomach of a 
38 days old CEA424-SV40 TAg transgenic mouse. Chromogranin A: yellow 
(Alexa-647); SV40 TAg: red (Alexa-546); DNA: blue (Hoechst 33342). Images of 
400 magnifications are shown.  
6.1.3.3 Detection of glucagon expression in the gastric tumors of 90 days old 
CEA424-SV40 TAg transgenic mice 
 
Glucagon is a peptide hormone secreted by A cells in the pancreas which can raise 
blood glucose levels by promoting gluconeogenesis and glycogenolysis. Abnormally 
elevated level of glucagon is a predominant clinical sign for glucagonoma which may 
occur alone or together with multiple endocrine neoplasia type 1. Double staining for 
SV40 TAg and glucagon was applied to mGC3, a cell line derived from the tumor. As 
shown in Figure 11, the nuclei of these tumor cells were positively stained by SV40 
TAg while glucagon was expressed in the cytoplasm.  
 
Figure 11. Immunofluorescent staining for SV40 TAg and glucagon in cell line 
mGC3. SV40 TAg: red (Alexa-546); glucagon: green (Alexa-488). Images of 400 
magnifications are shown. 
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In addition, stomach sections from 90-100 days old CEA424-SV40 TAg transgenic 
mice (n=7) were used for immunohistochemistry to detect the local distribution of 
glucagon. As shown in Figure 12, numerous glucagon positive cells were observed in 
the tumor areas.  
 
Figure 12. Immunohistochemistry for glucagon in the gastric tumors of 
CEA424-SV40 TAg transgenic mice. Staining images from three individual mice are 
shown. Scale bars: 50µm. 
 
6.1.3.4 Detection of secretin expression in the gastric tumors of CEA424-SV40 
TAg transgenic mice 
 
Secretin is a hormone that controls secretions into the duodenum. It is normally 
produced by the S cells of the duodenum which belong to the diffuse neuroendocrine 
system of the gut. In the microarray analysis, the expression level of secretin was 
highly elevated (fold change: 68.9) in the tumor tissue when compared with the 
normal antral tissue (Figure 7). It was also highly expressed in tumor derived cell line 
424GC as shown in Figure 8. To further confirm its overexpression in the 
CEA424-SV40 TAg gastric tumors, immunohistochemical staining for secretin was 
applied to stomach sections from transgenic mice over 90 days old. As shown in 
Figure 13, the tumor areas were intensively stained with the anti-secretin antibody. 
Double immunofluorescent staining for secretin and SV40 TAg revealed secretin 
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positive tumor cells (Figure 14).  
 
Figure 13. Immunohistochemistry for secretin in stomach of a 92 days old 
CEA424-SV40 TAg transgenic mouse. Left: secretin; right: negative control. In the 
lower part, an enlargement of the area from the upper picture is shown. Scale bars: 
100µm. 
 
 
Figure 14. Double staining for SV40 TAg and secretin in stomach of a 92 days 
old CEA424-SV40 TAg transgenic mouse. SV40 TAg: red (Alexa-546); secretin: 
green (Alexa-488); DNA: blue (Hoechst33342). Images of 400 magnifications are 
shown.  
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Elevated hormone concentration in the blood is typical for patients with functional 
NETs. As the tumor cells highly expressed secretin, the question was whether this 
hormone was elevated in the blood of tumor bearing mice. Thus, whole blood was 
taken from 90 days old CEA424-SV40 TAg transgenic mice and non-transgenic mice, 
and secretin concentration was measured by a specific ELISA. As shown in Figure 15, 
the hormone concentration of secretin in CEA424-SV40 TAg transgenic mice was 
significantly elevated when compared with the normal mice (CEA424-SV40 TAg 
transgenic mice: 23251094 pg/ml, control mice: 186.418.9 pg/ml, p<0.05).  
 
 
One of the consequences of high secretin level in the blood could be the reduction of 
acid output of the stomach because secretin functions as a feedback inhibitor of 
gastric acid secretion. Since the titration of the gastric acid output in mice is highly 
complicated, we used the number of acid producing cells as a surrogate marker for 
the acid output. Therefore, the number of H
+
-K
+
-ATPase positive cells was checked. 
Stomachs from five normal mice and five CEA424-SV40 TAg transgenic mice were 
used for H
+
-K
+
-ATPase staining. For each mouse, twelve 400 magnification fields 
were randomly selected for H
+
-K
+
-ATPase positive cell counting. As shown in Figure 
16, the number of H
+
-K
+
-ATPase positive cells in the stomachs of CEA424-SV40 
TAg transgenic mice was significantly reduced when compared with normal mice 
(normal mice: 202.455.34; CEA424-SV40 TAg transgenic mice: 164.0212.95; * 
p<0.0005), which indicated a suppression of acid output in the stomachs of the 
Figure 15. ELISA analysis of 
secretin level in the plasma of 
90-day-old CEA424-SV40 TAg 
mice and non-transgenic mice. 
T-mice: CEA424-SV40 TAg 
transgenic mice; n=4 in each 
group; * p<0.05. 
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transgenic mice. 
 
Figure 16. Analysis of H
+
-K
+
-ATPase expression in CEA424-SV40 TAg 
transgenic mice. a) Immunohistochemistry for H
+
-K
+
-ATPase in CEA424-SV40 
TAg transgenic mice and normal mice. Scale bars: 50µm. b) Number of 
H
+
-K
+
-ATPase positive cells in the stomach of EA424-SV40 TAg transgenic mice 
and normal mice. n=5 in each group, * p<0.0005 
 
6.1.3.5 Serotonin concentration in the plasma of 90-day-old CEA424-SV40 TAg 
mice. 
 
Serotonin, also known as 5-hydroxytryptamine (5-HT), is a neurotransmitter. 
Hypersecretion of serotonin can lead to the carcinoid syndrome. In clinical practice, it 
is considered as a biomarker for disease mornitoring (NCCN Guidelines Version 
1.2011). According to the transcriptome analysis, both the tumor tissue and isolated 
cell lines highly expressed mRNA for tryptophan hydroxylase 1 (Tph1). As Tph1 is 
the rate limiting enzyme for the biosynthesis of serotonin, we expected an elevated 
hormone level for serotonin in the blood. Thus, whole blood was taken from six 
90-day-old CEA424-SV40 TAg mice and non transgenic mice. EDTA plasma was 
used for measuring the hormone concentration by ELISA. As shown in Figure 17, 
dramatically elevated concentrations of serotonin in the plasma of the transgenic mice 
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were detected when compared to normal mice (CEA424-SV40 TAg transgenic mice: 
50589 ng/ml, control mice: 27.88.9 ng/ml, p<0.05). This confirmed that the Tph1 
gene was active which led to a high serotonin response. 
 
 
 
6.1.4 Expression analysis of transcription factors with a role in neuroendocrine 
cell differentiation.  
 
Results presented above gave a clear indication that the CEA424-SV40 TAg 
transgenic mice develped a neuroendocrine tumor in the antrum with severe 
consequences. We then asked whether specific transcription factors drive the tumor 
development. The crucial steps of the neuro/enteroendocrine cell differentiation 
process are controlled by the sequential expression of three basic helix-loop-helix 
transcription factors, Math1, Neurogenin3 and NeuroD, according to the current 
model of neuro/enteroendocrine cell differentiation
135
. While Math1 is an early 
transcription factor, both NeuroD and Nkx2.2 are believed to play a role in later 
events in the differentiation which confine the cells to an neuro/enteroendocrine cell 
fate
135
. In our former microarray analysis, the expression levels of NeuroD and 
Nkx2.2 were significantly up-regulated in day-90 CEA424-SV40 TAg tumors 
compared to normal antral tissue. To confirm their overexpression also at protein level, 
western blot was performed. Protein was isolated from the CEA424-SV40 TAg 
gastric tumor in the antral region (from a 85 days old mouse) as well as 3 cell lines 
Figure 17. ELISA analysis for 
serotonin concentration in the 
plasma of 90 days old 
CEA424-SV40 TAg mice and 
non-transgenic mice. T-mice: 
CEA424-SV40 TAg  transgenic 
mice; n=6 in each group, * 
p<0.05. 
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(424GC, mGC3, mGC8) derived from the primary tumors. Cell line End3, which is an 
endothelioma cell line, served as a negative control. As shown in Figure 18, all the 
three cell lines strongly expressed NeuroD and Nkx2.2. Nkx2.2 was also highly 
expressed in the tumor tissue. The expression level of NeuroD in the tumor tissue was 
lower, but still detectable. Thus, important transcription factors were found in tumor 
tissue and isolated cell lines which can explain the differentiation of the tumor cells. 
 
 
Figure 18. Western blot for transcription factors NeuroD and Nkx2.2 in tumor 
tissue and cell line 424GC, mGC3, mGC8. Cell line End3 was used as a negative 
control. NeuroD and Nkx2.2 proteins were detected at 49 kDa and 30 kDa, 
respectively.  
 
6.1.5 Summary for the characterization of the tumor 
 
Data from this part demonstrate that the CEA424-SV40 TAg transgenic mice 
develope solid tumors in the antral region of the stomach which are of high 
proliferative capacity. The CEA424-SV40 TAg gastric tumors express several 
neuroendocrine markers including chromogranin A, chromogranin B, secretin and 
glucagon. Dramatically elevated hormone levels of serotonin and secretin in the 
plasma of the transgenic mice prove that the up-regulated gene expression translates 
into functional consequences. Furthermore, the CEA424-SV40 TAg gastric tumor and 
tumor derived cell lines express transcription factors with a role in neuroendocrine 
cell differentiation. All these information indicate that CEA424-SV40 TAg gastric 
tumors exhibit a neuroendocrine phenotype which makes the CEA424-SV40 TAg 
transgenic mouse a clinically relevant model for gastric neuroendocrine tumors. 
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6.2 Testing of molecularly targeted therapies on CEA424-SV40 TAg 
transgenic mouse model system 
6.2.1 In vitro screening of molecularly targeted therapies for gastric 
neuroendocrine tumor 
 
For testing novel therapies in vitro, drugs targeting molecular markers for NETs were 
chosen. mTOR is a serine/threonine protein kinase which is essential for protein 
translation, cell growth, metabolism and autophagy
55-57
. Aberrant activation of 
PI3K-Akt-mTOR pathway has been identified as one of the mechanisms for the 
tumorigenesis of NETs. HSP90 is an ATP-dependent molecular chaperone frequently 
exploited by tumor cells to overcome environmental perturbations during oncogenic 
transformation
136
. Recently, it has also been included as a molecular marker for 
neuroendocrine (carcinoid) tumors
72
. Thus, two mTOR inhibitors RAD001 
(everolimus) and NVP-BEZ235 as well as one HSP90 inhibitor NW457 were selected 
for screening anti-tumor effects.  
Besides, drugs that target specific pathways activated by the TAg were also included. 
Two major targets of the transformation induced by TAg are Rb1 and Trp53 tumor 
suppressors. Inactivation of Rb1 sets free host E2F transcription factors which leads to 
the transcriptional activation of E2F-regulated S-phase genes
29
. Mdm2, a cellular 
antagonist of p53, is responsible for the degradation of p53 and may take an essential 
role in a trimeric TAg-p53-Mdm2 complex during the transformation
24
. So it makes 
sense to try agents targeting these two pathways which may take a major role in the 
tumorigenesis of the CEA424-SV40 TAg gastric tumors. Thus, Nutlin-3, which can 
stabilize p53 by inhibiting the interaction between Mdm2 and p53, and E2F inhibitor 
HLM006474 were selected for testing. Besides, the mitotic inhibitor paclitaxel was 
also used as an agent for traditional chemotherapy. 
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6.2.1.1 Cell proliferation assay 
 
As a first step, the drugs described above were tested for their ability to inhibit cell 
proliferation. Three cell lines derived from the primary CEA424-SV40 TAg gastric 
tumors (424GC, mGC3 and mGC8) were used throughout the experiment. Cells were 
incubated with normal culture medium and different concentrations of the drugs in 
96-well plate for 72 hours. Cell viability was estimated by WST-1 assay. As shown in 
Figure 19, all the drugs could dose dependently inhibit the proliferation of all the three 
cell lines. The concentration range for GI50 from several experiments was listed in 
Table 1. 
 
 
Figure 19. Cell proliferation after 72 hours treatment. WST-1 absorption was 
tested after 72 hours treatment. The experiments were performed in triplicate.  
 
 
RAD001 
(nM) 
NVP-BEZ23 
 (nM) 
NW457 
(nM) 
HLM006474 
 (M) 
Nutlin  
(M) 
Paclitaxel 
(g/ml) 
424GC 1-10 100-1000 100-200 20-30 6-8 1-10 
mGC3 0.1-1 10-100 10-100 5-10 2-4 0.01-0.1 
mGC8 0.1-1 10-100 10-100 10-20 2-4 0.01-0.1 
Table 1. The concentration range for GI50. The GI50 for each drug tested was shown 
in concentration range. 
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6.2.1.2  Colony formation with mTOR inhibitors (RAD001 and NVP-BEZ235) 
and Paclitaxel 
 
Another way to confirm the inhibitory effect of these drugs on cell proliferation is the 
colony formation assay. In contrast to the WST-1 assay which showed transient effect 
of the drugs, colony formation could display a long term effect of the treatment on the 
cell lines. mTOR inhibitors (RAD001 and NVP-BEZ235) and paclitaxel were selected 
in this assay. Cell lines were treated with 100 nM RAD001, 100 nM NVP-BEZ235 
and 1 g/ml Paclitaxel for 24 and 72 hours in 12-well plates before being seeded into 
6-well plates for colony formation. Cells without any treatment were used as control. 
After 3 weeks cultivation, colonies formed were fixed by methanol and stained with 
crystal violet. For all the three drugs, 72 hours treatment could significantly inhibit the 
ability to form colonies in all the three cell lines. In Figure 20, an example from each 
group is shown. A significant decrease of the colony number could be observed in the 
treated group when compared to the control group as shown in Figure 21. This effect 
could even be observed after a short 24 hours treatment in 424GC and mGC3, while 
in mGC8, the inhibitory effect from RAD001 was not significant. 
 
Figure 20. Colony formation assay with cells treated for 72 hours. Colonies 
stained with crystal violet in 6-well plate are shown for each treated group from the 
three cell lines 424GC, mGC3, mGC8. A significant reduced colony number could be 
observed in the treated group. 
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Figure 21. Colonies formed by cells treated for 24 (first row) and 72 hours 
(second row). Colony numbers from each group are shown. (n= 6 for each group, * 
p<0.05, treated group compared with control group) 
 
6.2.1.3  Induction of cell apoptosis by mTOR inhibitors RAD001 and 
NVP-BEZ235 
 
To find out whether the mTOR inhibitors can induce apoptosis in the cell lines, FACS 
analysis was applied on cells treated with 100 nM RAD001 or 100 nM NVP-BEZ235 
for 72 hours with Annexin V-FITC Kit. Cells without treatment were used as control. 
As shown in Figure 22, treated cells displayed higher early apoptotic rate. The 
induction of cell apoptosis may be one of the mechanisms involved in the anti-tumor 
effects of mTOR inhibitors. 
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Figure 22. Apoptotic rate analyzed by flow cytometry on cells treated with 100 
nM RAD001 or 100 nM NVP-BEZ235 for 72h. Cells without treatment were used 
as control. Y-axis shows the PI signal, and the X-axis shows the binding of Annexin 
V-FITC. 
 
6.2.2  In vivo study of molecularly targeted therapy on CEA424-SV40 TAg 
transgenic mice with mTOR inhibitor RAD001  
 
The in vitro studies above revealed anti-tumor potential of the tested drugs which 
made them promising candidates for further in vivo experiments. As a first step, the 
mTOR inhibitor RAD001, with a GI50 at 0.1-10 nM, was selected. To test the drug in 
a clinically relevant form, 50 days old CEA424-SV40 TAg mice were used for the in 
vivo study. Mice of this age were selected because at this time point, tumor lesions 
have been well formed in the antrum, which is also in line with the situation in the 
clinic. 
 
 
 71 
6.2.2.1  Effect of RAD001 treatment on tumor development of the 
CEA424-SV40 TAg transgenic mice 
 
Since we were interested only in strong effects, a sample size of 4 per group was 
calculated to be sufficient to give a significant result. Thus, 4 mice were included in 
both the RAD001 treated group and placebo group. 10 mg/kg RAD001 or placebo 
was given orally once per day from day 1 to day 5 every week, according to published 
protocols and suggestions from the company. Weight was monitored daily and the 
mice were sacrificed when they lost 20% of their peak weight which is a surrogate 
marker for terminal tumor growth. At the end of the experiment, the average survival 
time for both groups was evaluated. As shown in Figure 23, mice treated with 
RAD001 lived much longer than the mice in the control group. The survival time of 
the RAD001 treated mice was prolonged by 35 days on average (control group: 100±
4.97 day; RAD001 group: 135±4.90 day, p<0.0001). Compared with the overall 
survival time of tumor mice (on average 100 days), this is a dramatic increase by 35%. 
In Figure 23 a, the weight on day 90 was used as the base line because most of the 
CEA424-SV40 TAg transgenic mice started to lose weight around day 90. 
 
 
Figure 23. Effect of RAD001 treatment on the survival time of the CEA424-SV40 
TAg transgenic mice. a) Weight curves of the CEA424-SV40 TAg transgenic mice. 
Blue curve: control group; red curve: RAD001 treated group. b) Mean age of the 
CEA424-SV40 TAg transgenic mice when they lost 20% of the peak weight. * 
p<0.0001: RAD001 treated group compared with control group. 
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To further analyze the effects of the mTOR inhibitor RAD001, a different set up was 
chosen. Instead of testing the survival time when all tumors developed a terminal size, 
a fixed time protocol was chosen. The experiment was stopped when the first control 
mouse started to lose weight. In another word, instead of being sacrificed when 20% 
of the peak weight was lost, all the mice in this experiment were ended at the same 
age (on day 98). Four 50 days old CEA424-SV40 TAg transgenic mice were included 
in the RAD001 treated group and three of the same age in the placebo group. 10 
mg/kg RAD001 or placebo was given orally once per day from day 1 to day 5 every 
week as before. Weight was monitored daily, as in the first set up.  
After 48 days treatment, one of the mice in the control group started to lose weight. At 
that time, all the mice treated with RAD001 still showed a normal behaviour and no 
weigh loss could be observed. As shown in Figure 24, mice of both the control group 
and RAD001 treated group developed tumors in the antral region of the stomach with 
no visible difference of tumor size and morphology. However, the weight of the 
tumors in the RAD001 group was significantly lower when compared with the control 
group (control group: 0.1473±0.0197 g; RAD001 group: 0.1118±0.0114 g, p<0.05). 
This demonstrates that RAD001 treatment suppressed the tumor development in 
CEA424-SV40 TAg transgenic mice, although this effect was not strong enough to 
eliminate all the tumor cells and cure the mice. There were still some tumor cell 
population which could escape from the treatment and eventually led to the death of 
the host.  
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Figure 24. Tumor development in the RAD001 treated CEA424-SV40 TAg 
transgenic mice. a) Macroscopic pictures of the gastric tumors developed in the 
RAD001 treated mice and control mice. The numbers represent individual mice. b) 
Tumor weight of the RAD001 treated mice and control mice. * p<0.05.    
 
6.2.2.2  Effect of RAD001 treatment on the proliferative status of the tumor at 
the time point of terminal tumor growth  
 
To get an idea of how the RAD001 treatment affected the number of proliferating 
tumor cells at the time point of terminal tumor growth, stomachs of the four RAD001 
treated mice and four control mice from the first experiment (experiment A: all the 
mice were sacrificed when 20% of the peak weight was lost) were analyzed for the 
expression of proliferation marker Ki-67 by immunohistochemistry. Three 400×
magnification fields were selected randomly from each mouse and the percentage of 
Ki-67 positive cells was evaluated. As shown in Figure 25 and 26, both the control 
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mice and the RAD001 treated mice developed high proliferative tumors. The average 
Ki-67 index for RAD001 treated group and the control group was 59.68±12.42% 
and 55.43±11.07%, respectively (p>0.05). No significant difference of the Ki-67 
index was observed between the RAD001 treated group and the control group.  
 
 
Figure 25. Examples of Ki-67 staining on stomach sections from the RAD001 
treated mice and control mice. The numbers represent individual mice. Scale bars: 
50µm. 
  
 
Figure 26. Ki-67 index in the 
tumors of the RAD001 treated 
mice and control mice at the time 
point of terminal tumor growth. 
No significant difference was 
observed between the two groups. 
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6.2.2.3  Effect of the RAD001 treatment on the neuroendocrine phenotype of 
CEA424-SV40 TAg gastric tumor cells 
 
As shown above, RAD001 treatment did not change the proliferative status of the 
tumor cell at the time point of terminal tumor growth. To further study what the 
treatment did to the tumors, we checked if RAD001 affected the neuroendocrine 
phenotype of the tumor cells. 
Glucagon was one of the neuroendocrine tumor markers which were aberrantly 
expressed in the CEA424-SV40 TAg gastric tumors. To check if its expression was 
influenced by the RAD001 treatment, immunohistochemical staining for glucagon 
was applied on stomach sections from the four RAD001 treated mice and four control 
mice from animal experiment A (all the mice were sacrificed when 20% of the peak 
weight was lost). Six 400 magnification fields were selected randomly for each 
mouse and the percentage of glucagon positive cells was evaluated. As shown in 
Figure 27, a significant decrease of the glucagon positive cell number was observed 
in the RAD001 treated group when compared with the control group. The average 
glucagon positive cell number in each 400 magnification field for the control group 
and RAD001 treated group was 106.71±11.34% and 64.25±12.82%, respectively 
(p<0.05).  
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The down-regulation of the glucagon expression gave a clue that RAD001 treatment 
may affect the neuroendocrine phenotype of the CEA424-SV40 TAg gastric tumors. 
We then checked if RAD001 treatment influenced the expression of transcription 
factors with a role in the neuroendocrine cell differentiation. Protein lysate was 
obtained strictly from tumors of the mice in the second experiment (experiment B: all 
the mice were sacrificed at d98, 48 days after the treatment started). Western blot was 
carried out with primary antibody directed at transcription factor Nkx2.2, which was 
shown to be expressed in the tumor tissue and the cell lines (Figure 18). As shown in 
Figure 28, the expression level of Nkx2.2 was lower in all the tumor samples from 
RAD001 treated mice when compared with control mice.  
Figure 27. The effect of the RAD001 
treatment on glucagon expression in the 
gastric tumors of CEA424-SV40 TAg 
transgenic mice. a) Immunohistochemical 
staining of glucagon on gastric tumors from 
both the RAD001 treated mice and control 
mice. The numbers represent individual 
mice. Scale bars: 50µm. b) Statistic analysis 
of the glucagon positive cell numbers in the 
tumor area. (n=4 for each group, * p<0.05)  
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Figure 28. Nkx2.2 expression in the tumor tissue from RAD001 treated mice and 
control mice. Nkx2.2 protein was detected at 30 kDa. Actin was used as control. The 
numbers represent individual mice. 
 
These results indicated that the RAD001 treatment had some impact on the 
neuroendocrine phenotype of CEA424-SV40 TAg gastric tumors.  
 
6.2.3 Possible mechanisms of the anti-tumor effects induced by RAD001 in 
CEA424-SV40 TAg gastric tumors 
 
As RAD001 treatment in the CEA424-SV40 TAg transgenic mouse model was 
successful both in vitro and in vivo, possible mechanisms of these anti-tumor effects 
induced by RAD001 were analyzed. RAD001 is a mTOR inhibitor which specifically 
targets mTORC1. The p70 ribosomal S6 kinase (p70S6K) and the eukaryotic 
translation initiation factor 4E (eIF4E)-binding protein (4EBP1) are two well 
discribed mTORC1 substrates, which are responsible for the regulation of cell growth 
and proliferation
137
. Thus, the effect of RAD001 treatment on the activation of these 
two downstream targets of mTOR pathway was tested. 
6.2.3.1  Effect on mTOR- p70S6K pathway  
6.2.3.1.1  Effect on mTOR- p70S6K pathway in vitro 
 
p70S6 kinase (p70S6K) is a downstream target of the mTOR signaling pathway and 
its activation is essential to the regulation of cell growth and proliferation
55, 138
. To 
show the possible mechanism of the anti-proliferation effects induced by the mTOR 
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inhibitor RAD001, the expression of phosphorylated p70S6K (p-p70S6K), which was 
considered as the active form, was first analyzed in sample of cell lines treated with 
100 nM RAD001 for 2h, 24h and 72h. Cells incubated with culture medium were 
used as control. As shown in Figure 29, p-p70S6K was expressed in all the three cell 
lines which proved the activated mTOR-p70S6K signaling in the tumor derived cell 
lines. In addition, a completely suppressed expression of the p-p70S6K was observed 
in all the three cell lines after treatment which clearly demonstrated that RAD001 
efficiently inhibited this pathway in vitro.  
 
 
Figure 29. Western blot for phosphorylated p70S6K in cell lines treated with 100 
nM RAD001 for 2h, 24h and 72h. First row shows the phosphorylated form of 
p70S6K. As controls, the unphosphorylated form of p70S6K and Actin are shown. -: 
control; +: 100 nM RAD001. p70S6K and p-p70S6K proteins were detected at 70 
kDa while Actin was detected at 43 kDa. 
 
6.2.3.1.2 Effect on mTOR- p70S6K parthway in vivo 
 
Western blot for p-p70S6K was also carried out on tumor tissue from RAD001 treated 
mice to see if the mTOR-p70S6K signaling was also inhibited by RAD001 in vivo. 
As shown in Figure 30, the expression level of p-p70S6K in tumor tissue from 
RAD001 treated mice was reduced or almost absent.  
 
 
Figure 30. Western blot for 
p-p70S6K on tumor tissue from 
RAD001 treated mice and control 
mice. The numbers represent 
individual mice. p70S6K and 
p-p70S6K proteins were detected at 
70 kDa. 
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S6 ribosomal protein is a downstream target of p70S6K, which is involved in the 
regulation of translation. To see if RAD001 treatment could affect the mTOR- 
p70S6K pathway further down, immunohistochemistry for phospho-S6 ribosomal 
protein was carried out on tumor tissue from RAD001 treated mice and control mice. 
Staining for SV40 TAg, phospho-S6 ribosomal protein (Ser 235/236), and 
phospho-S6 ribosomal protein (Ser 240/244) were carried out on serial sections from 
the stomachs of RAD001 treated and control mice. In Figure 31, examples for the 
staining from two mice of each group are shown. Lower expression levels of 
phospho-S6 ribosomal protein (Ser 235/236) and phospho-S6 ribosomal protein (Ser 
240/244) could be observed in the RAD001 treated group.  
 
 
Figure 31. Immunohistochemistry for SV40 TAg and phospho-S6 ribosomal 
proteins on tumor tissue from RAD001 treated mice and control mice. Stainings 
from two mice of each group are shown. Scale bars: 50µm. 
 
For statistical analysis, 400 magnification areas where more than 50% nuclei were 
positively stained with SV40 TAg were randomly selected for counting. As shown in 
Figure 32, a significant decrease of the phospho-S6 ribosomal protein positive rate 
(phospho-S6 ribosomal protein positive cell number/total cell number) in the RAD001 
treated group was confirmed (Ser235/236: control group: 59.64±9.39%, RAD001 
group: 32.82±11.92%, p<0.05; Ser240/244: control group: 65.31±4.15%, RAD001 
group: 26.88±14.38%, p<0.05 ). These results indicated that the RAD001 treatment in 
vivo suppressed the activation of S6 ribosomal protein and further confirmed the 
influence of RAD001 treatment on p70S6K function since the S6 ribosomal protein is 
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activated by p70S6K. 
 
 
Figure 32. Number of Phospho-S6 ribosomal protein positive cells in tumors 
from RAD001 treated mice and control mice. Data are shown as positive rate 
(phospho-S6 ribosomal protein positive cell number/total cell number). n=4, * 
p<0.05: RAD001 treated group compared with control group, nonparametric test.  
 
These results indicated that RAD001 treatment inhibited the activation of 
mTOR-p70S6K signaling pathway also in vivo, although not completely. 
 
6.2.3.2  Effect on mTOR-4EBP1 pathway 
6.2.3.2.1  Effect on mTOR-4EBP1 pathway in vitro 
 
4EBP1 is another mTORC1 substrate responsible for transcription and translation 
initiation of genes involved in cell growth. Western blots for 4EBP1 and 
phospho-4EBP1 were applied to the protein samples from the cell lines treated with 
100 nM RAD001 for 2h, 24h and 72h. Cells incubated with culture medium were 
used as control. As shown in Figure 33, although transient treatment of 2h and 24h did 
not affect the phospho-4EBP1 level apparently, 72h treatment with RAD001 
significantly inhibited the phosphorylation of 4EBP1, especially in mGC3 and mGC8. 
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Figure 33. Western blot for 4EBP1 and phospho-4EBP1 (p-4EBP1) on cell lines 
treated with 100 nM RAD001 for 2h, 24h and 72h. -: control; +: 100 nM RAD001. 
4EBP1 and p-4EBP1 proteins were detected at 15-20 kDa. 
 
6.2.3.2.2  Effect on mTOR-4EBP1 pathway in vivo 
 
The effect of RAD001 treatment on the phosphorylation leve of 4EBP1 in vivo was 
also analyzed. Tumor tissue from the second RAD001 treatment experiment 
(experiment B, all the mice were treated with 10 mg/kg RAD001 for 48 days and 
sacrificed on d98) were used for western blot. In contract to the clear effect in vitro, 
the phosphorylation of 4EBP1 was not affected by the long term treatment of 
RAD001 in vivo (Figure 34).  
 
 
 
6.2.4  Summary for the molecularly targeted therapies in the CEA424-SV40 
TAg transgenic mouse model  
 
In this part, molecularly targeted therapies were tested in the CEA424-SV40 TAg 
transgenic mouse model system. The mTOR inhibitors RAD001 and NVP-BEZ235, 
HSP90 inhibitor NW457, p53 stabilizer Nutlin-3, E2F inhibitor HLM006474 and 
Figure 34. Western blot for 
4EBP1 and phospho-4EBP1 on 
tumor tissue. The numbers 
represent individual mice. 4EBP1 
and p-4EBP1 proteins were 
detected at 15-20 kDa. 
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mitotic inhibitor paclitaxel induced anti-proliferation effect in the preliminary 
screening. In more detailed analysis in vitro, mTOR inhibitors RAD001 and 
NVP-BEZ235 showed effects on inhibiting colony formation and inducing cell 
apoptosis. In the in vivo experiment, RAD001 turned out to be a safe and efficient 
drug. Treatment with RAD001 was well tolerated, and significantly prolonged the 
survival time of the tumor bearing mice as well as inhibited the tumor development 
(reduced tumor weight). RAD001 treatment also had some impact on the 
neuroendocrine phenotype of CEA424-SV40 TAg gastric tumor cells as the 
expression levels of neuroendocrine marker glucagon and the transcription factor 
Nkx2.2, which involved in the differentiation of neuroendocrine lineage, were 
reduced in the tumor tissue from RAD001 treated mice. The effects of mTOR 
inhibition could be demonstrated by the suppression of mTOR-p70S6K and 
mTOR-4EBP1 signaling pathways. In the in vitro experiment, the inhibition of 
p70S6K activation induced by RAD001 was of high-efficiency because a complete 
elimination of p70S6K phosphorylation was observed even after 2h treatment. The 
inhibition of 4EBP1 activation needed longer period of treatment because transient 
treatment of 2h and 24h did not change the phospho-4EBP1 level apparently and a 
decreased phospho-4EBP1 expression was achieved after 72h treatment. In the in vivo 
experiment, mTOR-p70S6K signaling was still efficiently suppressed while an 
inhibition of mTOR-4EBP1 signaling was not observed after 48 days of RAD001 
treatment in vivo. These results not only offered useful insights into the clinical 
aspects of a molecularly targeted therapy for neuroendocrine tumors, but also verified 
the practical utility of the CEA424-SV40 TAg transgenic mouse model system as 
powerful translational tools for human cancer research. 
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6.3  Possible “escape” mechanisms of tumor cells from RAD001 
treatment 
 
The results of the molecularly targeted therapies on CEA424-SV40 TAg transgenic 
mouse model system, especially the successful experience with mTOR inhibitor 
RAD001, raised some obvious questions. RAD001 treatment inhibited tumor 
development and significantly prolonged the survival time. However, the anti-tumor 
effect achieved was not strong enough to kill all the tumor cells and cure the mice. 
RAD001 treated mice still developed highly proliferative tumor mass and presented 
similar behavior when the cancer progressed, like losing weight. Thus, we tried to 
find possible escape mechanism of tumor cells from RAD001 treatment for even more 
efficient treatment protocols. Possible hypothesis were the selection of cells by the 
mTOR inhibition, or the change in differentiation. Besides, the feed back activation of 
PI3K-Akt pathway was also evaluated because this side effect induced by single 
RAD001 treatment has been reported on other neuroendocrine cell lines. 
6.3.1  The effect of the molecularly targeted therapy with mTOR inhibitors on 
the expression pattern of epithelial stem cell markers 
 
One possible explanation for the escape of tumor cells from RAD001 treatment could 
be a selection of a different tumor cell population with a more stem cell like 
appearance, which led to the final death of the mice. For this question, analysis for the 
expression level of certain stem cell markers could give some information. As the 
adult stem cell theory in small intestine was better described, certain markers from  
both the “crypt base columnar (CBC) cell” model and the “+4” model were used for 
testing. 
6.3.1.1  Revers-transcription analysis for epithelial stem cell marker expression 
in the cell lines 
 
Cells were analyzed for known epithelial stem cell markers and the influence of the 
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RAD001 treatment was tested. Reverse transcription RCR (RT-PCR) for the 
expression of stem cell markers was first applied to cells treated with 100 nM 
RAD001, 100 nM NVP-BEZ235, or 1 g/ml paclitaxel for 72 hours. Crypt base 
columnar (CBC) cell markers Lgr5, Sox9, Olfm4 and Prom1, “+4” cell markers Bmi1, 
Dclk1, Tert and Ahr were selected for RT-PCR analysis. However, no obvious change 
was detected after 72 hours treatment. In Figure 35, the results from crypt base 
columnar (CBC) cell markers Lgr5 and Olfm4 as well as “+4” cell markers Bmi1 and 
Tert are shown as examples. 
 
 
 
 
As 72 hours treatment did not have a significant effect on the expression of the tested 
stem cell markers, we asked if a long term selection in vitro could change the 
expression pattern. For this, RAD001 resistant cell lines were established. 424GC, 
Figure 35. RT-PCR for stem cell 
marker expression in cell lines 
after 72 hours treatment. C: 
control; R: 100nM RAD001; N: 
100nM NVP-BEZ235; P: 1g/ml 
paclitaxel. Marker bands correspond 
to 1000bp, 700bp, 500bp, 300bp, 
200bp from top to bottom. 
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mGC3, and mGC8 cell lines were treated by RAD001 with gradually increasing drug 
concentrations from 10nM to 400nM. Three different cell samples named as 
RAD-100, RAD-200 and RAD-400 were established during the whole treatment 
period. As shown in Table 2, cells were first treated with 10nM RAD001 for 3 days, 
followed with 9 days treatment with 100nM RAD001. Cell sample harvested at this 
time point was named as RAD-100. RAD-100 cells were then treated with 200nM 
RAD001 for 14 days (RAD-200) while the RAD-400 cell sample were further kept in 
culture with 400nM RAD001 for about one month.  
 
Sample name 10nM 100nM 200nM 400nM 
RAD-100 3 days 9 days   
RAD-200 3 days 9 days 14 days  
RAD-400 3 days 9 days 14 days 29 days 
Table 2. RAD001 treatment for establishing RAD001 resistant cell lines. Cell line 
424GC, mGC3, and mGC8 were included in the treatment. 
 
From this selection process, cell lines were established which could grow in the 
presence of 400nM RAD001. To test whether these cells could still respond to the 
same RAD001 concentration compared with the parental cells, WST-1 assay was 
applied to the RAD-400 cell samples with untreated cell lines used as controls. As 
shown in Figure 36, the selected cell lines (red curves) had much higher GI50s than the 
control cell lines. Even at high concentration of 1000nM, there were still about 
60-80% cells alive. 
 
 
Figure 36. Cell proliferation assay on normally cultured cell lines and RAD001 
selected cell lines. Blue curve: control cell line without pretreatment; red curve: 
RAD-400 cell line. The experiments were performed in triplicate. 
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Then, we asked if these selected cells are different from the parental cells. For this 
question, stem cell marker expression screening was applied to RAD-100, RAD-200, 
RAD400 cell samples to see if a long term selection in vitro could have any influence 
on the expression of stem cell markers. Epithelial stem cell markers for crypt base 
columnar (CBC) cells (Lgr5 and Olfm4) and “+4” cells (Bmi1 and Tert) were selected 
for screening. As shown in Figure 37, only Olfm4 expression was inhibited by the 
long term treatment of RAD001. There was no remarkable change observed in the 
expression of other stem cell markers checked.  
 
 
 
The screening was also applied to tumor tissue from mice treated with RAD001 to see 
if the situation in vivo was similar. The expression of “CBC” markers Lgr5, Olfm4, 
Prom1, Ascl2 and “+4” markers Bmi1, Tert, Hopx, Dclk1 were checked in tumor 
Figure 37. RT-PCR for stem cell 
marker expression in RAD001 
selected cell lines. C: control; R1: 
RAD-100; R2: RAD-200; R4: 
RAD-400. Marker bands correspond 
to 1000bp, 700bp, 500bp, 300bp, 
200bp from top to bottom. 
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tissue from three control mice and three RAD001 treated mice. As shown in Figure 38, 
a complete suppression of Ascl2 expression was observed in the RAD001 treated 
group. The expression levels of all the other markers checked were not significantly 
affected. 
 
 
 
The RT-PCR data showed that RAD001 treatment had no effect on the differentiation 
of the tumor cells and there was no indication that RAD001 could select for a more 
“cancer stem cell” like population.  
 
6.3.1.2  Protein analysis for epithelial stem cell marker expression after 
RAD001 treatment 
 
Data presented above showed that at mRNA level, RAD001 treatment did not induce 
a strong effect on differentiation of the tumor cells. However, RT-PCR shows only the 
presence of a certain RNA which may not reflect the protein expression. It still makes 
Figure 38. RT-PCR stem cell marker expression in 
tumor tissue. RNA samples of tumor tissue from 
control or RAD001 treated mice were used. n=3 for each 
group. Marker bands correspond to 1000bp, 700bp, 
500bp, 300bp, 200bp from top to bottom. 
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sense to check whether the treatment had an apparent influence on the expression of 
certain stem cell markers at protein level. Among several epithelial stem cell markers 
screened in the tumor derived cell lines, the “+4” marker Bmi1 was the most highly 
expressed. Thus, Bmi1 was selected for protein analysis. 
Cell lines treated with 100 nM RAD001 for 2h, 24h, and 72h were analyzed to check 
if the expression level of Bmi1 was changed. As shown in Figure 39, no significant 
change of the Bmi1 expression level was detected.  
 
Figure 39. Western blot for Bmi1 expression in cell lines treated with 100 nM 
RAD001 for 2h, 24h and 72h. -: untreated cells; +: cells treated with 100 nM 
RAD001. Bmi1 was detected at 41-43 kDa. Actin was detected at 43 kDa. 
 
Then, we asked if the situation was similar after a long term treatment. Cell lines from 
the long term RAD001 selection (RAD-400) as well as the tumor tissue from the 
second RAD001 experiment were used to analyze this effect both in vitro and in vivo. 
As shown in Figure 40, RAD001 resistant cells had the same Bmi1 expression level 
as the untreated cell line. In fact, the long term selection by RAD001 in vivo (48 days) 
did not change the Bmi1 expression level either (Figure 40). 
 
Figure 40. Western blot for Bmi1 expression in RAD001 selected cell lines and 
tumor tissue from RAD001 treated mice. C: Control (untreated cell lines); R: 
RAD001 selected cell lines (RAD-400); the numbers represent individual mice. Actin 
was used as control. Bmi1 protein was detected at 41-43 kDa. Actin protein was 
detected at 43 kDa. 
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So the RAD001 treatment had no effect neither in vitro nor in vivo on the 
differentiation of the tumor cells at least with regard to the Bmi1 expression. So it is 
obvious that the tumor cells do not change the phenotype and have to develop other 
machanisms for an escape from mTOR inhibition. 
 
6.3.2 The feedback activation of Akt induced by single RAD001 treatment 
 
Another possible mechanism for the escape of tumor cells from RAD001 treatment 
could be the loss of p70S6K-mediated negative feedback loop on the 
PI(3)K–Akt–mTOR pathway induced by single RAD001 treatment
137, 138
. This side 
effect could attenuate the anti-tumor efficiency of RAD001. To check if this effect 
also exists in our cell lines, western blot for Akt and phospho-Akt (Thr 308) was 
applied to the cell lines treated with 100 nM RAD001 for 2h, 24h, and 72h. As shown 
in Figure 41, after RAD001 treatment, a feed back activation of Akt could be 
detected.  
 
 
Figure 41. Western blot for phospho-Akt (Thr 308) on cell lines treated with 
RAD001. -: control; +: 100nM RAD001. Akt and p-Akt protein were detected at 60 
kDa. 
 
Since these data reflected only the short term effect of RAD001, it was interesting to 
check if the effect still existed in the long term RAD001 selected tumor cells. Protein 
samples from RAD-400 resistant cell lines were used for western blot. As shown in 
Figure 42, a feed back activation of phospho-Akt could still be observed in RAD001 
resistant cell line of 424GC and mGC3, while in mGC8, this effect was not obvious.  
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However, this effect was not significant after long term RAD001 treatment in vivo. 
As shown in Figure 43, the phosphorylated Akt protein could be detected in all the 
tumor samples from the control mice. Tumor tissue from the RAD001 treated by mice 
displayed similar phospho-Akt expression level as observed in the control mice. 
 
 
 
In summary, single RAD001 treatment in vitro induced a feed back activation of the 
PI(3)K–Akt–mTOR pathway, although in vivo, this side effect was not significant. 
 
6.3.3  Effect of long term RAD001 treatment on the activation of mTOR 
downstream target p70S6K 
 
The results presented before showed that short term treatment of RAD001 in vitro 
could efficiently suppressed the mTOR-p70S6K signaling in the tumor derived cells. 
We then asked if the tumor cells were still sensitive to RAD001 after a long term 
selection. Thus, the activation of p70S6K in the RAD001 resistant cell lines was 
tested. RAD-400 resistant cell lines were used for western blot. Cells without 
treatment were used as control. As shown in Figure 44, the expression of active form 
Figure 43. Expression of 
phospho-Akt (Thr 308) on tumor 
tissue. The numbers represent 
individual mice. Akt and p-Akt 
proteins were detected at 60 kDa. 
 
Figure 42. Phospho-Akt (Thr 308) 
expression in RAD001 selected cell 
lines. C: control cell lines without 
pretreatment; R: RAD-400 selected cell 
lines. Akt and p-Akt proteins were 
detected at 60 kDa. 
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of p70S6K (p-p70S6K) was completely inhibited in the RAD-400 resistant cell lines. 
This indicated that the mTOR- p70S6K signaling was still well in control of RAD001 
in these suvival tumor cells after long term selection. This pathway was not likely to 
be invovled in the escape mechanism for the resistant cell lines.  
 
  
 
6.3.4  Summary for the possible escape mechanisms 
 
In looking for the possible escape mechanisms for the tumor cells from RAD001 
treatment, the expression of stem cell markers, which was taken as a factor of the 
differentiation, was screened by RT-PCR. No apparent influence was observed after 
RAD001 treatment, neither in vitro nor in vivo. This indicated that RAD001 treatment 
had no influence on the differentiation of the tumor cells. On the other hand, a feed 
back activation of PI(3)K–Akt–mTOR signaling was observed after RAD001 
treatment in vitro. This could be one of the explanations of why the anti-tumor effect 
of RAD001 was not curable. 
 
6.4  Research on the tumor originating cells  
Although the CEA424-SV40 TAg transgenic mouse model was established some 
years ago, and the gastric tumors developed in these mice have only been recently 
better characterized, it is still not clear which cell type forms the tumor originating 
cells. The in vivo experiment for RAD001 showed that although RAD001 could 
Figure 44. Western blot for 
phospho-p70S6K on RAD001 
selected cell lines. C: control cell 
lines without pretreatment; R: 
RAD-400 resistant cell lines. p70S6K  
and p-p70S6K proteins were detected 
at 70 kDa. 
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significantly inhibit tumor development and prolong the survival time of the 
CEA424-SV40 TAg transgenic mouse, there were still some tumor cells which could 
escape from the therapy and finally lead to the death of the tumor bearing mice. This 
means that there might be a subpopulation of the tumor cells that may act like “cancer 
stem cells”. Thus, looking for the tumor originating cells may not only be helpful for a 
better understanding of the tumorigenesis of neuroendocrine tumor but also important 
for establishing more targeted and efficient therapies.  
The localization of the tumor in the gastric wall provided epithelial as well as 
mesenchymal stem cells as candidates for the tumor originating cells. Therefore, we 
looked for markers of these cells by several methods. 
6.4.1 Epithelial stem cell markers in the tumor initiating cells of CEA424-SV40 
TAg gastric tumor 
 
There are two principal epithelial stem cell pools identified, one representing the crypt 
base columnar cells (CBCs) and the other the “+4” cells. Lgr5 is a classic marker for 
crypt base columnar cells. In the microarray analysis for the tumor tissue of 30, 60, 90 
days old CEA424-SV40 TAg transgenic mice, the expression of Lgr5 was below the 
detection limit as shown in Figure 45 (probe sets exhibiting a fluorescence of >100 
(RFU) were considered as positive in this assay). In the RT-PCR analysis for tumor 
derived cell lines, 35 cycles were needed to detect the Lgr5 expression which also 
indicated a low mRNA level.  
 
 
 
Figure 45. Expression level for Lgr5 in 
tumor tissue (microarray). RNA samples 
from antral tissue of normal mice and gastric 
tumors of 30, 60, 90 days old CEA424-SV40 
TAg transgenic mice were used. n=3 for each 
age group. 
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Because there is no good anti-Lgr5 antibody available, the CEA424-SV40 TAg 
transgenic mice were crossed with Lgr5-EGFP-IRES-CreERT2 mice to analyze the 
Lgr5 expression. Although single Lgr5 positive cells could clearly be shown at the 
bottom of the gastric units, there was no GFP/TAg double-positive cell observed in 
the tumor area. Lineage tracing experiment could not provide supportive information 
for the hypothesis that the Lgr5
+
 cells might give rise to the tumor either (data from E. 
Vetter and W. Zimmermann, unpublished results). Thus, the Lrg5 expressing CBC 
cells seem not to be promising candidates for the tumor originating cells in 
CEA424-SV40 TAg transgenic mice although they can still not be fully excluded.  
Besides Lgr5
+
 cells, Bmi1
+
 cells have also been discussed as potential epithelial stem 
cells. In fact, when we screened the expression levels of many epithelial stem cell 
markers in cell line 424GC, mGC3 and mGC8 by RT-PCR, Bmi1 was found to be the 
most highly expressed marker (Figure 46). As shown in the figure, Bmi1 was much 
higher expressed than Lgr5, which was barely detectable even after 30 cycles’ 
amplification. Thus, Bmi1 expression was further analyzed in CEA424-SV40 TAg 
gastric tumor in more detail to check if the Bmi1 positive cells could be the candidates 
for the tumor originating cells in this model system. 
 
Figure 46. RT-PCR analysis for epithelial stem cell markers in cell lines derived 
from the tumor. Cell line 424GC, mGC3 and mGC8 were analyzed. OD values were 
normalized for the GAPDH expression to calculate the relative expression level for 
each marker. 
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6.4.1.1  RT-PCR for Bmi1 expression in tumor tissue and cell lines derived from 
the tumor 
 
RT-PCR was carried out for detecting the Bmi1 expression in mRNA level with RNA 
samples from tumor tissue of four CEA424-SV40 TAg transgenic mice (day 96-107) 
and three cell lines derived from the primary tumor. As shown in Figure 47, Bmi1 
expression could be detected in both the tumor tissue and the cell lines. Its expression 
level in the cell lines was even higher than in the tumor tissue, and could already be 
detected after 25 cycles. This may due to the fact that the cell lines were pure 
populations while the tumor tissue was mixed with supporting cells around the tumor 
cells.  
 
 
Figure 47. RT-PCR analysis for Bmi1 expression in the tumor tissue and cell 
lines derived from the tumor. Tumor tissue of four CEA424-SV40 TAg transgenic 
mice (day 96-107) and three tumor derived cell lines 424GC, mGC3, mGC8 were 
used. Marker bands correspond to 1000bp, 700bp, 500bp, 300bp, 200bp from top to 
bottom. 
 
So the tumor samples as well as the cell lines derived from the tumor expressed a high 
Bmi1 mRNA concentration. 
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6.4.1.2 Bmi1 protein in tumor tissue and cell lines derived from the tumor 
 
The expression of Bmi1 in CEA424-SV40 TAg gastric tumor was further analyzed by 
western blotting. Protein samples were obtained from tumor tissue of three 98 days 
old CEA424-SV40 TAg transgenic mice (#671, #673, #679) and three cell lines 
derived from the tumor (424GC, mGC3, mGC8). As shown in Figure 48, all the 
tumor tissue samples and the cell lines highly expressed Bmi1.  
 
  
 
6.4.1.3  Immunostainings for Bmi1 expression in tumor tissue and cell lines 
derived from the tumor 
 
To prove the correct expression of Bmi1 in tumor tissue, +4 cells, for which Bmi1 is a 
solid marker, were used as positive control. As shown in Figure 49, “+4” cells could 
be correctly detected in both stomach and duodenum by immunohistochemistry.  
 
Figure 49. Immunohistochemistry for Bmi1 on normal tissue of stomach and 
duodenum. Positive cells (arrow) could clearly be detected at “+4” position. Scale 
bars: 20 µm. 
Figure 48. Western blot for Bmi1 
expression in both tumor tissue 
and tumor derived cell lines. The 
numbers represent individual mice. 
Cell line 424GC, mGC3 and mGC8 
were used. Actin was used as 
control. Bmi1 protein was detected 
at 41-43 kDa. 
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Bmi1 staining was then applied to the tumor tissue from CEA424-SV40 TAg 
transgenic mice. In Figure 50, Bmi1 expression was detected in small tumor islands, 
while in Figure 51, numerous Bmi1 positive cells were found in big tumor masses.  
 
 
Figure 50. Bmi1 staining in the stomach of 92 days old CEA424-SV40 TAg 
transgenic mouse. Left: Double immunofluorescent labeling for SV40 TAg and 
Bmi1 identified small tumor island expressing Bmi1. Bmi1: green (Alexa-488), SV40 
TAg: red (Alexa-546), DNA: blue (Hoechst), images of 400 magnifications are 
shown; Right: immunohistochemical staining for Bmi1 showed a small positive area. 
Scale bars: 20 µm. 
 
 
 
Figure 51. Immunohistochemical staining for Bmi1 in the gastric tumor of a 92 
days old CEA424-SV40 TAg transgenic mouse. Scale bars: 20 µm. 
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Double immunofluorescent staining for SV40 TAg and Bmi1 on stomach sections 
from 92-107 days old CEA424-SV40 TAg transgenic mice identified Bmi1 and SV40 
TAg double positive cells (Figure 52), which clearly shows that these tumor cells 
expressed Bmi1.  
 
 
Figure 52. Double immunofluorescent staining for SV40 TAg and Bmi1 in the 
tumors from a 92 days old CEA424-SV40 TAg transgenic mouse. Two tumor 
areas are shown here. Bmi1: green (Alexa-488), SV40 TAg: red (Alexa-546); DNA: 
blue (Hoechst 33342). Images of 400 magnifications are shown. 
 
It is worth pointing out that quite a number of Bmi1 single positive cells were also 
observed around the tumor area or between two tumor areas (Figure 53-54), which 
suggests that these Bmi1 positive cells might contribute to the tumorigenic 
microenvironment. 
 
 
Figure 53. Double 
immunofluorescent staining 
for SV40 TAg and Bmi1 in 
the tumor from a 107 days 
old CEA424-SV40 TAg 
transgenic mouse. Bmi1: 
green (Alexa-488), SV40 
TAg: red (Alexa-546), DNA: 
blue (Hoechst). Images of 
400 magnifications are 
shown. 
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Besides, Bmi1 staining was also applied to the cell lines derived from the tumor. A 
strong expression of Bmi1 was found in all the three cell lines as shown in Figure 55. 
This was a clear nuclear staining with 100% positive rate.  
  
 
Figure 55. Immunofluorescent staining for Bmi1 on cell line 424GC, mGC3 and 
mGC8. Bmi1: green (Alexa-488), DNA: blue (Hoechst). Images of 400 
magnifications are shown. 
 
Figure 54. Double 
immunofluorescent staining 
for SV40 TAg and Bmi1 in 
the tumor from a 107 days 
old CEA424-SV40 TAg 
transgenic mouse. Bmi1: 
green (Alexa-488), SV40 
TAg: red (Alexa-546), DNA: 
blue (Hoechst 33342). Images 
of 400 magnifications are 
shown. 
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So in the tumor tissue an appreciable amount of SV40 TAg positive tumor cells were 
found to express Bmi1 while in the isolated tumor cell lines a 100% positive rate was 
observed. 
 
6.4.1.4  Bmi1-TAg interaction 
 
Data presented above showed that Bmi1 was expressed both in the tumor tissue and 
the cell lines. However, it was not clear whether there is a relationship between Bmi1 
expression and the activation of the TAg. To answer this question, cells were 
transfected with siRNA targeting the TAg. RNA was isolated 72 h after transfection 
and analyzed by testing the expression of several genes on a cDNA array. As shown 
in Figure 56, knockdown of TAg significantly decreased the Bmi1 expression level 
(Control group: 226.7711.32; TAg siRNA group: 117.3219.52, p<0.005). This 
suggests that TAg could drive the expression of Bmi1 and Bmi1 positive cells could 
be the target of the TAg induced transformation. 
 
 
 
As knocking down TAg could suppress Bmi1 expression, we then asked if this effect 
also works in the opposite direction. Therefore, the expression of Bmi1 was knocked 
down by esiRNA assay in cell line 424GC and mGC3. esiRNA is a new method for 
knocking down specific targets. It is a mixture of several synthetic siRNA targeting 
the same mRNA sequence and is suggested to be more efficient and with less 
off-target effects
139
. Cells were treated with different concentrations of Bmi1-esiRNA 
Figure 56. Microarray analysis for Bmi1 
expression level in cell line 424GC when 
TAg was knocked down by siRNA assay. 
n=3 for each group, *p<0.005. 
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(100, 200 or 400 ng/well) for 48 and 96h and harvested for western blotting. As 
shown in Figure 57, although 48h transfection did not apparently affect the Bmi1 
expression, 96h transfection with 200 and 400 ng Bmi1-esiRNA significantly reduced 
the Bmi1 expression level in both the cell lines. However, the expression of 
SV40-TAg was not changed in spite of Bmi1 knockdown.  
 
 
Figure 57. SV40-TAg expression in Bmi1 knocked down cell lines. Protein 
samples from cell line 424GC and mGC3 were used for western blotting. 0: control; 
100, 200 and 400: amount of Bmi1-esiRNA (ng) in each well. Bmi1 and SV40-TAg 
proteins were detected at 41-43 and 94 kDa, respectively. Actin was used as control. 
 
These results indicate that the Bmi1 expression had no strong effect on the TAg 
expression. Bmi1 expression is more likely a consequence of the TAg expression. 
 
6.4.2 Mesenchymal stem cell markers in the tumor initiating cells of 
CEA424-SV40 TAg gastric tumor 
 
Although the results above showed that the tumor cells were clearly Bmi1 positive, it 
is still intensively debated whether Bmi1 positive “+4” cells represent a true epithelial 
stem cell population. Bmi1 may be a marker for a more advanced epithelia as well as 
tumor cell populations. The position of the tumor cells in young mice as well as the 
screening for stem cell marker expression offered additional candidates for the tumor 
initiating cells of CEA424-SV40 TAg gastric tumor. One of these candidates is the 
Etv1 positive mesenchymal stem cell.  
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6.4.2.1  The distribution of SV40 TAg positive cells observed in the muscularis 
mucosae of antrum and duodenum 
 
When immunohistochemical staining for SV40 TAg was applied to the stomachs of 
CEA424-SV40 TAg transgenic mice for the identification of the tumor cells, some 
SV40 TAg positive cells were also found in the muscularis mucosa layer. In young 
mice aged 30-60 days, these SV40 TAg positive cells were mostly observed in the 
muscularis mucosae of the antrum, right below the tumor area. Few single SV40 TAg 
positive cells were also observed in the muscular layer of the duodenum. When the 
mice got older, these SV40 TAg positive cells could no longer be found in the 
muscularis mucosa layer of the antrum region while in the duodenum, especially in 
the part close to the antrum region where the mucosa of the duodenum was 
hyperplastic, these SV40 TAg positive cells infiltrated into the mucosa layer (Figure 
58). 
 
 
Figure 58. SV40-TAg expression in tissue sections from CEA424-SV40 TAg 
transgenic mice. SV40 TAg positive cells (arrow) were found in the muscularis 
mucosa layer of antrum and duodenum. The age of the mice is shown on top of the 
pictures. Scale bars: 50µm. 
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The location of these early tumors in the muscularis mucosa layer forced us to ask 
whether the tumor cells are of mesenchymal origin. This was further enhanced by the 
fact that Cajal cells, which are of mesenchymal origin
140
, are presumed to be the 
originating cells for another tumor in this area called gastrointestinal stromal tumour 
(GIST)
130
. Based on the fact that the SV40 TAg positive cells described above are in 
the same position as Cajal cells, and are in the neighbourhood of the tumor cells, we 
suspected that they might be the tumor initiating cells transformed by TAg. So the 
basic hypothesis was that these cells or a small population of these cells might migrate 
into the pyloric mucosa, settle down and give rise to the gastric tumors. In fact, c-Kit, 
a marker for Cajal cell, was expressed in d30, 60, and 90 CEA424-SV40 TAg gastric 
tumors according to the data from microarray analysis. A significant increase of the 
c-Kit expression level was observed in d90 gastric tumors when compared with 
normal antrum tissue (Figure 59). We then tried to stain the CEA424-SV40 TAg 
gastric tumor with anti-c-Kit antibody. However, neither the tumor cells in the 
epithelial layer nor the SV40 TAg positive cells in the muscularis mucosa layer were 
positively stained. So at the moment it is not clear whether this protein is expressed. 
 
 
Figure  59. Transcriptome analysis for c-Kit expression. Tumor tissue from d90 
CEA424-SV40 TAg transgenic mice and normal antrum tissue from non-transgenic 
mice were analyzed. n=3 for each group, * p<0.05. 
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6.4.2.2 Etv1 expression in CEA424-SV40 TAg gastric tumor 
 
Although the tumor cells were negative for c-Kit staining, the up-regulated expression 
of c-Kit in mRNA level in the tumor tissue as well as the appearance of the SV40 
TAg positive cells observed in the muscularis mucosa layer of antrum and duodenum, 
suggested the possibility that other cells of mesenchymal origin may give rise to the 
CEA424-SV40 TAg gastric tumor. 
One newly described mesenchymal stem cell marker Etv1, has been reported as a 
crucial regulator during the tumorigenesis of GIST in cooperation with Kit
130
. 
Interestingly, in our transcriptome analysis, Etv1 was present in the tumor tissue over 
time from d30, d60 and d90 CEA424-SV40 TAg transgenic mice. As shown in Figure 
60, the expression level of Etv1 in the tumor tissue increased with the tumor 
development. A significant increase was observed from d60 on, with an even further 
rise to day 90.  
 
 
 
Based on an elevated mRNA expression level of Etv1 in the tumor tissue, the analysis 
of the protein expression was followed. Immunofluorescent staining for Etv1 was 
applied to tumor tissue from CEA424-SV40 TAg transgenic mice. As shown in 
Figure 61, Etv1 could be clearly stained in the tumor area. This stainning was defined 
to the nucleus of the tumor cells, which is characteristic for a transcription factor. In 
Figure 60. Transcriptome analysis 
for Etv1 expression. Tumor tissue 
from d30, 60, 90 CEA424-SV40 TAg 
transgenic mice and normal antrum 
tissue from non-transgenic mice were 
analyzed. n=3 for each time point, * 
p<0.05, d60, d90 group compared 
with control group. 
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addition, the same staining could be shown in the cell lines derived from the tumor 
with 100% positive rate (Figure 62).  
 
 
Figure 61. Etv1 staining in gastric tumor from a 92 days old CEA424-SV40 TAg 
transgenic mouse. Etv1: green (Alexa488); DNA: blue (Hoechst). Images of 400 
magnifications are shown. 
 
 
Figure 62. Etv1 staining in three cell lines derived from CEA424-SV40 TAg 
gastric tumor. Etv1: green (Alexa488); DNA: blue (Hoechst 33342). Images of 400 
magnifications are shown. 
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In summary, the mesenchymal stem cell marker Etv1 was found to be highly 
expressed in the tumor tissue and isolated tumor cell lines. More interestingly, Etv1 
expression level was up-regulated over the time course of the tumor development. 
From these, Etv1 positive mesenchymal stem cells seem to be a possible candidate for 
the transformation induced by TAg.  
 
6.4.3  Summary for the tumor originating cells 
 
Here, two hypotheses were presented. In the first part, the “+4” marker Bmi1 was 
shown to be highly expressed in gastric tumors developed in CEA424-SV40 TAg 
transgenic mice as well as in the cell lines derived from the primary tumor. Bmi1 
expression could also be down-regulated by knockdown of TAg, thus showing the 
interrelationship. However, there is still an intensive debate on whether Bmi1 positive 
cells represent a real epithelial stem cell population. On the other hand, the SV40 TAg 
positive cells observed in the muscularis mucosa layer in the neighbourhood of the 
tumor cells, as well as the expression of mesenchymal markers in the transcriptome 
analysis revealed the possibility of mesenchymal stem cells as tumor initiating cells of 
CEA424-SV40 TAg gastric tumor. Our results showed that the mesenchymal stem 
cell marker ETV1 was expressed in the tumor tissue and cell lines derived from the 
tumor. The expression level of ETV1 in the tumor tissue also increased over the time 
course of the tumor development. Since the CEA-promotor used for the generation of 
the T-antigen transgenic animals contains Etv1 binding sites, it is tempting to 
speculate, that this may drive the transcription of the T-antigen. Further studies using 
e.g. lineage tracing are needed to make this conclusion more solid. 
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7  DISCUSSION 
7.1  In depth characterization of the CEA424-SV40 T Ag transgenic 
mouse showed a clear neuroendocrine phenotype which made it a 
clinically relevant model for gastric neuroendocrine tumors 
 
GEP-NETs is a rare disease with an incidence of about 2.5 to 5 cases per 100 000. 
However, as has been introduced before, the incidence and prevalence of GEP-NETs 
has increased substantially during the past 30 years. The progress in the management 
of this disease has been slow and this may to a large extent be due to the limited 
understanding of the cellular and molecular biology of neuroendocrine cells and the 
mechanism of tumorigenesis. Thus, neuroendocrine tumor cell lines and animal 
models are urgently needed for preclinical study. The two most frequently used 
neuroendocrine cell lines are BON1 and GOT1. BON1 is derived from a human 
pancreatic carcinoid
141
, but it is not a pure neuroendocrine cell line and additional 
mutations may have been aquired during the in vitro cultivation
3
. GOT1 is derived 
from a liver metastasis of a human midgut carcinoid and is maintained as a mouse 
xenograft
3
. Although there are several mouse models which develop tumors with a 
neuroendocrine phynotype in the pancrease
142, 143
 and prostate
50-52, 144, 145
, there are 
very few mouse models for gastrointestinal carcinoids, expecially for gastric 
neuroendocrine tumors
54
. The shortage of in vitro and animal models is one of the 
major barrier for research in this area.  
SV40 TAg is a potent oncogene that has often been used to generate organ-specific 
cancers in transgenic mice. The CEA424-SV40 TAg transgenic mouse presented here 
was established by Thompson et al in 2000. A 424-bp CEA promoter was used to 
drive the expression of SV40 TAg. One transgenic line (L5496) developed tumors in 
the pyloric region of the stomach in 100% of the offspring
30
. These gastric tumors 
were tentatively classified as adenocacinomas in a large part due to the transgenic 
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CEA and the expression of EpCAM and CEACAM1 in cell lines derived from the 
primary tumor
31, 37
.  
In order to characterize these tumors in more detail, genome-wide expression analysis 
with RNA from tumor-bearing mice and normal littermates were performed. To our 
surprise, transcriptome analyses revealed an enrichment of typical gene signature for 
neuroendocrine tumors. Gene expression analysis of 424GC, a cell line derived from 
the primary tumor, showed similarity to the gene expression profile in the tumor 
tissue from 90-day-old CEA424-SV40 TAg-transgenic mice, which reflects the 
neuroendocrine phenotype of the parental tumor. Furthermore, when SV40 T antigen 
expression was knocked down by siRNA, a down-regulation of neuroendocrine gene 
expression in this cell line was observed
37
.  
These previous studies inspired the work presented in this thesis. The CEA424-SV40 
TAg gastric tumor was further analyzed for the expression of neuroendocrine markers, 
the proliferation status which is important for the grading, and its ability to cause 
aberrant physical signs like hormone levels. Data from the first part of the result 
section demonstrated that the CEA424-SV40 TAg transgenic mice developed solid 
tumors in the antral region of the stomach which are of high proliferative capacity. 
These gastric tumors expressed several neuroendocrine markers including 
chromogranin A, chromogranin B, secretin and glucagon. Overexpression of secretin 
and Tph1 as observed in the transcriptome microarray analysis led to elevated 
hormone levels of secretin and serotonin as shown in the ELISA experiment. One of 
the consequences of high secretin secretion is the suppression of gastric acid out put. 
As it is quite difficult to measure the pH in the stomach directly, the expression of a 
key component of the acid production, H
+
-K
+
-ATPase, was evaluated. As expected, a 
decreased H
+
-K
+
-ATPase positive cell number was observed in the CEA424-SV40 
TAg transgenic mice comparing to the non-transgenic mice. Thus, the tumor shows 
strong hormone activity. Furthermore, the CEA424-SV40 TAg gastric tumor and 
tumor derived cell lines express transcription factors with crucial roles in 
neuroendocrine cell differentiation. All these information indicate that the 
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CEA424-SV40 TAg gastric tumors exhibit a neuroendocrine phenotype which make 
the CEA424-SV40 TAg transgenic mouse a clinically relevant model for gastric 
neuroendocrine tumors.  
 
7.2  Possible connection between SV40 TAg transforming ability 
and the neuroendocrine features of the mouse tumor model 
 
The reason why CEA424-SV40 TAg gastric tumor turns out to be a neuroendocrine 
carcinoma is not well understood. It is not likely that the very short CEA promoter 
used in this mouse model takes a leading role in the development of the 
neuroendocrine features because CEA is a tumor marker widely used for 
adenocarcinomas
30
. Then, the question was whether the neuroendocrine phenotype is 
a result from the specific effects of the TAg. 
The transforming ability of SV40 TAg is in large part due to its involvment in 
inactivating cellular tumor suppressors like p53 and retinoblastoma (RB) proteins. 
There have been reports that abnormalities of the p53 and RB pathway are frequently 
detectable in neuroendocrine tumors. Tang et al tested 92 cases of well-differentiated 
Pan-NETs, and found that 68% of the samples were positive for phospho-RB. They 
were also able to show that RB phosphorylation coincided with high expression of 
Cdk4, which is responsible for phosphorylating RB
146
. As regard to the poorly 
differentiated neuroendocrine carcinomas (NECs) of the pancreas, the study from 
Yachida et al showed high frequences of abnormal immunolabeling patterns of p53 
and RB (95% and 74%, respectively). This observation correlated with the intragenic 
mutations of TP53 and RB1 genes
147
. Another tumor with a neuroendocrine 
phenotype is the small cell lung carcinoma (SCLC). It is the most aggressive type of 
lung cancers with poor prognosis. Numerous investigations have shown that 
dysfunction of both the RB1 and TP53 gene are crucial for the carcinogenesis of 
SCLC
148, 149
. By inactivating both p53 and Rb1 gene, Zhou et al successfully 
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developed mouse prostate tumor models with carcinomas showing both luminal 
epithelial and neuroendocrine differentiation
150
. As p53 and retinoblastoma (RB) 
proteins are among the major targets of SV40 TAg, their roles in the tumorigenesis of 
these neuroendocrine tumors may explain why SV40 TAg is capable of inducing 
neuroendocrine tumors in transgenic mouse models.  
This hypothesis can also get some supportive informations from our CEA424-SV40 
TAg transgenic mouse model system. Former transcriptome microarray analysis 
showed that Cdk4, which is responsible for the phosphorylation of Rb1, is highly 
expressed in the tumor tissue and cell lines from the tumor. More interestingly, Cdk4 
expression level went down after TAg was blocked by siRNA in the cell line 424GC. 
The kockdown of TAg expression also contributed to a reduced expression level of 
genes considered to be typically active in neuroendocrine tumors
37
. These information 
indicate that there is an obvious connection between the TAg expression and the 
neuroendocrine phenotype.  
However, the hypothesis given above might not apply in general because loss of Rb1 
function not always results in a neuroendocrine phenotype. For example, Hill et al 
showed that inactivation of the Rb1 family proteins (Rb/p107/p130) in genetically 
engineered mice led to prostate adenocarcinomas with no evidence of neuroendocrine 
tumors
151
. One possible explanation for this is that the chance for a neuroendocrine 
feature might be bigger when both p53 and Rb1 are suppressed, which is the case for 
SV40 TAg induced transformation. Therefore it seems quite plausible that the 
changes by the expression of the SV40 TAg in the model presented here heavily 
contributes to the neuroendocrine phenotype.  
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7.3  Testing of molecularly targeted therapy on CEA424-SV40 TAg 
transgenic mouse model offered promising candidates for the 
treatment of neuroendocrine tumors 
 
The CEA424-SV40 TAg transgenic mice develop spontaneous tumors in the stomach. 
This mirrors the pathophysiology of the tumor disease probably much better than the 
xenograft models. In addition, several cell lines derived from the tumor were also well 
established which is another advantage. These in vitro and in vivo systems offered the 
opportunity to test new targeted treatment protocols for gastric neuroendocrine tumors 
in a preclinical setting. 
To choose reasonable targets for testing novel therapies, agents belonging to the 
following two families were taken into consideration: agents targeting molecular 
markers for NET (like mTOR inhibitors and HSP90 inhibitors) and agents targeting 
certain signaling pathways aberrantly regulated by SV40 TAg (like E2F inhibitors and 
the p53 stabilizer Nutlin-3). These selected agents induced anti-proliferation effects in 
vitro which revealed their potential for in vivo study. 
The majority of the in vivo experiments included in this thesis focused on the use of 
mTOR inhibitors. The crucial role taken by the PI(3)K–Akt–mTOR pathway has been 
implicated in the tumorigenesis of many malignancies. Former studies have also 
revealed the link between aberrant PI(3)K–Akt–mTOR signaling and neuroendocrine 
tumors
72, 152-155
. The PI(3)K–Akt–mTOR pathway is also shown to be active in the 
CEA424-SV40 TAg gastric tumor cells as all the tumor derived cell lines tested 
displayed a high expression level of the phosphorylated p70S6K, which is a hallmark 
of TOR-activation. In the in vitro study, the mTOR inhibitors RAD001 and 
NVP-BEZ235 (Novartis) suppressed cell proliferation and induced cell apoptosis in 
all the three cell lines at clinically relevant low concentrations. All these information 
provided a rationale for testing their anti-tumor efficiency in vivo.  
Two different experimental setting were used for the RAD001 in vivo studies. In the 
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first set up (experiment A), mice were sacrificed when they lost 20% of their peak 
weight. This was the end point according to the legal restrictions by animal rights. 
From this setting, the effect of the treatment on survival time could be learned. In the 
second set up (experiment B), the experiment was stopped when the mice reached the 
same age (d98, this was when the first control mouse started to lose weight) for a 
timely more precise analysis of the molecular biological changes of the tumor cells. 
Daily feeding the CEA424-SV40 TAg transgenic mice with 10 mg/kg RAD001 
significantly prolonged the survival time of the tumor bearing mice by 35 days on 
average. Significantly decreased tumor weights were observed in the second 
experiment with a 48-day treatment. RAD001 treatment in vivo had a slight influence 
on the neuroendocrine phenotype of the tumor as the expression levels of glucagon 
and Nkx2.2 were reduced. 
To dig into the mechanism of how RAD001 induced the anti-tumor effects both in 
vitro and in vivo, the active state of two major mTORC1 substrates, the eukaryotic 
translation initiation factor 4E (eIF4E)-binding protein(4EBP1) and p70 ribosomal S6 
kinase (p70S6K)
137, 138
, was checked. In the in vitro study, a suppressed 
phospho-4EBP1 expression was observed 72 hours after RAD001 treatment while a 
complete elimination of phosphorylation of p70S6K could already be achieved even 
after 2 hours treatment. This clearly shows that the treatment of RAD001 was 
efficient in vitro. In the in vivo experiment, daily RAD001 treatment also significantly 
decreased the expression of the active form of p70S6K (p-p70S6K). The active 
p70S6K promotes translation and growth by phosphorylating cellular substrates, such 
as S6. A significantly decreased number of phospho-S6 positive cells in the tumor 
areas were observed in the RAD001 treated mice when compared with the control 
mice, which indicates a suppressed S6 ribosomal protein function. As both p70S6K 
and 4EBP1 are essential for regulating cell growth and proliferation, their suppression 
can explain the therapeutic effects induced by RAD001 both in vitro and in vivo. On 
the other hand, not all of these substrates were suppressed in vivo. The mTOR-4EBP1 
and mTOR-p70S6K pathway were still active in some tumor cells. This observation 
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showed either that the local concentration was too low or single cells escape from the 
active drug. 
 
7.4  Possible escape mechanism for the tumor cells under RAD001 
treatment  
 
In the in vivo experiment, the RAD001 treatment did not eliminate all the tumor cells 
and the RAD001 treated mice still developed highly proliferative tumors which 
eventually led to the death of these mice. This is similar to the situation in the clinic. 
Although the treatment with everolimus prolonged the progression-free survival of the 
patients
62
, the patients were not cured.  
There were several possibilities for the incomplete elimination of tumor cells in the in 
vivo experiment. First, the concentration used in the in vivo experiment may not be 
high enough. RAD001 could kill 100% of the tumor cells in vitro at a concentration of 
10M. An estimate of the serum concentration after total absorption clearly gave a 
concentration higher than 10M. In the complex in situ environment, however, the 
real drug concentration may be too low to cause a lethal effect, especially when the 
tumor cells were under the protection of supportive cells around them. In addition, the 
metabolic process may reduce the drug activity. To answer this question, tumor tissue 
as well as other organs like liver and kidney were taken from the RAD001 treated 
mice and analyzed by MALDI Imaging technique to see if RAD001 could be detected 
in these tissues. The signal for RAD001, however, was quite low in the tested tissue 
(data not shown). Another form of escape mechanism is the loss of the 
p70S6K-mediated negative feedback loop on the PI(3)K–Akt–mTOR pathway. IRS-1 
can activate the PI(3)K–Akt signaling through IGF-1. By phosphorylating IRS-1, 
S6K1 destabilizes IRS-1 and blocks its effect on the PI(3)K–Akt signaling
138
. An 
increase of phospho-Akt expression could clearly been shown in the RAD001 treated 
tumor cells which indicates that single RAD001 treatment induced the feedback 
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activation of PI(3)K–Akt–mTOR signaling and this may explain why the elimination 
of tumor cells was not complete. This effect has also been reported in other 
neuroendocrine tumor cell lines which may attenuate the anti-tumor efficacy of the 
drug
137
.   
However, the most likely explanation for ongoing tumor growth in the RAD001 
treated mice could be the induction of drug resistance in the tumor cells. The 
treatment may select a certain population of the primary tumor cells which 
successfully escape the treatment. Long term RAD001 selection may either enrich 
potential “cancer stem cells” in this population or induce further transformation of the 
tumor cells to overcome the tough anti-tumor environment. To answer this question, 
RAD001 resistant cell lines were established and the expression of several stem cell 
markers, some of which were also considered as “cancer stem cell” markers, was 
screened. Epithelial stem cell markers from the “CBC” model (Lgr5, Olfm4), and the 
“+4” model (Bmi1, Tert) were included. From the markers selected, a down-regulated 
expression level was only observed for Olfm4 in the RAD001 selected cell lines. The 
expression of all the other markers was not affected by the long term RAD001 
treatment. Similar experiments were applied to the tumor tissue from the second 
RAD001 in vivo experiment to see if a long term selection in vivo could have some 
effect on the expression of certain markers. Except for Ascl2, which was suppressed 
after RAD001 treatment, all the other markers checked were not significantly affected. 
Thus, these studies showed that the RAD001 treatment had no strong effect on the 
expression of stem cell markers and therefore not induce dedifferentiation of the 
tumor cells. It is hard to see if the treatment enriched a “cancer stem cell” like 
population. However, these results were from single experiment and the RT-PCR 
itself may not be sensitive enough to detect these effects. In fact, our microarray 
analysis with RNA from tumor tissue of RAD001 treated mice and control mice 
revealed a series of genes significantly up or down regulated by RAD001 treatment in 
vivo (data not shown), including genes of neuroendocrine lineage (Chga, Cck, Nkx2.2, 
Tph1), epithelial stem cell markers (Olfm4, Sox9) and mesenchymal stem cell 
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markers (c-Kit, Etv1), although more detailed analysis on the array data is needed to 
obtain a deeper insight into this issue.  
 
7.5 Possible candidates for the tumor originating cells in 
CEA424-SV40 TAg transgenic mouse 
 
The origin of the cells from which GEP-NETs arise is poorly understood. The 
transformation may take place either on precursor/stem cells or terminally 
differentiated neuroendocrine cells. There is a theory which describes the 
transformative events in the development of GEP-NETs. It postulates that the earlier 
the damage is, the poorer the prognosis is. In other word, damages occuring at a 
committed neuroendocrine precursor stage are more likely to induce 
well-differentiated NETs (NET-G1) while damages occuring early in stem cell 
progress may probably lead to the development of high grade or poorly differentiated 
neuroendocrine carcinomas (NECs)
42
.  
Based on the mophology and the Ki-67 index, the gastric tumors developed in the 
CEA424-SV40 TAg transgenic mice were defined as neuroendocrine carcinomas. 
According to the theory described above, the tumor initiating cells may be the 
neuroendocrine precursor/stem cells. In addition, the tumor cells express multiple 
neuroendocrine markers and could produce several peptide, which further indicates 
that the transformation may have taken place in an early stage.  
Gut neuroendocrine cells exist throughout the length of the gut and are the largest 
population of hormone-producing cells in the body
3
. At present, there have been at 
least 17 different neuroendocrine cells identified in the gastrointestinal tract including 
the pancreas which derive from local multipotent gastrointestinal stem cells, although 
in the past they are thought to migrate from the neural crest
42, 156
. Therefor, the newly 
described stem cell models in the gastrointestinal system may give some indications 
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where the tumor cells in the CEA424-SV40 TAg transgenic mouse model come from.  
Nick Barker et al described a population of Lgr5
+ve
 cells, which are predominantly 
restricted to the base of adult pyloric glands, as multi-potent, self-renewing stem cells 
responsible for the long-term renewal of the gastric epithelium
84
. And it has been 
reported that Lgr5 positive cells can give rise to chromogranin A expressing cells
123
. 
To see if these Lgr5
+ve
 cells might be the tumor initiating cells targeted by TAg, 
CEA424-SV40 TAgLgr5-EGFP-IRES-CreERT2 double transgenic mouse line was 
generated. However, there was no GFP/TAg double-positive cells observed in the 
gastric mucosa or in gastric tumors even in young mice. Lineage tracing experiment 
could not provide supportive information for the hypothesis that the Lgr5
+ve
 cells may 
give rise to the tumor either (data from E. Vetter and W. Zimmermann, unpublished 
results). It seems unlikely that Lgr5
+ve
 cells in the stomach could be the primary target 
of TAg.  
Both the stomach and the small intestine are of common endodermal origin and have 
a constantly renewing epithelium. Moreover, the gastric units are somehow similar to 
the crypts in the small intestine with “stem cell zone” at the bottom. Since the stem 
cell theories for stomach and small intestine share some common ground and the stem 
cell markers of small intestine are better described, the stem cell models for the small 
intestine were used for reference. There are currently two epithelial stem cell pools 
described in the small intestine, the crypt base columnar (CBC) cells pool and the 
“+4” cell pool. As the typical “CBC” marker Lgr5 is not likely to be expressed in the 
tumor originating cells of the CEA424-SV40 TAg gastric tumor, the “+4” cell pool 
was taken into consideration. Bmi1 is the most prominent marker for the “+4” cells 
and is the most highly expressed epithelial stem cell marker tested in the cell lines 
derived from the CEA424-SV40 TAg gastric tumors. The tumor cell lines derived 
from the tumor showed a high expression of Bmi1 in RT-PCR and cDNA expression 
array. This could be further substantiated by western-blotting and 
immunohistochemistry. Consequently, Bmi1 message could also be found in the 
growing tumors by RT-PCR and cDNA expression array. Immunohistologic staining 
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for Bmi1 revealed TAg and Bmi1 double positive cells in the tumor tissue while a 
100% positive rate was observed in the isolated cell lines. In addition, when 
SV40-TAg expression was knocked down by siRNA assay, the expression level of 
Bmi1 in cell line 424GC also went down, thus showing the interrelationship.  
These observations indicate that these Bmi1 positive cells may be one target of the 
transformation induced by TAg. In fact, when we take a close look at Bmi1 function 
and the signaling pathway in which it is involved, more supportive information came 
up. Bmi1 is a component of polycomb group (PcG) multiprotein PRC1-like 
complex
157
. There have been studies which characterized the role of Bmi1 in multiple 
biological processes. For example, Bmi1 is involved in the self-renewal, maintenance 
and differentiation of normal stem cells in intestine
95
, lung
158
, liver
159
, prostate
160
, 
pancreas
161
, as well as in neural and hemopoietic system
162, 163
. It is found to be 
frequently up-regulated in various types of human cancers, including bladder 
cancer
164
, breast cancer
165
, gastric cancer
166-169
, liver cancer
170
, lymphoma
171
, prostate 
cancer
160, 172
 and skin cancer
173
, and is responsible for chemoresistance
157, 174-178
 . 
Except for contributing to epithelial-mesenchymal transition (EMT)
179-181
 and 
senescence regulation
182
, Bmi1 also takes part in the maintenance of “cancer stem 
cell” in some tumor types
159, 183-186
. Bmi1 performs these functions by regulating 
p16
Ink4a
 and p19
Arf
 genes. p16
Ink4a
 regulates the formation of cyclin D/Cdk4/6 complex. 
This complex can phosphorylate RB1, thus promoting transcriptional activation of 
E2F1-regulated S-phase genes. On the other hand, p19
Arf
 helps to maintain a certain 
level of p53 through inhibiting MDM2-mediated p53 degradation
182
. By controlling 
the activation of p16
Ink4a
 and p19
Arf
, Bmi1 plays an essential role in cell cycle 
progression and DNA synthesis. It is worth noting that through these two pathways 
Bmi1 has an impact on RB1 and p53 indirectly, which are two major targets of TAg. 
This may indicate a closer internal relationship between Bmi1 and the CEA424-SV40 
TAg gastric tumor. Our data clearly show that Bmi1 declines after inhibition of the 
TAg expression. So in the model presented here, TAg drives the expression of Bmi1 
which may lead to a further enhancement of the TAg effects on RB1 and p53. On the 
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other hand, we observed that the TAg expression was not strongly affected by the 
knockdown of Bmi1. Therefore, the Bmi1 expression is more likely a consequence of 
TAg expression rather than the other way around.    
In addition to epithelial stem cells, the possibility of mesenchymal stem cells as tumor 
originating cell in the CEA424-SV40 TAg transgenic mouse model was also 
presented in this thesis. The observation of the TAg positive cells in the muscularis 
mucosae of antrum and duodenum in young mice suggested a possible mesenchymal 
origin of the tumor. The expression of Etv1 in both the cell lines and the tumor tissue 
added more supportive information for this hypothesis. The more interesting 
observation was that, Etv1 expression level in the tumor tissue increased over the time 
course of the tumor development, while no significant difference of Bmi1 expression 
was observed between different age groups. Since the CEA-promoter, which 
controled the expression of TAg in the transgenic mice, contains Etv1 binding sites 
(A/CGGAAG), it is tempting to speculate that this may drive the transcription of the 
TAg.  
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8  PERSPECTIVES 
So far, the neuroendocrine phenotype developed in the CEA424-SV40 TAg 
transgenic mouse model has been confirmed. Testing of molecularly targeted 
therapies like the studies on mTOR inhibitors achieved promising anti-tumor effects. 
Analysis on the expression patterns of epithelial and mesenchymal stem cell markers 
offered some clues for the originating cells of the CEA424-SV40 TAg gastric tumor. 
However, there are still several questions to be answered: 
 Except for inactivating pRB and p53, are there other important tumorigenesis 
mechanisms for the transformation induced by the TAg in the CEA424-SV40 
TAg transgenic mouse? Is the TAg directly involved in the development of the 
neuroendocrine phenotype and how is this achieved?  
 Will other molecularly targeted agents, like the ones targeting angiogenesis and 
growth factors, have efficient anti-tumor effects in CEA424-SV40 TAg 
transgenic mouse as well? What about combination strategies?  
 Is there a specific cell type which is first transformed by the TAg? 
It would be fascinating to continue research based on these questions with this mouse 
model system. Thus, this model could be of great value not only for further studies on 
the mechanisms of how SV40 TAg induces neuroendocrine tumors but also for testing 
new treatment protocols in a preclinical setting. 
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9  CONCLUSIONS 
The main goal of this thesis was to characterize the CEA424-SV40 TAg transgenic 
mouse model in more detail including the identification of the tumor originating cells 
in this model system and to test novel molecularly targeted therapies for gastric 
neuroendocrine tumors. Specifically, the following results were obtained: 
 The CEA424-SV40 TAg gastric tumors exhibit a typical neuroendocrine 
phenotype and the tumors were classified as neuroendocrine carcinomas. 
 Testing of the molecularly targeted therapy both in vitro and in vivo offered 
promising candidates for further clinical evaluation to improve current 
management of neuroendocrine tumors. 
 Bmi1 is highly expressed in the CEA424-SV40 TAg gastric tumor as well as the 
tumor derived cell lines. Instead of being involved in the tumor initiating issue, 
Bmi1 expression is more likely a result of the TAg expression. 
 Etv1 expressing mesenchymal stem cells may be the tumor originating cells of 
the CEA424-SV40 TAg transgenic mouse model. 
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10  EQUIPMENT AND CONSUMABLES 
10.1  General materials 
 
Equipment and consumables Manufacturers 
Ice machine ZIEGRA, Isernhagen, Germany 
Autoclave MMM, Munich, Germany 
Freezer -80°C Hettich, Germany 
Freezer -20°C Siemens, Germany 
Freezer 4°C Liebherr, Germany 
microplate ELISA reader Tecan, Crailsheim, Germany 
Micropipettor Eppendorf, Germany 
Vortex mix IKA, Wilmington, USA 
Heating plate IKA-Werke, Germany 
Centrifuge Eppendorf, Germany 
 
10.2 Cell culture 
 
Equipment and consumables Manufacturers 
Flow Cytometer Beckman Coulter, Germany 
Sterile tissue culture plastic flasks NUNC, Roskilde, Denmark 
Centrifuge tubes 15 mL   Greiner Bio-One, Germany 
50ml Polypropylene Conical Tube BD, NJ, USA 
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6-well culture plates Corning, NY, USA 
12-well culture plates Corning, NY, USA 
96-well culture plates NUNC, Roskilde, Denmark 
100 mm Cell Culture Dish BD Falcon, USA 
Cryotube (1.0 ml) NUNC, Roskilde, Denmark 
Corning® Costar® Stripette® serological 
pipettes (2.0 mL, 5.0ml, 10ml, 25ml) 
Corning, NY, USA 
Pipetboy Pipet Controller IBS Integra, Swiss 
Hemacytometer and cover-slip Optik Labor, Germany 
CO2 incubator BINDER, Germany 
Microscope Leitz, Germany 
Biological safety cabinet Heraeus, Germany 
Water bath B. Braun, USA 
Stericup® Filter Unit Millipore 
Burner Schütt Labortechnik, Germany 
Vaccum gas pump  VWR, France 
Parafilm American National Can Company, USA 
 
10.3  Animal experiments 
 
Equipment and consumables Manufacturers 
INTRAMEDIC polyethylene tube (ID: Clay Adams, USA 
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0.76mm; OD: 1.22mm) 
Syringe BD Plastipak
TM
, Madrid, Spain 
Injection needle BD Microlance
TM
, Spain 
Electronic scales 
Waagendienst Winkler GmbH,  
Munich, Germany 
Forceps Dosch GmbH, Heidelberg, Germany 
Scissors, sharp / blunt Dosch GmbH, Heidelberg, Germany 
Cryotube (1ml) NUNC, Roskilde, Denmark 
 
10.4  RNA isolation and reverse transcription PCR  
 
Equipments/consumables Manufacturers 
Tissue grind machine Heidolph, Germany 
Electrophoresis power supply MWG Biotech, Germany 
Heating plate IKA-Werke, Germany 
Electrophoresis chamber PEQLAB Biotechnologie, Germany 
Vortexer IKA-Werke, Germany 
PCR soft tubes Biozym Biotech Trading, Wien, Austria 
Stratagene Robocycler Gradient 40 Stratagene, USA 
DNA Thermal Cycler  Perkin Elmer, USA 
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10.5 Immunohistochemistry and immunofluorescence 
 
Equipment and consumables Manufacturers 
Microscope Carl Zeiss, Germany 
Microtome  Leica, Germany 
Microtome blade Feather, Japan 
Forceps/brush Leica, Germany 
Water bath GFL, Germany 
Oven Heraeus, Germany 
Coverplate chamber Thermo Shandon, Pittsburgh, USA 
Superfrost® Plus microscope slides 
Thermo Scientific Gerhard Menzel, 
Braunschweig, Germany 
Coverslip 
Thermo Scientific Gerhard Menzel, 
Braunschweig, Germany 
24 well plate Corning, NY, USA 
Cover glass Thermo Scientific, Germany 
PH meter WTW, Germany 
 
10.6  Western blot 
 
Equipment and consumables Manufacturers 
Electrophoresis chamber Pharmacia Biotech, USA 
Power supply SERVA, Germany 
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Electrophoresis transfer unit LKB, Sweden 
Shaker GFL, Germany 
Hamamatsu aequoria imaging system 
Hamamatsu Photonics, Herrsching, 
Germany 
Cooling centrifuge Eppendorf, Germany 
Protran™ nitrocellulose (NC) membranes Whatman, Germany 
Gel Transfer filter paper Whatman, Germany 
8-16% Precise Protein Gels  Thermo Scientific, USA 
96-well-plates NUNC, Roskilde, Denmark 
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11  ABBREVIATIONS  
4EBP1, Eukaryotic translation initiation factor 4E-binding protein 1 
5-FU, 5-fluorouracil 
AEC, 3-Amino-9-Ethylcarbazole 
Ascl2, Achaete-scute complex homolog 2 
Bmi1, B lymphoma Mo-MLV insertion region 1 homolog 
BSA, Bovine serum albumin 
C57BL/6, C57 black 6 mouse 
CBCs, crypt base columnar cells 
CEA, Carcinoembryonic antigen 
DAB, 3,3'-Diaminobenzidine 
DCAMKL-1, doublecortin-like kinase 1 
DMSO, Dimethyl sulfoxide 
dNTP, PCR Nucleotide Mix 
EDTA, Ethylenediaminetetraacetic acid 
EGFR, Epidermal growth factor receptor 
ELISA, Enzyme-linked immunosorbent assay 
EMR, Endoscopic mucosal resection 
EMT, Epithelial-mesenchymal transition  
Etv1, ETS translocation variant 1  
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase 
GEP-NETs, Gastroenteropancreatic neuroendocrine tumors 
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Hopx, Homeodomain-only protein 
HRP, Horseradish peroxidase 
HSP, Heat shock protein 
IFN, Interferon 
IGF-1, Insulin-like growth factor 1 
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IL-6, Interleukin-6 
ISCs, Intestinal stem cells 
Lgr5, Leucine-rich repeat-containing G-protein coupled receptor 5 
Lrig1, Leucine-rich repeats and immunoglobulin-like domains protein 1  
MEN1, neoplasia type 1  
MgCl2, Magnesium chloride 
Msi1, Musashi homolog 1 
mTOR, mammalian target of rapamycin 
NCCN, National Comprehensive Cancer Network 
NECs, neuroendocrine carcinomas 
NF-1, neurofibromatosis-1 
Olfm4, Olfactomedin 4 
PCR, polymerase chain reaction 
PDGF, platelet-derived growth factor  
PFS, Progression-free survival  
PI3K, Phosphatidylinositol 3-kinase 
Prom1, Prominin 1 
PRRT, Peptide receptor radionuclide therapy 
PTEN, Phosphatase and tensin homolog 
PVDF, Polyvinylidene Fluoride 
Tris, Tris hydroxymethyl aminomethane 
SDS, Sodium dodecyl sulfate 
SEER, The Surveillance, Epidemiology, and End Results database 
sFRP5, Secreted frizzled-related protein 5  
SSAs, Somastostatin analogues  
SOX, SRY-related HMG-box 
STAT3, Signal transducer and activator of transcription 3 
STZ, streptozotocin 
SV40 TAg, Simian Vacuolating Virus 40 large T antigen  
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TERT, Telomerase reverse transcriptase  
TSC2, tuberous sclerosis 2 
VEGF, vascular endothelial growth factor 
VEGFR-1, Vascular endothelial growth factor receptor-1 
VHL, von Hippel-Lindau disease 
 
 
 
 
 
 
 
 
 
 128 
12  REFERENCES 
1. DePinho RA, Jacks T: Introduction. The laboratory mouse in cancer research, 
Semin Cancer Biol 2001, 11:175-176 
2. Hanahan D, Wagner EF, Palmiter RD: The origins of oncomice: a history of the 
first transgenic mice genetically engineered to develop cancer, Genes Dev 2007, 
21:2258-2270 
3. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, 
Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, 
Salazar R, Ruszniewski P, Sundin A: Gastroenteropancreatic neuroendocrine tumours, 
Lancet Oncol 2008, 9:61-72 
4. Jones KB, Haldar M, Schiffman JD, Cannon-Albright L, Lessnick SL, Sharma S, 
Capecchi MR, Randall RL: Of mice and men: opportunities to use genetically 
engineered mouse models of synovial sarcoma for preclinical cancer therapeutic 
evaluation, Cancer Control 2011, 18:196-203 
5. Olive KP, Tuveson DA: The use of targeted mouse models for preclinical testing 
of novel cancer therapeutics, Clin Cancer Res 2006, 12:5277-5287 
6. Singh M, Johnson L: Using genetically engineered mouse models of cancer to aid 
drug development: an industry perspective, Clin Cancer Res 2006, 12:5312-5328 
7. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, 
Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA: Relationships 
between drug activity in NCI preclinical in vitro and in vivo models and early clinical 
trials, Br J Cancer 2001, 84:1424-1431 
8. Carver BS, Pandolfi PP: Mouse modeling in oncologic preclinical and 
translational research, Clin Cancer Res 2006, 12:5305-5311 
9. Abate-Shen C: A new generation of mouse models of cancer for translational 
research, Clin Cancer Res 2006, 12:5274-5276 
10. Rathi AV, Cantalupo PG, Sarkar SN, Pipas JM: Induction of 
interferon-stimulated genes by Simian virus 40 T antigens, Virology 2010, 
406:202-211 
11. Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, 
Sanda MG: A safety-modified SV40 Tag developed for human cancer 
immunotherapy, Drug Des Devel Ther 2009, 2:17-24 
12. David H, Mendoza S, Konishi T, Miller CW: Simian virus 40 is present in human 
lymphomas and normal blood, Cancer Lett 2001, 162:57-64 
13. Shivapurkar N, Harada K, Reddy J, Scheuermann RH, Xu Y, McKenna RW, 
Milchgrub S, Kroft SH, Feng Z, Gazdar AF: Presence of simian virus 40 DNA 
sequences in human lymphomas, Lancet 2002, 359:851-852 
14. Jasani B, Cristaudo A, Emri SA, Gazdar AF, Gibbs A, Krynska B, Miller C, 
Mutti L, Radu C, Tognon M, Procopio A: Association of SV40 with human tumours, 
Semin Cancer Biol 2001, 11:49-61 
15. Klein G, Powers A, Croce C: Association of SV40 with human tumors, Oncogene 
2002, 21:1141-1149 
 
 129 
16. Garcea RL, Imperiale MJ: Simian virus 40 infection of humans, J Virol 2003, 
77:5039-5045 
17. Cuesta I, Nunez-Ramirez R, Scheres SH, Gai D, Chen XS, Fanning E, Carazo JM: 
Conformational rearrangements of SV40 large T antigen during early replication 
events, J Mol Biol 2010, 397:1276-1286 
18. Ahuja D, Saenz-Robles MT, Pipas JM: SV40 large T antigen targets multiple 
cellular pathways to elicit cellular transformation, Oncogene 2005, 24:7729-7745 
19. Shah KV: Does SV40 infection contribute to the development of human cancers?, 
Rev Med Virol 2000, 10:31-43 
20. Ali SH, DeCaprio JA: Cellular transformation by SV40 large T antigen: 
interaction with host proteins, Semin Cancer Biol 2001, 11:15-23 
21. Kierstead TD, Tevethia MJ: Association of p53 binding and immortalization of 
primary C57BL/6 mouse embryo fibroblasts by using simian virus 40 T-antigen 
mutants bearing internal overlapping deletion mutations, J Virol 1993, 67:1817-1829 
22. Pipas JM, Levine AJ: Role of T antigen interactions with p53 in tumorigenesis, 
Semin Cancer Biol 2001, 11:23-30 
23. Oren M, Maltzman W, Levine AJ: Post-translational regulation of the 54K 
cellular tumor antigen in normal and transformed cells, Mol Cell Biol 1981, 
1:101-110 
24. Henning W, Rohaly G, Kolzau T, Knippschild U, Maacke H, Deppert W: MDM2 
is a target of simian virus 40 in cellular transformation and during lytic infection, J 
Virol 1997, 71:7609-7618 
25. DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, Lee WH, Marsilio E, 
Paucha E, Livingston DM: SV40 large tumor antigen forms a specific complex with 
the product of the retinoblastoma susceptibility gene, Cell 1988, 54:275-283 
26. Sullivan CS, Gilbert SP, Pipas JM: ATP-dependent simian virus 40 
T-antigen-Hsc70 complex formation, J Virol 2001, 75:1601-1610 
27. Johnson JL, Pillai S, Pernazza D, Sebti SM, Lawrence NJ, Chellappan SP: 
Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 
interaction as a novel target for metastatic disease, Cancer Res 2012, 72:516-526 
28. Gordon GM, Du W: Conserved RB functions in development and tumor 
suppression, Protein Cell 2011, 2:864-878 
29. Munro S, Carr SM, La Thangue NB: Diversity within the pRb pathway: is there a 
code of conduct?, Oncogene 2012,  
30. Thompson J, Epting T, Schwarzkopf G, Singhofen A, Eades-Perner AM, van Der 
Putten H, Zimmermann W: A transgenic mouse line that develops early-onset 
invasive gastric carcinoma provides a model for carcinoembryonic antigen-targeted 
tumor therapy, Int J Cancer 2000, 86:863-869 
31. Nockel J, van den Engel NK, Winter H, Hatz RA, Zimmermann W, Kammerer R: 
Characterization of gastric adenocarcinoma cell lines established from CEA424/SV40 
T antigen-transgenic mice with or without a human CEA transgene, BMC Cancer 
2006, 6:57 
32. Regel I, Merkl L, Friedrich T, Burgermeister E, Zimmermann W, Einwachter H, 
Herrmann K, Langer R, Rocken C, Hofheinz R, Schmid R, Ebert MP: Pan-histone 
 
 130 
deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via 
induction of CITED2, Gastroenterology 2012, 143:99-109 e110 
33. Yuan G, Regel I, Lian F, Friedrich T, Hitkova I, Hofheinz RD, Strobel P, Langer 
R, Keller G, Rocken C, Zimmermann W, Schmid RM, Ebert MP, Burgermeister E: 
WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin 
in human gastric cancer cells, Oncogene 2012,  
34. van den Engel NK, Ruttinger D, Rusan M, Kammerer R, Zimmermann W, Hatz 
RA, Winter H: Combination immunotherapy and active-specific tumor cell 
vaccination augments anti-cancer immunity in a mouse model of gastric cancer, J 
Transl Med 2011, 9:140 
35. Bourquin C, von der Borch P, Zoglmeier C, Anz D, Sandholzer N, Suhartha N, 
Wurzenberger C, Denzel A, Kammerer R, Zimmermann W, Endres S: Efficient 
eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T 
cell transfer in an SV40 T antigen mouse model, J Immunol 2010, 185:2580-2588 
36. Ballesta AM, Molina R, Filella X, Jo J, Gimenez N: Carcinoembryonic antigen in 
staging and follow-up of patients with solid tumors, Tumour Biol 1995, 16:32-41 
37. Ihler F, Vetter EV, Pan J, Kammerer R, Debey-Pascher S, Schultze JL, 
Zimmermann W, Enders G: Expression of a neuroendocrine gene signature in gastric 
tumor cells from CEA 424-SV40 large T antigen-transgenic mice depends on SV40 
large T antigen, PLoS One 2012, 7:e29846 
38. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, 
Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after "carcinoid": 
epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in 
the United States, J Clin Oncol 2008, 26:3063-3072 
39. Buchanan KD, Johnston CF, O'Hare MM, Ardill JE, Shaw C, Collins JS, Watson 
RG, Atkinson AB, Hadden DR, Kennedy TL, et al.: Neuroendocrine tumors. A 
European view, Am J Med 1986, 81:14-22 
40. Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: a 
nationwide epidemiologic study from Sweden, Cancer 2001, 92:2204-2210 
41. Levi F, Te VC, Randimbison L, Rindi G, La Vecchia C: Epidemiology of 
carcinoid neoplasms in Vaud, Switzerland, 1974-97, Br J Cancer 2000, 83:952-955 
42. Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM: The diversity and 
commonalities of gastroenteropancreatic neuroendocrine tumors, Langenbecks Arch 
Surg 2011, 396:273-298 
43. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge 
U, Sasano H, Tomassetti P, Salazar R, Ruszniewski P: ENETS Consensus Guidelines 
for the management of patients with gastroduodenal neoplasms, Neuroendocrinology 
2012, 95:74-87 
44. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, 
McNicol AM, Reed N, Sutton R, Thakker R, Aylwin S, Breen D, Britton K, 
Buchanan K, Corrie P, Gillams A, Lewington V, McCance D, Meeran K, Watkinson 
A: Guidelines for the management of gastroenteropancreatic neuroendocrine 
(including carcinoid) tumours, Gut 2005, 54 Suppl 4:iv1-16 
45. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors, 
 
 131 
Cancer 2003, 97:934-959 
46. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M: 
Chromogranin A--biological function and clinical utility in neuro endocrine tumor 
disease, Ann Surg Oncol 2010, 17:2427-2443 
47. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E: Priorities for 
improving the management of gastroenteropancreatic neuroendocrine tumors, J Natl 
Cancer Inst 2008, 100:1282-1289 
48. Hanahan D: Heritable formation of pancreatic beta-cell tumours in transgenic 
mice expressing recombinant insulin/simian virus 40 oncogenes, Nature 1985, 
315:115-122 
49. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, Barbacid M: 
Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results 
in beta-islet cell hyperplasia, Nat Genet 1999, 22:44-52 
50. Garabedian EM, Humphrey PA, Gordon JI: A transgenic mouse model of 
metastatic prostate cancer originating from neuroendocrine cells, Proc Natl Acad Sci 
U S A 1998, 95:15382-15387 
51. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha 
GR, Balmain A: Dissociation of epithelial and neuroendocrine carcinoma lineages in 
the transgenic adenocarcinoma of mouse prostate model of prostate cancer, Am J 
Pathol 2008, 172:236-246 
52. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, 
Tsukamoto T, Shappell SB, Matusik RJ: A probasin-large T antigen transgenic mouse 
line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic 
potential, Cancer Res 2001, 61:2239-2249 
53. Czeh M, Loddenkemper C, Shalapour S, Schon C, Robine S, Goldscheid E, Stein 
H, Schuler T, Willimsky G, Blankenstein T: The immune response to sporadic 
colorectal cancer in a novel mouse model, Oncogene 2010, 29:6591-6602 
54. Syder AJ, Karam SM, Mills JC, Ippolito JE, Ansari HR, Farook V, Gordon JI: A 
transgenic mouse model of metastatic carcinoma involving transdifferentiation of a 
gastric epithelial lineage progenitor to a neuroendocrine phenotype, Proc Natl Acad 
Sci U S A 2004, 101:4471-4476 
55. Yang Q, Guan KL: Expanding mTOR signaling, Cell Res 2007, 17:666-681 
56. Capdevila J, Salazar R, Halperin I, Abad A, Yao JC: Innovations therapy: 
mammalian target of rapamycin (mTOR) inhibitors for the treatment of 
neuroendocrine tumors, Cancer Metastasis Rev 2011, 30 Suppl 1:27-34 
57. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism, 
Cell 2006, 124:471-484 
58. Pavel M: Translation of Molecular Pathways into Clinical Trials of 
Neuroendocrine Tumors, Neuroendocrinology 2012,  
59. Chiu CW, Nozawa H, Hanahan D: Survival benefit with proapoptotic molecular 
and pathologic responses from dual targeting of mammalian target of rapamycin and 
epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine 
carcinogenesis, J Clin Oncol 2010, 28:4425-4433 
60. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang 
 
 132 
LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA, Jr., Vogelstein B, Kinzler 
KW, Hruban RH, Papadopoulos N: DAXX/ATRX, MEN1, and mTOR pathway 
genes are frequently altered in pancreatic neuroendocrine tumors, Science 2011, 
331:1199-1203 
61. Strimpakos AS, Syrigos KN, Saif MW: Pancreatic neuroendocrine tumors: role of 
novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". 
San Francisco, CA, USA. January 20-22, 2011, JOP 2011, 12:117-119 
62. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, 
Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, 
Lincy J, Lebwohl D, Oberg K: Everolimus for advanced pancreatic neuroendocrine 
tumors, N Engl J Med 2011, 364:514-523 
63. de Gramont A, Van Cutsem E: Investigating the potential of bevacizumab in 
other indications: metastatic renal cell, non-small cell lung, pancreatic and breast 
cancer, Oncology 2005, 69 Suppl 3:46-56 
64. Duran I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu LL, Yao J, Tabernero 
J: New drug development in digestive neuroendocrine tumors, Ann Oncol 2007, 
18:1307-1313 
65. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K, 
Yao JC: Elevated expression of vascular endothelial growth factor correlates with 
increased angiogenesis and decreased progression-free survival among patients with 
low-grade neuroendocrine tumors, Cancer 2007, 109:1478-1486 
66. Knosel T, Chen Y, Altendorf-Hofmann A, Danielczok C, Freesmeyer M, 
Settmacher U, Wurst C, Schulz S, Yang LL, Petersen I: High KIT and PDGFRA are 
associated with shorter patients survival in gastroenteropancreatic neuroendocrine 
tumors, but mutations are a rare event, J Cancer Res Clin Oncol 2012, 138:397-403 
67. Grande E, Diez JJ, Pachon V, Carrato A: Advances in the therapy of 
gastroenteropancreatic-neuroendocrine tumours (GEP-NETs), Clin Transl Oncol 2010, 
12:481-492 
68. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng 
C, Abbruzzese JL, Ajani JA: Targeting vascular endothelial growth factor in advanced 
carcinoid tumor: a random assignment phase II study of depot octreotide with 
bevacizumab and pegylated interferon alpha-2b, J Clin Oncol 2008, 26:1316-1323 
69. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, 
Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van 
Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib 
malate for the treatment of pancreatic neuroendocrine tumors, N Engl J Med 2011, 
364:501-513 
70. Welin S, Fjallskog ML, Saras J, Eriksson B, Janson ET: Expression of tyrosine 
kinase receptors in malignant midgut carcinoid tumors, Neuroendocrinology 2006, 
84:42-48 
71. Wulbrand U, Wied M, Zofel P, Goke B, Arnold R, Fehmann H: Growth factor 
receptor expression in human gastroenteropancreatic neuroendocrine tumours, Eur J 
Clin Invest 1998, 28:1038-1049 
72. Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis 
 
 133 
MM, Ames MM: Molecular markers for novel therapies in neuroendocrine (carcinoid) 
tumors, Endocr Relat Cancer 2010, 17:623-636 
73. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames 
MM, Lloyd RV: Epidermal growth factor receptor and activated epidermal growth 
factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine 
carcinomas, Mod Pathol 2005, 18:1329-1335 
74. Bergmann F, Breinig M, Hopfner M, Rieker RJ, Fischer L, Kohler C, Esposito I, 
Kleeff J, Herpel E, Ehemann V, Friess H, Schirmacher P, Kern MA: Expression 
pattern and functional relevance of epidermal growth factor receptor and 
cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?, 
Am J Gastroenterol 2009, 104:171-181 
75. Srirajaskanthan R, Shah T, Watkins J, Marelli L, Khan K, Caplin ME: Expression 
of the HER-1-4 family of receptor tyrosine kinases in neuroendocrine tumours, Oncol 
Rep 2010, 23:909-915 
76. Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, 
Komina O, Wesierska-Gadek J, Haitel A, Filipits M, Berger W, Schmid K: 
Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and 
Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR Pathway, 
Neuroendocrinology 2012,  
77. Kaltsas GA, Cunningham JL, Falkmer SE, Grimelius L, Tsolakis AV: Expression 
of connective tissue growth factor and IGF1 in normal and neoplastic gastrointestinal 
neuroendocrine cells and their clinico-pathological significance, Endocr Relat Cancer 
2011, 18:61-71 
78. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, 
Wiedenmann B, Boehm BO, Adler G, Seufferlein T: Insulin-like growth factor-I is an 
autocrine regulator of chromogranin A secretion and growth in human neuroendocrine 
tumor cells, Cancer Res 2000, 60:4573-4581 
79. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, 
Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, 
Puzanov I: Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a 
fully human monoclonal antibody to insulin-like growth factor receptor 1, J Clin 
Oncol 2009, 27:5800-5807 
80. Reidy-Lagunes DL, Vakiani E, Segal MF, Hollywood EM, Tang LH, Solit DB, 
Pietanza MC, Capanu M, Saltz LB: A phase 2 study of the insulin-like growth 
factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated 
neuroendocrine tumors, Cancer 2012,  
81. Barker N, Bartfeld S, Clevers H: Tissue-resident adult stem cell populations of 
rapidly self-renewing organs, Cell Stem Cell 2010, 7:656-670 
82. Bjerknes M, Cheng H: Multipotential stem cells in adult mouse gastric epithelium, 
Am J Physiol Gastrointest Liver Physiol 2002, 283:G767-777 
83. McDonald SA, Greaves LC, Gutierrez-Gonzalez L, Rodriguez-Justo M, 
Deheragoda M, Leedham SJ, Taylor RW, Lee CY, Preston SL, Lovell M, Hunt T, 
Elia G, Oukrif D, Harrison R, Novelli MR, Mitchell I, Stoker DL, Turnbull DM, 
Jankowski JA, Wright NA: Mechanisms of field cancerization in the human stomach: 
 
 134 
the expansion and spread of mutated gastric stem cells, Gastroenterology 2008, 
134:500-510 
84. Barker N, Huch M, Kujala P, van de Wetering M, Snippert HJ, van Es JH, Sato T, 
Stange DE, Begthel H, van den Born M, Danenberg E, van den Brink S, Korving J, 
Abo A, Peters PJ, Wright N, Poulsom R, Clevers H: Lgr5(+ve) stem cells drive 
self-renewal in the stomach and build long-lived gastric units in vitro, Cell Stem Cell 
2010, 6:25-36 
85. Hattori T, Fujita S: Tritiated thymidine autoradiographic study on cellular 
migration in the gastric gland of the golden hamster, Cell Tissue Res 1976, 
172:171-184 
86. Karam SM, Leblond CP: Dynamics of epithelial cells in the corpus of the mouse 
stomach. I. Identification of proliferative cell types and pinpointing of the stem cell, 
Anat Rec 1993, 236:259-279 
87. Karam SM, Leblond CP: Dynamics of epithelial cells in the corpus of the mouse 
stomach. V. Behavior of entero-endocrine and caveolated cells: general conclusions 
on cell kinetics in the oxyntic epithelium, Anat Rec 1993, 236:333-340 
88. Karam SM, Leblond CP: Dynamics of epithelial cells in the corpus of the mouse 
stomach. III. Inward migration of neck cells followed by progressive transformation 
into zymogenic cells, Anat Rec 1993, 236:297-313 
89. Karam SM, Leblond CP: Dynamics of epithelial cells in the corpus of the mouse 
stomach. II. Outward migration of pit cells, Anat Rec 1993, 236:280-296 
90. Barker N, Clevers H: Leucine-rich repeat-containing G-protein-coupled receptors 
as markers of adult stem cells, Gastroenterology 2010, 138:1681-1696 
91. Bjerknes M, Cheng H: Clonal analysis of mouse intestinal epithelial progenitors, 
Gastroenterology 1999, 116:7-14 
92. Hermiston ML, Green RP, Gordon JI: Chimeric-transgenic mice represent a 
powerful tool for studying how the proliferation and differentiation programs of 
intestinal epithelial cell lineages are regulated, Proc Natl Acad Sci U S A 1993, 
90:8866-8870 
93. Cairnie AB, Lamerton LF, Steel GG: Cell proliferation studies in the intestinal 
epithelium of the rat. I. Determination of the kinetic parameters, Exp Cell Res 1965, 
39:528-538 
94. Potten CS: Extreme sensitivity of some intestinal crypt cells to X and gamma 
irradiation, Nature 1977, 269:518-521 
95. Sangiorgi E, Capecchi MR: Bmi1 is expressed in vivo in intestinal stem cells, Nat 
Genet 2008, 40:915-920 
96. Tian H, Biehs B, Warming S, Leong KG, Rangell L, Klein OD, de Sauvage FJ: A 
reserve stem cell population in small intestine renders Lgr5-positive cells dispensable, 
Nature 2011, 478:255-259 
97. Montgomery RK, Carlone DL, Richmond CA, Farilla L, Kranendonk ME, 
Henderson DE, Baffour-Awuah NY, Ambruzs DM, Fogli LK, Algra S, Breault DT: 
Mouse telomerase reverse transcriptase (mTert) expression marks slowly cycling 
intestinal stem cells, Proc Natl Acad Sci U S A 2011, 108:179-184 
98. Breault DT, Min IM, Carlone DL, Farilla LG, Ambruzs DM, Henderson DE, 
 
 135 
Algra S, Montgomery RK, Wagers AJ, Hole N: Generation of mTert-GFP mice as a 
model to identify and study tissue progenitor cells, Proc Natl Acad Sci U S A 2008, 
105:10420-10425 
99. Takeda N, Jain R, LeBoeuf MR, Wang Q, Lu MM, Epstein JA: Interconversion 
between intestinal stem cell populations in distinct niches, Science 2011, 
334:1420-1424 
100. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, 
Higginbotham JN, Juchheim A, Prasad N, Levy SE, Guo Y, Shyr Y, Aronow BJ, 
Haigis KM, Franklin JL, Coffey RJ: The pan-ErbB negative regulator Lrig1 is an 
intestinal stem cell marker that functions as a tumor suppressor, Cell 2012, 
149:146-158 
101. Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, 
Anti M, Van Gijn ME, Suijkerbuijk S, Van de Wetering M, Marra G, Clevers H: The 
Intestinal Wnt/TCF Signature, Gastroenterology 2007, 132:628-632 
102. Gregorieff A, Pinto D, Begthel H, Destree O, Kielman M, Clevers H: 
Expression pattern of Wnt signaling components in the adult intestine, 
Gastroenterology 2005, 129:626-638 
103. Gregorieff A, Clevers H: Wnt signaling in the intestinal epithelium: from 
endoderm to cancer, Genes Dev 2005, 19:877-890 
104. Giannakis M, Stappenbeck TS, Mills JC, Leip DG, Lovett M, Clifton SW, 
Ippolito JE, Glasscock JI, Arumugam M, Brent MR, Gordon JI: Molecular properties 
of adult mouse gastric and intestinal epithelial progenitors in their niches, J Biol 
Chem 2006, 281:11292-11300 
105. May R, Riehl TE, Hunt C, Sureban SM, Anant S, Houchen CW: 
Identification of a novel putative gastrointestinal stem cell and adenoma stem cell 
marker, doublecortin and CaM kinase-like-1, following radiation injury and in 
adenomatous polyposis coli/multiple intestinal neoplasia mice, Stem Cells 2008, 
26:630-637 
106. Gerbe F, Brulin B, Makrini L, Legraverend C, Jay P: DCAMKL-1 
expression identifies Tuft cells rather than stem cells in the adult mouse intestinal 
epithelium, Gastroenterology 2009, 137:2179-2180; author reply 2180-2171 
107. Bezencon C, Furholz A, Raymond F, Mansourian R, Metairon S, Le Coutre J, 
Damak S: Murine intestinal cells expressing Trpm5 are mostly brush cells and express 
markers of neuronal and inflammatory cells, J Comp Neurol 2008, 509:514-525 
108. Cheng H, Leblond CP: Origin, differentiation and renewal of the four main 
epithelial cell types in the mouse small intestine. V. Unitarian Theory of the origin of 
the four epithelial cell types, Am J Anat 1974, 141:537-561 
109. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, 
Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H: Identification of stem cells 
in small intestine and colon by marker gene Lgr5, Nature 2007, 449:1003-1007 
110. dos Santos CM, Hilgert JB, Padilha DM, Hugo FN: Denture stomatitis and 
its risk indicators in south Brazilian older adults, Gerodontology 2010, 27:134-140 
111. Snippert HJ, van der Flier LG, Sato T, van Es JH, van den Born M, 
Kroon-Veenboer C, Barker N, Klein AM, van Rheenen J, Simons BD, Clevers H: 
 
 136 
Intestinal crypt homeostasis results from neutral competition between symmetrically 
dividing Lgr5 stem cells, Cell 2010, 143:134-144 
112. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, 
van Es JH, Abo A, Kujala P, Peters PJ, Clevers H: Single Lgr5 stem cells build 
crypt-villus structures in vitro without a mesenchymal niche, Nature 2009, 
459:262-265 
113. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, 
Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ: Prominin 1 marks intestinal 
stem cells that are susceptible to neoplastic transformation, Nature 2009, 457:603-607 
114. Snippert HJ, van Es JH, van den Born M, Begthel H, Stange DE, Barker N, 
Clevers H: Prominin-1/CD133 marks stem cells and early progenitors in mouse small 
intestine, Gastroenterology 2009, 136:2187-2194 e2181 
115. van der Flier LG, Haegebarth A, Stange DE, van de Wetering M, Clevers H: 
OLFM4 is a robust marker for stem cells in human intestine and marks a subset of 
colorectal cancer cells, Gastroenterology 2009, 137:15-17 
116. Formeister EJ, Sionas AL, Lorance DK, Barkley CL, Lee GH, Magness ST: 
Distinct SOX9 levels differentially mark stem/progenitor populations and 
enteroendocrine cells of the small intestine epithelium, Am J Physiol Gastrointest 
Liver Physiol 2009, 296:G1108-1118 
117. Mori-Akiyama Y, van den Born M, van Es JH, Hamilton SR, Adams HP, 
Zhang J, Clevers H, de Crombrugghe B: SOX9 is required for the differentiation of 
paneth cells in the intestinal epithelium, Gastroenterology 2007, 133:539-546 
118. van der Flier LG, van Gijn ME, Hatzis P, Kujala P, Haegebarth A, Stange DE, 
Begthel H, van den Born M, Guryev V, Oving I, van Es JH, Barker N, Peters PJ, van 
de Wetering M, Clevers H: Transcription factor achaete scute-like 2 controls intestinal 
stem cell fate, Cell 2009, 136:903-912 
119. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den 
Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H: Crypt stem cells as the 
cells-of-origin of intestinal cancer, Nature 2009, 457:608-611 
120. Munoz J, Stange DE, Schepers AG, van de Wetering M, Koo BK, Itzkovitz S, 
Volckmann R, Kung KS, Koster J, Radulescu S, Myant K, Versteeg R, Sansom OJ, 
van Es JH, Barker N, van Oudenaarden A, Mohammed S, Heck AJ, Clevers H: The 
Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell 
markers, EMBO J 2012, 31:3079-3091 
121. Wong VW, Stange DE, Page ME, Buczacki S, Wabik A, Itami S, van de 
Wetering M, Poulsom R, Wright NA, Trotter MW, Watt FM, Winton DJ, Clevers H, 
Jensen KB: Lrig1 controls intestinal stem-cell homeostasis by negative regulation of 
ErbB signalling, Nat Cell Biol 2012, 14:401-408 
122. Li L, Clevers H: Coexistence of quiescent and active adult stem cells in 
mammals, Science 2010, 327:542-545 
123. Sato T, van Es JH, Snippert HJ, Stange DE, Vries RG, van den Born M, 
Barker N, Shroyer NF, van de Wetering M, Clevers H: Paneth cells constitute the 
niche for Lgr5 stem cells in intestinal crypts, Nature 2011, 469:415-418 
124. Le Blanc K, Mougiakakos D: Multipotent mesenchymal stromal cells and the 
 
 137 
innate immune system, Nat Rev Immunol 2012, 12:383-396 
125. Uccelli A, Moretta L, Pistoia V: Mesenchymal stem cells in health and 
disease, Nat Rev Immunol 2008, 8:726-736 
126. Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, 
Boggs SS, Greenberger JS, Goff JP: Bone marrow as a potential source of hepatic 
oval cells, Science 1999, 284:1168-1170 
127. Oh S, Shin S, Janknecht R: ETV1, 4 and 5: An oncogenic subfamily of ETS 
transcription factors, Biochim Biophys Acta 2012, 1826:1-12 
128. Kubo H, Shimizu M, Taya Y, Kawamoto T, Michida M, Kaneko E, Igarashi 
A, Nishimura M, Segoshi K, Shimazu Y, Tsuji K, Aoba T, Kato Y: Identification of 
mesenchymal stem cell (MSC)-transcription factors by microarray and knockdown 
analyses, and signature molecule-marked MSC in bone marrow by 
immunohistochemistry, Genes Cells 2009, 14:407-424 
129. Rubin BP: Bioinformatic mining of gene expression datasets identifies ETV1 
as a critical regulator of oncogenesis in gastrointestinal stromal tumors, Cancer Cell 
2010, 18:407-408 
130. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, 
Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL: ETV1 is a 
lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours, 
Nature 2010, 467:849-853 
131. Taupenot L, Harper KL, O'Connor DT: The chromogranin-secretogranin 
family, N Engl J Med 2003, 348:1134-1149 
132. Banks P, Helle K: The release of protein from the stimulated adrenal medulla, 
Biochem J 1965, 97:40C-41C 
133. Helle KB: Some chemical and physical properties of the soluble protein 
fraction of bovine adrenal chromaffin granules, Mol Pharmacol 1966, 2:298-310 
134. Taupenot L, Harper KL, O'Connor DT: Role of H+-ATPase-mediated 
acidification in sorting and release of the regulated secretory protein chromogranin A: 
evidence for a vesiculogenic function, J Biol Chem 2005, 280:3885-3897 
135. Li HJ, Ray SK, Singh NK, Johnston B, Leiter AB: Basic helix-loop-helix 
transcription factors and enteroendocrine cell differentiation, Diabetes Obes Metab 
2011, 13 Suppl 1:5-12 
136. Neckers L, Workman P: Hsp90 molecular chaperone inhibitors: are we there 
yet?, Clin Cancer Res 2012, 18:64-76 
137. Zitzmann K, Ruden J, Brand S, Goke B, Lichtl J, Spottl G, Auernhammer CJ: 
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale 
for dual-targeted therapy approaches in neuroendocrine tumor disease, Cancer Lett 
2010, 295:100-109 
138. Dancey J: mTOR signaling and drug development in cancer, Nat Rev Clin 
Oncol 2010, 7:209-219 
139. Kittler R, Putz G, Pelletier L, Poser I, Heninger AK, Drechsel D, Fischer S, 
Konstantinova I, Habermann B, Grabner H, Yaspo ML, Himmelbauer H, Korn B, 
Neugebauer K, Pisabarro MT, Buchholz F: An endoribonuclease-prepared siRNA 
screen in human cells identifies genes essential for cell division, Nature 2004, 
 
 138 
432:1036-1040 
140. Young HM: Embryological origin of interstitial cells of Cajal, Microsc Res 
Tech 1999, 47:303-308 
141. Parekh D, Ishizuka J, Townsend CM, Jr., Haber B, Beauchamp RD, Karp G, 
Kim SW, Rajaraman S, Greeley G, Jr., Thompson JC: Characterization of a human 
pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion, 
Pancreas 1994, 9:83-90 
142. Asa SL, Lee YC, Drucker DJ: Development of colonic and pancreatic 
endocrine tumours in mice expressing a glucagon-SV40 T antigen transgene, 
Virchows Arch 1996, 427:595-606 
143. Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y: Functional 
collaboration between different cyclin-dependent kinase inhibitors suppresses tumor 
growth with distinct tissue specificity, Mol Cell Biol 2000, 20:6147-6158 
144. Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong 
M, Krasnoperov V, Gill PS, Duarte A: Combination of Dll4/Notch and 
Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor 
angiogenesis, BMC Cancer 2010, 10:641 
145. Perez-Stable C, Altman NH, Mehta PP, Deftos LJ, Roos BA: Prostate cancer 
progression, metastasis, and gene expression in transgenic mice, Cancer Res 1997, 
57:900-906 
146. Tang LH, Contractor T, Clausen R, Klimstra DS, Du YC, Allen PJ, Brennan 
MF, Levine AJ, Harris CR: Attenuation of the retinoblastoma pathway in pancreatic 
neuroendocrine tumors due to increased cdk4/cdk6, Clin Cancer Res 2012, 
18:4612-4620 
147. Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de 
Wilde RF, Maitra A, Hicks J, Demarzo AM, Shi C, Sharma R, Laheru D, Edil BH, 
Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue 
CA: Small cell and large cell neuroendocrine carcinomas of the pancreas are 
genetically similar and distinct from well-differentiated pancreatic neuroendocrine 
tumors, Am J Surg Pathol 2012, 36:173-184 
148. Kitamura H, Yazawa T, Sato H, Okudela K, Shimoyamada H: Small cell 
lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, 
phenotype, and biology, Endocr Pathol 2009, 20:101-107 
149. Swarts DR, Ramaekers FC, Speel EJ: Molecular and cellular biology of 
neuroendocrine lung tumors: Evidence for separate biological entities, Biochim 
Biophys Acta 2012, 1826:255-271 
150. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, 
Roy-Burman P, Nikitin AY: Synergy of p53 and Rb deficiency in a conditional mouse 
model for metastatic prostate cancer, Cancer Res 2006, 66:7889-7898 
151. Hill R, Song Y, Cardiff RD, Van Dyke T: Heterogeneous tumor evolution 
initiated by loss of pRb function in a preclinical prostate cancer model, Cancer Res 
2005, 65:10243-10254 
152. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP, Caplin ME: 
Epidermal growth factor receptor expression and activation in neuroendocrine 
 
 139 
tumours, J Neuroendocrinol 2006, 18:355-360 
153. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer 
HH, Auernhammer CJ: The novel mTOR inhibitor RAD001 (everolimus) induces 
antiproliferative effects in human pancreatic neuroendocrine tumor cells, 
Neuroendocrinology 2007, 85:54-60 
154. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira 
A, Jr., Dalino P, Salahuddin N, Korbonits M, Grossman AB: Octreotide and the 
mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the 
Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line, 
Neuroendocrinology 2008, 87:168-181 
155. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares 
JE, Landgraf AN, Rashid A, Meric-Bernstam F: Efficacy of RAD001 (everolimus) 
and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: 
results of a phase II study, J Clin Oncol 2008, 26:4311-4318 
156. Pearse AG: The cytochemistry and ultrastructure of polypeptide 
hormone-producing cells of the APUD series and the embryologic, physiologic and 
pathologic implications of the concept, J Histochem Cytochem 1969, 17:303-313 
157. Siddique HR, Saleem M: Role of BMI1, a stem cell factor, in cancer 
recurrence and chemoresistance: preclinical and clinical evidences, Stem Cells 2012, 
30:372-378 
158. Zacharek SJ, Fillmore CM, Lau AN, Gludish DW, Chou A, Ho JW, Zamponi 
R, Gazit R, Bock C, Jager N, Smith ZD, Kim TM, Saunders AH, Wong J, Lee JH, 
Roach RR, Rossi DJ, Meissner A, Gimelbrant AA, Park PJ, Kim CF: Lung stem cell 
self-renewal relies on BMI1-dependent control of expression at imprinted loci, Cell 
Stem Cell 2011, 9:272-281 
159. Lessard J, Sauvageau G: Bmi-1 determines the proliferative capacity of 
normal and leukaemic stem cells, Nature 2003, 423:255-260 
160. Lukacs RU, Memarzadeh S, Wu H, Witte ON: Bmi-1 is a crucial regulator of 
prostate stem cell self-renewal and malignant transformation, Cell Stem Cell 2010, 
7:682-693 
161. Fukuda A, Morris JPt, Hebrok M: Bmi1 is required for regeneration of the 
exocrine pancreas in mice, Gastroenterology 2012, 143:821-831 e822 
162. Molofsky AV, He S, Bydon M, Morrison SJ, Pardal R: Bmi-1 promotes 
neural stem cell self-renewal and neural development but not mouse growth and 
survival by repressing the p16Ink4a and p19Arf senescence pathways, Genes Dev 
2005, 19:1432-1437 
163. Hosen N, Yamane T, Muijtjens M, Pham K, Clarke MF, Weissman IL: 
Bmi-1-green fluorescent protein-knock-in mice reveal the dynamic regulation of 
bmi-1 expression in normal and leukemic hematopoietic cells, Stem Cells 2007, 
25:1635-1644 
164. Zhang Y, Wang Z, Yu J, Shi J, Wang C, Fu W, Chen Z, Yang J: Cancer 
stem-like cells contribute to cisplatin resistance and progression in bladder cancer, 
Cancer Lett 2012, 322:70-77 
165. Glinsky GV: Stem cell origin of death-from-cancer phenotypes of human 
 
 140 
prostate and breast cancers, Stem Cell Rev 2007, 3:79-93 
166. Zhang XW, Sheng YP, Li Q, Qin W, Lu YW, Cheng YF, Liu BY, Zhang FC, 
Li J, Dimri GP, Guo WJ: BMI1 and Mel-18 oppositely regulate carcinogenesis and 
progression of gastric cancer, Mol Cancer 2010, 9:40 
167. Lu YW, Li J, Guo WJ: Expression and clinicopathological significance of 
Mel-18 and Bmi-1 mRNA in gastric carcinoma, J Exp Clin Cancer Res 2010, 29:143 
168. Li W, Li Y, Tan Y, Ma K, Cui J: Bmi-1 is critical for the proliferation and 
invasiveness of gastric carcinoma cells, J Gastroenterol Hepatol 2010, 25:568-575 
169. Yang DD, Cui BB, Sun LY, Zheng HQ, Huang Q, Tong JX, Zhang QF: The 
co-expression of USP22 and BMI-1 may promote cancer progression and predict 
therapy failure in gastric carcinoma, Cell Biochem Biophys 2011, 61:703-710 
170. Marquardt JU, Factor VM, Thorgeirsson SS: Epigenetic regulation of cancer 
stem cells in liver cancer: current concepts and clinical implications, J Hepatol 2010, 
53:568-577 
171. Jares P, Campo E: Advances in the understanding of mantle cell lymphoma, 
Br J Haematol 2008, 142:149-165 
172. Cooper CS, Foster CS: Concepts of epigenetics in prostate cancer 
development, Br J Cancer 2009, 100:240-245 
173. Balasubramanian S, Lee K, Adhikary G, Gopalakrishnan R, Rorke EA, 
Eckert RL: The Bmi-1 polycomb group gene in skin cancer: regulation of function by 
(-)-epigallocatechin-3-gallate, Nutr Rev 2008, 66 Suppl 1:S65-68 
174. Bhattacharyya J, Mihara K, Ohtsubo M, Yasunaga S, Takei Y, Yanagihara K, 
Sakai A, Hoshi M, Takihara Y, Kimura A: Overexpression of BMI-1 correlates with 
drug resistance in B-cell lymphoma cells through the stabilization of survivin 
expression, Cancer Sci 2012, 103:34-41 
175. Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H, Gong C, Chen J, Su F, Zhang 
Y, Song E: Reduced miR-128 in breast tumor-initiating cells induces 
chemotherapeutic resistance via Bmi-1 and ABCC5, Clin Cancer Res 2011, 
17:7105-7115 
176. Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, Zhang W, Chen W, Pan C, Liu 
Q, Song E, Li J: MiR-200b and miR-15b regulate chemotherapy-induced 
epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1, 
Oncogene 2012, 31:432-445 
177. Choijamts B, Jimi S, Kondo T, Naganuma Y, Matsumoto T, Kuroki M, 
Iwasaki H, Emoto M: CD133+ cancer stem cell-like cells derived from uterine 
carcinosarcoma (malignant mixed Mullerian tumor), Stem Cells 2011, 29:1485-1495 
178. Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, 
Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R: Enhancing 
chemotherapy response with Bmi-1 silencing in ovarian cancer, PLoS One 2011, 
6:e17918 
179. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, Huang CH, 
Kao SY, Tzeng CH, Tai SK, Chang SY, Lee OK, Wu KJ: Bmi1 is essential in 
Twist1-induced epithelial-mesenchymal transition, Nat Cell Biol 2010, 12:982-992 
180. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, 
 
 141 
Liu WL, Li MZ, Zhang L, Kang TB, Fu LW, Huang WL, Xia YF, Tsao SW, Li M, 
Band V, Band H, Shi QH, Zeng YX, Zeng MS: The polycomb group protein Bmi-1 
represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition 
in human nasopharyngeal epithelial cells, J Clin Invest 2009, 119:3626-3636 
181. Martin A, Cano A: Tumorigenesis: Twist1 links EMT to self-renewal, Nat 
Cell Biol 2010, 12:924-925 
182. Park IK, Morrison SJ, Clarke MF: Bmi1, stem cells, and senescence 
regulation, J Clin Invest 2004, 113:175-179 
183. Oishi N, Wang XW: Novel therapeutic strategies for targeting liver cancer 
stem cells, Int J Biol Sci 2011, 7:517-535 
184. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, 
Huang TH, Nephew KP: Identification and characterization of ovarian 
cancer-initiating cells from primary human tumors, Cancer Res 2008, 68:4311-4320 
185. Cui H, Hu B, Li T, Ma J, Alam G, Gunning WT, Ding HF: Bmi-1 is essential 
for the tumorigenicity of neuroblastoma cells, Am J Pathol 2007, 170:1370-1378 
186. Wiederschain D, Chen L, Johnson B, Bettano K, Jackson D, Taraszka J, 
Wang YK, Jones MD, Morrissey M, Deeds J, Mosher R, Fordjour P, Lengauer C, 
Benson JD: Contribution of polycomb homologues Bmi-1 and Mel-18 to 
medulloblastoma pathogenesis, Mol Cell Biol 2007, 27:4968-4979 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 142 
13  ACKNOWLEDGEMENTS   
First of all, I would like to express my sincere gratitude to my supervisor -- Prof. Dr. 
med. Georg Enders, for his continuous support and encouragement of my doctoral 
study and research, for his patience, motivation, enthusiasm, inspiration and immense 
knowledge. From the initial study to the final thesis, he provided nice guidance, sound 
advice, good teaching, big support and creative ideas. He made great efforts to explain 
things clearly and simply, which helped me develop an understanding of the subject 
and fall in love with scientific research. Without his help, this thesis could not be 
finished. I would also like to thank him for his kind support on my life in Munich. 
I would like to thank Prof. Dr. rer. nat. Wolfgang Zimmermann, for his great support 
on my doctoral program. He is always available for a nice discussion and is never 
hesitate to offer help. His creativeness, open mind and precise attitude helped me to 
get fresh ideas and be more critical to my work. I would also like to thank him for 
including me as a group member in their weekly lab meetings and yearly out going. I 
also appreciated the support from him and Dr. Christoph J. Auernhammer on my 
pre-examination. 
I am grateful to our group members—Bärbel Lorenz and Claudia Fahney, for their 
great technical assistance. Thanks for their patience and enthusiasm whenever I had 
questions or got into difficulties. It was really a wonderful experience to be with you 
for the past three years. 
I would like to thank all the other lab members, for all the help and support which I 
can not list all down but will never forget. 
I would also like to thank the colleagues and students from Prof. Dr. rer. nat. 
Wolfgang Zimmermann’s group for their help and kindness. 
I would like to thank Chinese Scholarship Council to provide the economic support. I 
 
 143 
would like to thank Prof. Dr. Ulrich Pohl for his support for the CSC-LMU program. I 
would like to thank Prof. Dr. Alexender Baethmann, who helped our CSC students 
with great efforts before and after we came here. I would like to thank Dr. Matthias 
Hadesbeck, Ms. Munique Esnof and all the other members from the International 
Office, LMU to give the orientation course and living assistance. I would like to thank 
Mr. Jiqiang Dai from Chinese Consulate Munich for the help on my overseas issues. 
Last but not least, I wish to thank my parents – Jianxin Pan and Hao Zhou. They bore 
me, raised me, and loved me. In particular, I would like to express heartfelt thanks to 
my mother, who provided understanding and support on my way pursuing my dream. 
I would also like to thank my husband – Qi Bao. To them I dedicate this thesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
